

Financial news for NVS dated on 2020-06-11: Shares of several healthcare companies are trading lower in sympathy with the overall market following an increase in coronavirus cases in some US states that have reopened, leading to concerns of a potential second wave of the virus.

Financial news for NVS dated on 2020-06-11: The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO

Financial news for NVS dated on 2020-06-11: Novartis Says FDA Approves Updated Beovu Label to Include Additional Safety Information

Financial news for NVS dated on 2020-06-05: The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets \$400M Bid

Financial news for NVS dated on 2020-06-05: Novartis Phase IIIb ARGON Study Meets Primary Endpoint in a Comparison of Enerzair Breezhaler (QVM149) vs Free Combination of Two Existing Inhaled Treatments in Uncontrolled Asthma

Financial news for NVS dated on 2020-06-04: The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

Financial news for NVS dated on 2020-06-04: Novartis Says PREVENT Data Show Cosentyx Helps Patients Realize Early and Lasting Relief in Axial Spondyloarthritis

Financial news for NVS dated on 2020-06-03: The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study

Financial news for NVS dated on 2020-06-02: FDA Extends Review Of SBLA, Submitted By Novartis, For Ofatumumab In Relapsing Multiple Sclerosis

Financial news for NVS dated on 2020-05-29: European Medicines Authority Says Novartis' Piqray Received Positive Opinion From CHMP

Financial news for NVS dated on 2020-05-28: Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.

Financial news for NVS dated on 2020-05-28: 'Novartis agrees to manufacture a #coronavirus vaccine being developed by Harvard, Mass Eye & Ear and Mass. General...' -Tweet From CNBC's Squawk Box

Financial news for NVS dated on 2020-05-28: Novartis Data Highlight Benefit of Early Treatment Initiation in Patients With Secondary Progressive Multiple Sclerosis (

Financial news for NVS dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for NVS dated on 2020-05-27: Novartis Announces Exploratory Analysis To Be Presented During ASCO 2020 Demonstrating Kisqali Shows 'Overall Survival Benefit In Hr+/Her2- Advanced Breast Cancer With Consistent Findings In Patients With More Aggressive Disease'

Financial news for NVS dated on 2020-05-27: Novartis Announces New Late-breaking Ofatumumab Data at EAN Demonstrating Robust Efficacy and Safety in the Treatment of Relapsing Forms of Multiple Sclerosis

Financial news for NVS dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for NVS dated on 2020-05-19: Novartis Announces AveXis Receives EC Approval and Activates Day One Access Program for Zolgensma for Patients With Spinal Muscular Atrophy

Financial news for NVS dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for NVS dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for NVS dated on 2020-05-09: Chinese Regulators Approved Novartis' Mayzent to Treat Relapsing MS in Adults

Financial news for NVS dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To

Join S&P 500

Financial news for NVS dated on 2020-05-06: Codexis Reports Achieved Wave 2 Milestone Associated With CodeEvolver Platform, License Deal With Novartis

Financial news for NVS dated on 2020-05-06: Incyte Issues Press Release Highlighting FDA Approval Of Novartis' Tabrecta

Financial news for NVS dated on 2020-05-06: Novartis Press Release Confirms FDA Approval Of Tabrecta For Metastatic Non-Small Cell Lung Cancer With METex14

Financial news for NVS dated on 2020-05-06: FDA Approves Novartis' Tabrecta For Metastatic Non-Small Cell Lung Cancer

Financial news for NVS dated on 2020-05-06: EXUMA Biotech Is 'Revolutionizing CAR-T Therapy,' Increasing Patient Access, CEO Says

Financial news for NVS dated on 2020-05-01: The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO

Financial news for NVS dated on 2020-05-01: Novartis Receives CHMP Positive Opinion for Enerzair Breezhaler for Uncontrolled Asthma

Financial news for NVS dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for NVS dated on 2020-04-29: Novartis Cosentyx Gains Fourth Indication in Eu With First-in-class Approval in Axial Spondyloarthritis Spectrum

Financial news for NVS dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for NVS dated on 2020-04-28: Earnings Scheduled For April 28, 2020

Financial news for NVS dated on 2020-04-25: 'Psyched': ATAI Closes \$24M Convertible Round, MindMed To Begin Trading On OTCQB, Investor Presentations Available Online

Financial news for NVS dated on 2020-04-22: The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership

Financial news for NVS dated on 2020-04-22: Novartis Kymriah Receives FDA Regenerative Medicine Advanced Therapy Designation in Follicular Lymphoma

Financial news for NVS dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for NVS dated on 2020-04-21: Novartis Announces New Mayzent Data Show Sustained Effect in Delaying Disability for Up to Five Years in Patients With Secondary Progressive MS

Financial news for NVS dated on 2020-04-20: Novartis NOVN.S has won the go-ahead from the U.S. Food and Drug Administration to conduct a randomized trial of malaria drug hydroxychloroquine against COVID-19 disease

Financial news for NVS dated on 2020-04-16: Novartis Announces Data in Neurology Reinforcing the Real-world and Long-term Effectiveness and Safety of Aimovig as a Preventive Treatment Across the Full Spectrum of Migraine

Financial news for NVS dated on 2020-04-14: Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for NVS dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for NVS dated on 2020-04-03: The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

Financial news for NVS dated on 2020-04-02: The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation

Financial news for NVS dated on 2020-04-02: Novartis Announces Mutual Agreement to

Terminate Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo

Financial news for NVS dated on 2020-03-31: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for NVS dated on 2020-03-31: Intellia Therapeutics Announces FDA Has Accepted IND Application Submitted By Collaborator Novartis For CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate

Financial news for NVS dated on 2020-03-29: U.S. HHS Says Accepted 30M Doses of Hydroxychloroquine Sulfate Donated by Novartis's Sandoz as Possible Treatments for Covid-19 Patients

Financial news for NVS dated on 2020-03-27: Novartis CEO Talks Coronavirus Vaccine Progress, Timeline

Financial news for NVS dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for NVS dated on 2020-03-27: Novartis' AveXis Reports Receives Positive CHMP Opinion For Zolgensma For Spinal Muscular Atrophy

Financial news for NVS dated on 2020-03-27: Novartis Reports Its Cosentyx Gains Positive CHMP Opinion For New Indication In Axial Spondyloarthritis Spectrum

Financial news for NVS dated on 2020-03-26: Shares of several healthcare companies are trading higher following Senate passage of a \$2 trillion economic stimulus package, which has lifted stocks across sectors.

Financial news for NVS dated on 2020-03-26: Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundatio

Financial news for NVS dated on 2020-03-24: Chloroquine, Hydroxychloroquine And Coronavirus: What You Should Know

Financial news for NVS dated on 2020-03-24: The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

Financial news for NVS dated on 2020-03-24: Novartis' AveXis Unit Says Zolgensma Data Shows Rapid, Significant, Clinically Meaningful Benefit in Sma Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability Now Up to 5 Years Post-dosing

Financial news for NVS dated on 2020-03-23: Novartis' Sandoz Reports Purchase Of US Distribution Rights For Daptomycin, Fosaprepitant, Antibiotic For Infections, Antiemetic Drug For Nausea, Vomiting, Respectively

Financial news for NVS dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Lateststage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for NVS dated on 2020-03-19: Novartis Receives Approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma for Patients with Spinal Muscular Atrophy

Financial news for NVS dated on 2020-03-18: Novartis Highlights Publication Of 3 Pivotal Trials Showing Durable, Potent Efficacy Of Inclisiran In New England Journal Of Medicine

Financial news for NVS dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for NVS dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for NVS dated on 2020-03-13: Intec Pharma Posts Q4 Net Loss Of \$6.6M, Down By Nearly Half Year-Over-Year

Financial news for NVS dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for NVS dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains

FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for NVS dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for NVS dated on 2020-03-12: Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.

Financial news for NVS dated on 2020-03-11: Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.

Financial news for NVS dated on 2020-03-10: Shares of several healthcare companies are trading higher as markets rebound following Monday's selloff. US President Trump on Monday indicated the US may implement payroll tax cuts and other measures to support the economy amid the coronavirus outbreak.

Financial news for NVS dated on 2020-03-04: 36 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVS dated on 2020-03-04: Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for NVS dated on 2020-03-04: Novartis Says Still Does Not Anticipate a Supply Chain Disruption Due to the New Coronavirus

Financial news for NVS dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for NVS dated on 2020-03-03: Novartis Receives Health Canada Approval For Mayzent To Treat Secondary Progressive Multiple Sclerosis With Active Disease

Financial news for NVS dated on 2020-03-02: Novartis' Sandoz To Pay \$195M For Price-Fixing

Financial news for NVS dated on 2020-03-02: US Dept. Of Justice Says Novartis Unit Sandoz Has Agreed To Pay \$195M To Resolve Antitrust Claims

Financial news for NVS dated on 2020-03-02: Novartis Offers update On Use, Safety Of Beovu In Patients with Wet AMD: says To Date Safety Data Continue To Support Favorable Benefit-Risk Profile

Financial news for NVS dated on 2020-02-28: 'Novartis employee claims she was fired for complaining about incorrect data' -STAT News

Financial news for NVS dated on 2020-02-25: Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug

Financial news for NVS dated on 2020-02-25: Guggenheim Securities Downgrades Novartis to Neutral

Financial news for NVS dated on 2020-02-25: Novartis and DNDi to Collaborate on Development of New Oral Drug to Treat Visceral Leishmaniasis

Financial news for NVS dated on 2020-02-24: Regeneron Shares Higher; It Was Earlier Reported The ASRS Announced Reports Of Vasculitis Tied To Beovu, A Drug From Competitor Novartis

Financial news for NVS dated on 2020-02-24: Novartis Confirms ASRS Reports Of Vasculitis Tied To Beovu; ASRS Reports Show 14 Cases Of Vasculitis Since Approval

Financial news for NVS dated on 2020-02-24: Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.

Financial news for NVS dated on 2020-02-17: Novartis Receives EC Approval for Beovu, Next-generation Anti-VEGF Treatment for Wet AMD

Financial news for NVS dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for NVS dated on 2020-02-12: Zydus, Novartis Settle Patent Suit on

Generic Version of Jadenu

Financial news for NVS dated on 2020-02-12: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVS dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for NVS dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for NVS dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for NVS dated on 2020-02-11: Novartis announces MET Inhibitor Capmatinib for Treatment of METex14 Mutated Advanced Non-small Cell Lung Cancer, Granted Priority FDA Review

Financial news for NVS dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for NVS dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for NVS dated on 2020-02-04: United Therapeutics Reports Defeat Of Prelim. Injunction Motion In Litigation With Sandoz, RareGen

Financial news for NVS dated on 2020-01-29: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVS dated on 2020-01-29: The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut

Financial news for NVS dated on 2020-01-29: Novartis CEO Says Could See a Coronavirus Vaccine in Around a Year

Financial news for NVS dated on 2020-01-29: Novartis CEO Says Key Risk That Impacts Shares of Healthcare Companies is U.S. Healthcare Reform

Financial news for NVS dated on 2020-01-29: Earnings Scheduled For January 29, 2020

Financial news for NVS dated on 2020-01-20: Novartis Announces EU Approval of Mayzent for Adult Patients with Secondary Progressive MS with Active Disease

Financial news for NVS dated on 2020-01-20: 7 Blockbuster Drugs Expected To Be Launched In 2020

Financial news for NVS dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for NVS dated on 2020-01-13: Inclisiran To Be Studied In UK Patients Under NHS Clinical Trial Expected To Start Later This Year

Financial news for NVS dated on 2020-01-13: Novartis CEO Says "Don't Believe In Big M&A"; Says Company Expects To Double Business In China By 2024

Financial news for NVS dated on 2020-01-09: Novartis Announces Ligelizumab More Effective Than Xolair at Inhibiting Immunoglobulin E Pathway

Financial news for NVS dated on 2020-01-06: Novartis Completes Tender Offer for All Outstanding Shares of The Medicines Company for \$85/Share

Financial news for NVS dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for NVS dated on 2019-12-27: Stocks That Hit 52-Week Highs On Friday

Financial news for NVS dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Drug, Correvio Awaits FDA Verdict

Financial news for NVS dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for NVS dated on 2019-12-23: Stocks That Hit 52-Week Highs On Monday

Financial news for NVS dated on 2019-12-22: 550 Cases Confirmed of H1N1 Virus with 26 Deaths Reported in Past 3 Weeks in Sana'a Yemen

Financial news for NVS dated on 2019-12-19: The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Financial news for NVS dated on 2019-12-19: Novartis to Give Away 100 doses of its \$2.1M/Patient Zolgensma for Spinal Muscular Atrophy in 2020

Financial news for NVS dated on 2019-12-18: 30 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVS dated on 2019-12-17: Aduro Biotech On Dec. 11 Received Notification For Novartis That Novartis Removed ADU-S100 from Portfolio Based On Clinical Data; Removal Was Not Result Of Any Safety Concern

Financial news for NVS dated on 2019-12-16: Why Gossamer Bio Shares Are Plunging

Financial news for NVS dated on 2019-12-16: Novartis Announces LUSTER Phase III Studies Patients with Uncontrolled GINA 4/5 Asthma did Not Meet Clinically Relevant Threshold

Financial news for NVS dated on 2019-12-13: EMA Reports Committee Recommended Granting Marketing Authorization For Novartis' Beovu For Treatment Of Neovascular Age-Related Macular Degeneration

Financial news for NVS dated on 2019-12-12: Novartis Reports Its Pharma Canada Sites In Ontario Certified In Accordance With Applicable Requirements to Treat Eligible Patients With Kymriah

Financial news for NVS dated on 2019-12-11: Intec Announces Termination Of Feasibility And Option Agreement With Novartis For The Development Of Accordion Pill; Novartis To Pay Intec \$1.5M

Financial news for NVS dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for NVS dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for NVS dated on 2019-12-06: Novartis Says Phase III Data on New Inhaled Dual Combination QMF149 Show Significant Improvement Across Key Asthma Outcomes Versus Monotherapy

Financial news for NVS dated on 2019-12-05: Novartis Research Head Says Looks Forward To Bringing Gene Therapy For Friedreich's Ataxia To Patients 'Very Soon'

Financial news for NVS dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for NVS dated on 2019-12-05: Novartis Says Expects to Sustain Long-term Growth With a Robust Pipeline of 25+ Potential Blockbusters

Financial news for NVS dated on 2019-12-05: Novartis Tender Offer for The Medicines Company Commences

Financial news for NVS dated on 2019-12-04: Amazon's Amazon Web Services Reports Strategic Collaboration With Novartis To Accelerate Digital Transformation Of Its Business Operations

Financial news for NVS dated on 2019-12-03: The Gene Therapy Names Moving On The Audentes Buyout Deal

Financial news for NVS dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for NVS dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for NVS dated on 2019-11-29: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for NVS dated on 2019-11-29: National Business Daily Reports Drugmakers including Johnson & Johnson, Roche, Novartis and Merck have Agreed to Massively Cut the Prices of Some Drugs to Get Included in China's Medical Reimbursement List

Financial news for NVS dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for NVS dated on 2019-11-25: PreMarket Prep Recap: Merger Monday, Tesla Two-Step, Street Fades Netflix Downgrade

Financial news for NVS dated on 2019-11-25: Novartis Confirms Deal To Acquire Medicines Company For \$9.7B

Financial news for NVS dated on 2019-11-25: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for NVS dated on 2019-11-24: Novartis Confirms Agreement to Acquire the Medicines Company for \$85/Share

Financial news for NVS dated on 2019-11-23: Novartis Nears Deal to Buy Medicines Co. for \$85/Share; ~\$7B

Financial news for NVS dated on 2019-11-20: Cramer Gives His Opinion on Ford, American Tower And More

Financial news for NVS dated on 2019-11-19: Medicines Company Shares Soar On Rumored Buyout Interest From Novartis

Financial news for NVS dated on 2019-11-19: Novartis Declines Comment on Media Report That It is Considering Offer for The Medicines Co

Financial news for NVS dated on 2019-11-15: FDA Approves Novartis' Sickle Cell Disease Treatment Adakveo 100 Mg/10 Ml Injection

Financial news for NVS dated on 2019-11-15: EU's CHMP Gives Positive Opinion For Novartis' Mayzent For Adult Patients With Secondary Progressive Multiple Sclerosis

Financial news for NVS dated on 2019-11-15: EU's CHMP Recommends Conditional Marketing Authorization For Roche's Polivy To Treat Relapsed, Refractory Diffuse Large B-Cell Lymphoma; Separately Reports Marketing Authorization For Novartis' Isturisa

Financial news for NVS dated on 2019-11-12: Sandoz Presents Real-world Data Showing Effectiveness of Erelzi in Rheumatic Disease Treatment

Financial news for NVS dated on 2019-11-12: Novartis Announces New PREVENT Data Show Cosentyx Delivers Early Relief in Axial Spondyloarthritis

Financial news for NVS dated on 2019-11-11: Novartis Unit Sandoz Announces Agreement to Acquire Aspen's Japanese Operations and Associated Assets for EUR300M in Cash

Financial news for NVS dated on 2019-11-10: The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict

Financial news for NVS dated on 2019-11-08: 10 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for NVS dated on 2019-11-06: AstraZeneca Named The Most Innovative Global Pharma Company

Financial news for NVS dated on 2019-11-05: Sandoz Receives US FDA Approval for Long-acting Oncology Supportive Care Biosimilar Ziextenzo

Financial news for NVS dated on 2019-11-01: Novartis Says Cosentyx Shows Encouraging Results vs Humira from Frst-of-its-kind Head-to-head trial in Psoriatic Arthritis

Financial news for NVS dated on 2019-10-30: 13 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVS dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for NVS dated on 2019-10-30: Novartis Says FDA Placed Partial Hold On Avxs-101 Intrathecal Trials For SMA Patients

Financial news for NVS dated on 2019-10-29: The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

Financial news for NVS dated on 2019-10-24: The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise

Financial news for NVS dated on 2019-10-24: Novartis Receives Approval for Cosentyx Label Update in Europe to Include Dosing Flexibility in Ankylosing Spondylitis

Financial news for NVS dated on 2019-10-22: The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug

Financial news for NVS dated on 2019-10-22: Earnings Scheduled For October 22, 2019

Financial news for NVS dated on 2019-10-22: Novartis Reports Q3 Sales of \$12.2B vs \$11.7B Reuters Est

Financial news for NVS dated on 2019-10-21: Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition

Financial news for NVS dated on 2019-10-16: Novartis Reports Jakavi Phase 3 Trial Met Primary Endpoint

Financial news for NVS dated on 2019-10-13: The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings

Financial news for NVS dated on 2019-10-11: Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.

Financial news for NVS dated on 2019-10-08: Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on \$250 billion worth of goods from 25% to 30% on Oct 15.

Financial news for NVS dated on 2019-10-08: Novartis Data Show More Patients Are Completely Symptom-free From Chronic Spontaneous Urticaria With Ligelizumab (QGE031) than Xolair(r) 300 mg

Financial news for NVS dated on 2019-10-08: Novartis Receives FDA Approval for Beovu

Financial news for NVS dated on 2019-10-06: The Week Ahead In Biotech: Pfenex And Clinuvcl On The Radar Ahead of FDA Decisions, 2 IPOs On Deck

Financial news for NVS dated on 2019-10-04: Conatus Pharmaceuticals And Novartis Mutually Agree To Terminate Collaboration Agreement Dated December 19, 2016

Financial news for NVS dated on 2019-10-03: Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar

Financial news for NVS dated on 2019-10-02: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.

Financial news for NVS dated on 2019-10-02: The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Financial news for NVS dated on 2019-10-02: Novartis Says Positive 52-week PREVENT Data Confirm Cosentyx Efficacy in Addressing Entire axSpA Spectrum

Financial news for NVS dated on 2019-10-01: Novartis And Microsoft Announce Medical/Artificial Intelligence Collaboration; Joint Research Activities To Include Personalized Therapies For Macular Degeneration, Cell & Gene Therapy, Drug Design

Financial news for NVS dated on 2019-09-30: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for NVS dated on 2019-09-27: The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

Financial news for NVS dated on 2019-09-26: XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets For \$10M

Financial news for NVS dated on 2019-09-25: Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company

Financial news for NVS dated on 2019-09-24: The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger

Financial news for NVS dated on 2019-09-22: The Week Ahead In Biotech: Spotlight On ESMO Conference

Financial news for NVS dated on 2019-09-20: 15 Healthcare Stocks Moving In Friday's Pre-Market Session



Financial news for NVS dated on 2019-09-19: The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO

Financial news for NVS dated on 2019-09-19: Novartis Announces its Avexis Unit Presents New Data at Epns Continuing to Show Significant Therapeutic Benefit of Zolgensma in Prolonging Event-free Survival Now Up to 5 Years of Age in Patients With Spinal Muscular Atrophy Type 1

Financial news for NVS dated on 2019-09-17: 9 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for NVS dated on 2019-09-17: The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study

Financial news for NVS dated on 2019-09-17: Novartis Announces Cosentyx Positive 16-week Prevent Results Advance Potential New Indication for Patients With Axial Spondyloarthritis

Financial news for NVS dated on 2019-09-13: Novartis AG shares are trading lower after a test in Canutillo High School revealed 4 confirmed Tuberculosis cases among students and staff.

Financial news for NVS dated on 2019-09-13: Novartis Reports OMB157 Was Superior to Aubagio, 2 Studies Met Primary Endpoints

Financial news for NVS dated on 2019-09-13: The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

Financial news for NVS dated on 2019-09-13: Novartis Says New Data Show That Neuronal and Glial Filaments, Biomarkers of Disease Activity, Have the Potential to Support Decision Making in the Management of MS Patient

Financial news for NVS dated on 2019-09-12: Four TB Cases Confirmed at El Paso, TX High School

Financial news for NVS dated on 2019-09-12: Novartis Announces New Data at ECTRIMS Showing Mayzent Can Help Preserve Mobility for Longer in Patients With Secondary Progressive Multiple Sclerosis

Financial news for NVS dated on 2019-09-10: Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.

Financial news for NVS dated on 2019-09-10: Novartis Data at ECTRIMS to Highlight Innovative Approach to Reimagining Care for People Living With MS

Financial news for NVS dated on 2019-09-08: The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

Financial news for NVS dated on 2019-09-06: Novartis Investigational Lung Cancer Therapy Capmatinib (Inc280) Granted FDA Breakthrough Therapy Designation for Patients With Met-mutated Advanced Non-small Cell Lung Cancer

Financial news for NVS dated on 2019-09-04: Sandoz Announces Global Deal to Commercialize Proposed Biosimilar Natalizumab, a Key MS Medicine

Financial news for NVS dated on 2019-09-03: Sandoz Announces Global Deal to Commercialize Proposed Biosimilar Natalizumab, a Key Multiple Sclerosis Medicine

Financial news for NVS dated on 2019-09-02: Novartis Says Entresto Improved Measures of Heart Structure and Function in HFrEF Patients in New Study

Financial news for NVS dated on 2019-08-30: 18 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for NVS dated on 2019-08-30: The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation

Financial news for NVS dated on 2019-08-30: Novartis Announces Ofatumumab Demonstrates Superiority vs Aubagio in Two Head-to-head Phase III MS Studies

Financial news for NVS dated on 2019-08-30: Genmab Acknowledges Novartis Announcement that Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III MS Studies

Financial news for NVS dated on 2019-08-24: 10 Biopharmaceutical Companies Trying To Cure Cancer

Financial news for NVS dated on 2019-08-19: Novartis Says will Answer U.S. Senate

## Demand for Data Manipulation Details

Financial news for NVS dated on 2019-08-18: Unnamed Novartis Executive Sold \$946,000 Worth of Shares Less Than Three Weeks Prior to FDA Announcement that Data From Tests of Its Gene Therapy Zolgensma Had Been Manipulated

Financial news for NVS dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for NVS dated on 2019-08-14: 'Novartis ousted top scientists over manipulation of data for gene therapy' -STAT

Financial news for NVS dated on 2019-08-13: Biotech Stock On The Radar: Is Vanda A Buy Ahead Of Its PDUFA Date?

Financial news for NVS dated on 2019-08-12: Novartis Benefits from Faster China Drug Approvals

Financial news for NVS dated on 2019-08-11: The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Financial news for NVS dated on 2019-08-08: Novartis AG shares are trading higher on seemingly no company specific news.

Financial news for NVS dated on 2019-08-07: FDA Investigates Data Manipulation Issue With Newly Approved Novartis Drug Zolgensma

Financial news for NVS dated on 2019-08-07: From Novartis Call: CEO Sees Zolgensma Data Manipulation As An Isolated Incident Related To Single Set Of Labs

Financial news for NVS dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for NVS dated on 2019-08-07: Novartis Says Stands Behind Zolgensma for the Treatment of Children Less Than 2 Years of Age With Spinal Muscular Atrophy

Financial news for NVS dated on 2019-08-06: FDA's Center for Biologics Evaluation And Research Makes Statement On Data Accuracy Issues With AveXis's Zolgensma

Financial news for NVS dated on 2019-07-29: Novartis Says Phase III PARAGON-HF Trial Narrowly Missed Statistical Significance for Its Composite Primary Endpoint of Reducing Cardiovascular Death and Total Heart Failure Hospitalizations

Financial news for NVS dated on 2019-07-26: European CHMP Says Has Recommended Novartis' Gilenya Must Not Be Used In Pregnant Women, Women Able To Have Children Who Are Not Using Effective Contraceptive

Financial news for NVS dated on 2019-07-22: STAT News Article Highlights CAR-T Therapy Innovations

Financial news for NVS dated on 2019-07-22: Novartis Unit Sandoz Announces First Patient Enrolled in Clinical Study for Proposed Biosimilar Denosumab in Osteoporosis

Financial news for NVS dated on 2019-07-19: Gilead Will Buy Exclusive Global Rights To Develop, Commercialize Novel Small Molecules Against 3 Undisclosed Targets From Novartis, Novartis Will Receive Upfront Payment, Eligible For Added \$291M

Financial news for NVS dated on 2019-07-19: 58 Biggest Movers From Yesterday

Financial news for NVS dated on 2019-07-19: Novartis' Key MS Product Gilenya Approved in China

Financial news for NVS dated on 2019-07-18: 42 Stocks Moving In Thursday's Mid-Day Session

Financial news for NVS dated on 2019-07-18: Novartis CEO Says US Government Policy Environment 'Very Fluid' Regarding Drug Pricing After Trump Administration Drops Rebate Rule

Financial news for NVS dated on 2019-07-18: Novartis Trades Higher On Q2 Earnings, Guidance Raise

Financial news for NVS dated on 2019-07-18: 28 Stocks Moving In Thursday's Pre-Market Session

Financial news for NVS dated on 2019-07-18: Novartis shares are trading higher after the company reported Q2 EPS and sales results higher from last year. The company also

raised its Q3 sales guidance.

Financial news for NVS dated on 2019-07-18: Earnings Scheduled For July 18, 2019

Financial news for NVS dated on 2019-07-16: Novartis Announces FDA Accepts File and Accelerates Review of Sickle cell Disease Medicine Crizanlizumab (SEG101)

Financial news for NVS dated on 2019-07-12: Recordati To Acquire Worldwide Rights To Signifor And Osilodrostat; Upon Completion Of Transaction A Consideration Of \$390M Will Be Due To Novartis

Financial news for NVS dated on 2019-07-12: Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug

Financial news for NVS dated on 2019-07-12: Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans.

Financial news for NVS dated on 2019-07-12: The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study

Financial news for NVS dated on 2019-07-11: Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention

Financial news for NVS dated on 2019-07-10: The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV

Financial news for NVS dated on 2019-07-09: Novartis Shares Closed Up ~0.4%, Did Not Appear To Be Impacted By Tues. Morning Report 'Novartis to sell epinephrine shot in U.S. pharmacies amid EpiPen shortage'

Financial news for NVS dated on 2019-07-05: The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTD Conferences In The Spotlight

Financial news for NVS dated on 2019-07-02: Novartis to Launch Generic Iressa When Patent Expires in Europe

Financial news for NVS dated on 2019-07-01: Amazon, Sears Veteran Joins Cresco Labs As Chief Information Officer

Financial news for NVS dated on 2019-07-01: Lonza to Acquire Sterile Fill and Finish Facility from Novartis; Financial Terms Not Disclosed

Financial news for NVS dated on 2019-07-01: Novartis Announces Data Show Aimovig Cuts Acute Migraine Medication Days By Half in Patients Who Failed Prior Preventive Therapies at #EAN2019

Financial news for NVS dated on 2019-06-28: PeptiDream Announces New Peptide Drug Conjugate Collaboration Agreement with Novartis

Financial news for NVS dated on 2019-06-25: NASH Disappointment Forces Conatus To Explore Strategic Alternatives

Financial news for NVS dated on 2019-06-24: Glenmark Pharmaceuticals To Partner With Novartis In Brazil on Three Respiratory Products

Financial news for NVS dated on 2019-06-23: The 5 Most Expensive Drugs In US: What You Should Know

Financial news for NVS dated on 2019-06-20: Top 10 Most Overbought Stocks Via Benzinga Pro's Radar Tool For Thur., June 20, 2019

Financial news for NVS dated on 2019-06-19: Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz, Momenta, Sandoz to Pay Amphastar \$59.9M

Financial news for NVS dated on 2019-06-14: Novartis Said Combining its Asciminib with Tyrosine Kinase Inhibitors in Treatment for Leukemia Showed Promising Results

Financial news for NVS dated on 2019-06-12: The Daily Biotech Pulse: Nuvecetra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

Financial news for NVS dated on 2019-06-12: Novartis Announces Cosentyx Provides Long-lasting Inhibition of Radiographic Progression in Psoriatic Arthritis

Financial news for NVS dated on 2019-06-07: Sanofi's Leadership Transition: What You Need To Know

Financial news for NVS dated on 2019-06-07: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

Financial news for NVS dated on 2019-06-06: Sanofi CEO Brandicourt to Leave Company from September 1; Paul Hudson to become New Sanofi CEO Effective September 1

Financial news for NVS dated on 2019-06-06: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

Financial news for NVS dated on 2019-06-06: Novartis Announced New Early Stage Histology Data in Kidney Transplantation, Suggesting That With Investigational Compound Iscalimab it May Be Possible to Prolong Durability of Transplanted Kidneys

Financial news for NVS dated on 2019-06-04: Novartis Says Long-Term Survival Benefit Shown For Metastatic Melanoma Patients Treated With Novartis Tafinlar + Mekinist

Financial news for NVS dated on 2019-06-02: Aduro Biotech, Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas at #ASCO19

Financial news for NVS dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for NVS dated on 2019-06-01: Novartis Announces Kisqali Significantly Extends Life in Women with HR+/HER2- Advanced Breast Cancer in MONALEESA-7 Trial at #ASCO19

Financial news for NVS dated on 2019-05-31: Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Financial news for NVS dated on 2019-05-30: Top 10 Most Overbought Stocks Via Benzinga Pro's Radar Tool For Thur., May 30, 2019

Financial news for NVS dated on 2019-05-30: The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug

Financial news for NVS dated on 2019-05-30: Novartis' Phase III QUARTZ Study of New Investigational Inhaled Combination Treatment QMF149 Meets Primary, Key Secondary Endpoints in Patients With Inadequately Controlled Asthma

Financial news for NVS dated on 2019-05-29: BioLife Solutions Joint Venture Partner SAVSU Technologies Selected by Novartis To Supply Advanced Cold Chain Management Platform For Newly Approved Gene Therapy

Financial news for NVS dated on 2019-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for NVS dated on 2019-05-25: Barron's Picks And Pans: Boston Beer, MGM, Target, Visa And More

Financial news for NVS dated on 2019-05-24: FDA Approves Zolgensma Gene Therapy To Treat Children Less Than Two Years Of Age With Spinal Muscular Atrophy

Financial news for NVS dated on 2019-05-24: Novartis shares are trading higher after the company's valid Marketing Authorisation Application was accepted by the EU Regulatory Authorities for the approval of QVM149, a potential new inhaled combination therapy for inadequately controlled asthma.

Financial news for NVS dated on 2019-05-24: The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

Financial news for NVS dated on 2019-05-24: Vectura Group to Receive \$2.5M Milestone Payment Under Exclusive Licence Agreement With Novartis Ag

Financial news for NVS dated on 2019-05-22: Ideaya Biosciences IPO: What You Need To Know

Financial news for NVS dated on 2019-05-22: The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

Financial news for NVS dated on 2019-05-22: Jim Cramer Weighs In On Nektar, L Brands And More

Financial news for NVS dated on 2019-05-22: Novartis Announces Phase II Data for New Inhaled Combination Treatment Demonstrates Significant Improvements Over Current Standard-of-care Inhaled Treatment

Financial news for NVS dated on 2019-05-18: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for NVS dated on 2019-05-17: ACCC Says GSK, Novartis Misled Consumers With Voltaren Osteo Gel Claims

Financial news for NVS dated on 2019-05-15: Japan Government Panel Approves \$305,800 Price for Novartis' Cancer Treatment Kymriah

Financial news for NVS dated on 2019-05-13: Shares of several drug manufacturers are trading lower after the United States filed a lawsuit against Teva alleging price fixing.

Financial news for NVS dated on 2019-05-13: Teva Plummets Amid Massive Price Fixing Accusations; Other Generic Drugmakers Also Fall

Financial news for NVS dated on 2019-05-13: Novartis in Talks With Insurers Regarding Price Discounts on Gene Therapy for Spinal Muscular Atrophy

Financial news for NVS dated on 2019-05-10: UPDATE: Novartis Is In Advanced Talks With Health Insurers, Expecting 'Major' Contracts Soon After US Approval Of Zolgensma

Financial news for NVS dated on 2019-05-10: Novartis Exec Has Discussed Discounts On Zolgensma To Secure US Insurer Coverage, Seeking Insurer Support For Newborn Screening, Quick Authorization

Financial news for NVS dated on 2019-05-10: Novartis Data at #AAN2019 Show Gilenya Is the First and Only Disease-modifying Therapy With Proven Superiority vs Glatiramer Acetate in Relapsing Remitting MS

Financial news for NVS dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for NVS dated on 2019-05-09: Novartis to Acquire Xiidra from Takeda for \$3.4B Upfront, Up to \$1.9B in Potential Milestones

Financial news for NVS dated on 2019-05-09: Novartis Announces Sandoz Demonstrates Strategic Focus on China, With First-of-a-kind Generic Approval Under Quality Consistency Evaluation System

Financial news for NVS dated on 2019-05-08: 'Novartis Considers Offer for Takeda Eye-Disease Assets' -Bloomberg Earlier Reported

Financial news for NVS dated on 2019-05-08: Novartis Data at AAN Show Mayzent's Positive Impact on Cognitive Processing Speed, a Core Element of Cognitive Function, in People Living With Secondary Progressive MS

Financial news for NVS dated on 2019-05-07: Novartis Highlights New AveXis Data Showed Long-Term Durability For Zolgensma As Treatment for Spinal Muscular Atrophy Type 1

Financial news for NVS dated on 2019-05-07: In The Search For Safety, Don't Miss The Swiss

Financial news for NVS dated on 2019-05-07: Shares of several healthcare companies are trading lower after several companies in the space reported weak earnings with Mylan leading the selloff.

Financial news for NVS dated on 2019-05-04: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for NVS dated on 2019-05-02: What's The Buzz Around Novartis' Gene Therapy Zolgensma?

Financial news for NVS dated on 2019-04-30: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for NVS dated on 2019-04-30: Shares of several pharmaceutical companies are trading higher in sympathy with Pfizer and Merck after the companies reported strong Q1 earnings.

Financial news for NVS dated on 2019-04-30: The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

Financial news for NVS dated on 2019-04-30: Sandoz Announces Agreement for Proposed

Trastuzumab Biosimilar, Currently in Phase III Development, to Treat Selected HER2-positive Cancer Tumors

Financial news for NVS dated on 2019-04-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for NVS dated on 2019-04-25: Benzinga's Top Upgrades, Downgrades For April 25, 2019

Financial news for NVS dated on 2019-04-25: Guggenheim Upgrades Novartis AG Common Stock to Buy

Financial news for NVS dated on 2019-04-24: Novartis Earlier Reported Q1 EPS \$1.21 Beats \$1.2 Estimate, Sales \$11.1B Miss \$11.78B Estimate

Financial news for NVS dated on 2019-04-24: 24 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVS dated on 2019-04-24: The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova

Financial news for NVS dated on 2019-04-24: Novartis Reports Core Operating Income Grew 18%; Says Catalyst Rich 2019 with Potential Blockbuster Launches on Track

Financial news for NVS dated on 2019-04-24: Novartis Starts 2019 With Strong Sales And Double Digit Core Operating Income Growth, Mayzent Launch And Alcon Spin-off; Profit Guidance Upgraded

Financial news for NVS dated on 2019-04-24: Earnings Scheduled For April 24, 2019

Financial news for NVS dated on 2019-04-23: Shares of several healthcare-related stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'.

Financial news for NVS dated on 2019-04-23: Novartis Says Baby's Death May Be Tied to Gene Therapy

Financial news for NVS dated on 2019-04-22: Novartis Option Alert: May 17 \$77.5 Calls Sweep (33) near the Ask: 500 @ \$0.95 vs 247 OI; Earnings 4/24 Before Open Ref=\$75.49

Financial news for NVS dated on 2019-04-20: Novartis Says Investigation Underway into Death of 6-Month Old Patient in Trial of Experimental Gene Therapy for Spinal Muscular Atrophy

Financial news for NVS dated on 2019-04-18: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for NVS dated on 2019-04-17: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for NVS dated on 2019-04-17: The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO

Financial news for NVS dated on 2019-04-16: Novartis' AveXis Highlights Interim Data From Phase 3 STRIVE Trial Of Zolgensma In Spinal Muscular Atrophy Type-1 'showed prolonged event-free survival, an early and rapid increase in CHOP-INTEND scores and significant milestone achievement'

Financial news for NVS dated on 2019-04-16: Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.

Financial news for NVS dated on 2019-04-16: The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

Financial news for NVS dated on 2019-04-15: Novartis Announces FDA Filing Acceptance And Priority Review Of Brolucizumab (RTH258) For Patients With Wet AMD

Financial news for NVS dated on 2019-04-12: The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug

Financial news for NVS dated on 2019-04-11: The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

Financial news for NVS dated on 2019-04-11: Novartis' Sandoz Announces Deal with Shionogi for Commercialization of Opioid Induced Constipation Treatment

Financial news for NVS dated on 2019-04-10: Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds

Financial news for NVS dated on 2019-04-10: Second Time's The Charm For Amgen As FDA OKs Bone-Building Osteoporosis Drug

Financial news for NVS dated on 2019-04-10: Benzinga's Top Upgrades, Downgrades For April 10, 2019

Financial news for NVS dated on 2019-04-10: Q1 Cannabis Wholesale Report: Best-Selling Brands And Products, Pharma, CBD And Interstate Commerce

Financial news for NVS dated on 2019-04-10: Morgan Stanley Downgrades Novartis to Underweight

Financial news for NVS dated on 2019-04-10: 46 Biggest Movers From Yesterday

Financial news for NVS dated on 2019-04-10: Morgan Stanley Downgrades Novartis to Underweight from Equal Weight; Lowers Price Target to SFR 80 from SFR 88

Financial news for NVS dated on 2019-04-09: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NVS dated on 2019-04-09: The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing

Financial news for NVS dated on 2019-04-09: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NVS dated on 2019-04-09: Novartis shares are trading lower after the company spun off Alcon into an independent publicly traded company.

Financial news for NVS dated on 2019-04-09: Alcon Begins Trading as Independent, Publicly Traded Company

Financial news for NVS dated on 2019-04-05: The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership

Financial news for NVS dated on 2019-04-04: Novartis Announces That There Is A Legal Dispute With Amgen Regarding Collaboration Agreements In Field Of Migraine

Financial news for NVS dated on 2019-04-03: The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

Financial news for NVS dated on 2019-04-03: Sandoz Resubmits Biosimilar Pegfilgrastim Application to FDA

Financial news for NVS dated on 2019-04-02: Bank Of America Reiterates Buy On Novartis As Firm Foresees 'expansion driven by Novartis's continued metamorphosis into a focused innovative biopharma story with a strong new product cycle and multiple pipeline catalysts in 19E'

Financial news for NVS dated on 2019-04-02: The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

Financial news for NVS dated on 2019-04-02: Novartis Cosentyx Approved in China for Psoriasis Patients

Financial news for NVS dated on 2019-04-01: Novartis Announces \$1.575B Acquisition Of IFM Tre

Financial news for NVS dated on 2019-04-01: For Cannabis Industry Investment, 2018 Was Terrific But 2019 Looks Even Better

Financial news for NVS dated on 2019-04-01: 5 Stocks To Watch For April 1, 2019

Financial news for NVS dated on 2019-04-01: Novartis Adds Clinical and Preclinical Anti-inflammatory Programs to Portfolio with Acquisition of IFM Tre

Financial news for NVS dated on 2019-04-01: Novartis to Acquire IFM Therapeutics for \$310M Upfront; Up to \$1.265B in Milestone Payments

Financial news for NVS dated on 2019-03-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for NVS dated on 2019-03-29: The Daily Biotech Pulse: Safety Board

Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead

Financial news for NVS dated on 2019-03-28: The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO

Financial news for NVS dated on 2019-03-27: 6 Gene Therapy M&A Targets On The Radar

Financial news for NVS dated on 2019-03-27: FDA Approves Novartis Drug To Treat More Severe Form Of Multiple Sclerosis

Financial news for NVS dated on 2019-03-27: The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO

Financial news for NVS dated on 2019-03-27: Novartis Announces FDA Approval for Mayzent to Treat Secondary Progressive MS with Active Disease

Financial news for NVS dated on 2019-03-26: The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Financial news for NVS dated on 2019-03-26: Novartis Announces Kymriah Gets Approval as First Car-T therapy in Japan

Financial news for NVS dated on 2019-03-25: Sandoz Has Exclusively Launched Generic Version Of United Therapeutics Remodulin, Treprostinil

Financial news for NVS dated on 2019-03-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for NVS dated on 2019-03-22: Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'

Financial news for NVS dated on 2019-03-22: Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo

Financial news for NVS dated on 2019-03-22: The Daily Biotech Pulse: Immuteq Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback

Financial news for NVS dated on 2019-03-22: Novartis Plans For Alcon Spin-off On April 9, 2019

Financial news for NVS dated on 2019-03-18: Novartis Unit Alcon Announces Acquisition of PowerVision for \$285M Plus Potential Milestones

Financial news for NVS dated on 2019-03-15: The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA

Financial news for NVS dated on 2019-03-14: Tilray Adds Former Goldman Sachs Managing Director To Senior Management Team

Financial news for NVS dated on 2019-03-06: Top 15 Most-Volatile Stocks For Wed., Mar. 6, 2019 Via Benzinga's Securities Lending Volatility Index Powered By Tidal Markets

Financial news for NVS dated on 2019-03-06: Tilray Harvests Medical Cannabis In Portugal, Ramps European Business

Financial news for NVS dated on 2019-03-05: Piper Jaffray: Tilray, GW Pharma Are Early Leaders In Medical Cannabis

Financial news for NVS dated on 2019-03-05: Novartis Chairman Says 33% Stake In Roche Is Strategic, Says Expects To Double Sales In China Over Next 5 Years

Financial news for NVS dated on 2019-03-05: Novartis Chair Says Cell, Gene Therapy Could Make Up 10-15% Of Overall Portfolio In 10 Years

Financial news for NVS dated on 2019-03-05: Novartis Chair Does Not 'Rule Out Anything On Sandoz'

Financial news for NVS dated on 2019-03-05: The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings

Financial news for NVS dated on 2019-03-05: Novartis Cosentyx Shows Superior Improvements In Psoriasis Patients' Quality Of Life vs Janssen's Il-23 Stelara

Financial news for NVS dated on 2019-03-04: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for NVS dated on 2019-03-04: Novartis Data Confirm Rapid Response And High Efficacy Of Cosentyx In Psoriasis Patients For First Time In China; 87% of



Patients Who Received Cosentyx 300mg Achieved Clear Or Almost Clear Skin During First 16 Weeks Of Treatment

Financial news for NVS dated on 2019-03-03: Barron's On: Pharma's Big Hope

Financial news for NVS dated on 2019-02-27: Cohen Says Drugmaker Novartis Wanted Cohen To Lobby For Them But He Refused

Financial news for NVS dated on 2019-02-27: Blackstone Life Sciences, Novartis Launch Anthos Therapeutics to Develop Innovative Medicines for Cardiovascular Disease

Financial news for NVS dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for NVS dated on 2019-02-25: Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Financial news for NVS dated on 2019-02-25: Akcea Announces Novartis Exercised Option to License AKCEA-APO(a)-LRx; Akcea, Ionis to Equally Split \$150M License Fee

Financial news for NVS dated on 2019-02-22: Amarin Shares Spike ~5% Over Last Min. Amid Unconfirmed Takeover Chatter In Name

Financial news for NVS dated on 2019-02-20: The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering

Financial news for NVS dated on 2019-02-20: Mitsubishi Tanabe Pharma Says Novartis Pharma Has Filed Request For Arbitration Against It

Financial news for NVS dated on 2019-02-15: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for NVS dated on 2019-02-14: The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial

Financial news for NVS dated on 2019-02-13: A Peek Into The Markets: US Stock Futures Gain Ahead Of Earnings, Inflation Data

Financial news for NVS dated on 2019-02-13: Clinigen to Acquire US Rights to Novartis' Cancer Drug Proleukin for \$210M

Financial news for NVS dated on 2019-02-06: Novartis Ag CEO Says Trying To Limit Our Net Price Increases To Medical Inflation, Or Less

Financial news for NVS dated on 2019-02-03: The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Financial news for NVS dated on 2019-02-01: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

Financial news for NVS dated on 2019-01-30: The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance

Financial news for NVS dated on 2019-01-30: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVS dated on 2019-01-30: Earnings Scheduled For January 30, 2019

Financial news for NVS dated on 2019-01-28: Novartis Data Show Psoriasis Patients Treated With Cosentyx Reported Improvements In Quality Of Life Measures As Early As Week 4

Financial news for NVS dated on 2019-01-25: Novartis UK Says Building Increased Inventories Across Portfolio Of Medicines In UK Ahead Of Brexit

Financial news for NVS dated on 2019-01-23: Philogen S.p.a. Entered Collaboration And License Agreement With Novartis; No Financial Details Of Agreement Were Released

Financial news for NVS dated on 2019-01-17: The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

Financial news for NVS dated on 2019-01-16: Novartis Division, Sandoz, Announces Launch Of SYMJEPI Epinephrine Injection In US; Sandoz Is A Partner Of Adamis Pharmaceuticals

Financial news for NVS dated on 2019-01-10: Novartis Response To Nice Appraisal Consultation Document For Aimovig For The Prevention Of Migraine

Financial news for NVS dated on 2019-01-08: The Daily Biotech Pulse: Amgen Slashes

Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase

Financial news for NVS dated on 2019-01-08: Novartis Investigational Therapy Crizanlizumab Receives FDA Breakthrough Therapy Designation For The Prevention Of Vaso-occlusive Crises In Sickle Cell Disease

Financial news for NVS dated on 2018-12-28: UPDATE: Cellular Biomedicine Says Novartis Seeks To Entrust Co.'s China Unit To Perform Certain Processing, Supply, Managerial Aspects Of Certain Products In China Region

Financial news for NVS dated on 2018-12-28: Cellular Biomedicine 8-K Shows Toll Manufacturing, Supply Deal With Beijing Novartis Pharma

Financial news for NVS dated on 2018-12-21: Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Financial news for NVS dated on 2018-12-21: A Peek Into The Markets: US Stock Futures Down Ahead Of GDP Report

Financial news for NVS dated on 2018-12-21: Novartis Receives EC Approval for Expanded Indication for Kisqali

Financial news for NVS dated on 2018-12-20: Novartis Reports Offer To Purchase CellforCure, No terms Disclosed

Financial news for NVS dated on 2018-12-20: Endocyte Stockholders Approve Merger Agreement With Novartis AG; Novartis Will Acquire Co. For \$24/Share

Financial news for NVS dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for NVS dated on 2018-12-19: Nearly 30 Drug Companies, Including Novartis, Bayer, Amgen, Biogen Notified Payers In California Of Plans To Raise Prices In January

Financial news for NVS dated on 2018-12-19: Intec Pharma Sends Letter To Shareholders

Financial news for NVS dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for NVS dated on 2018-12-19: UPDATE: AVEO/Novartis Deal Provides Novartis Will Make 1-Time \$2.3M Payment To AVEO On Or Before Jan. 2, 2019, Provide AV380 Drug Supply To Co. At No Charge

Financial news for NVS dated on 2018-12-19: UPDATE: AVEO AV380 Agreement With Novartis Provides For Continued Transfer To AVEO Of Preclinical, Technical, Manufacturing, Other Data, Materials Developed By Novartis For Program

Financial news for NVS dated on 2018-12-19: AVEO Pharma 8-K Shows Deal With Novartis For AVEO's AV380 Program

Financial news for NVS dated on 2018-12-19: Novartis Unit Sandoz Enters Commercialization and Supply Agreement for Insulin Biosimilars

Financial news for NVS dated on 2018-12-19: Novartis Announces Alcon Acquires Tear Film Innovations; Financial Terms Not Disclosed

Financial news for NVS dated on 2018-12-19: Anji Pharmaceuticals Licenses Regional Rights to a Clinical Asset from Novartis for \$2M

Financial news for NVS dated on 2018-12-18: Cowen: What The Sandoz Deal Means For Tilray Investors

Financial news for NVS dated on 2018-12-18: Tilray Shares Jump On The Back Of Novartis Partnership

Financial news for NVS dated on 2018-12-18: Tilray shares are trading higher after the company announced a partnership with German pharmaceutical company Sandoz to distribute non-smokable medical cannabis products.

Financial news for NVS dated on 2018-12-18: Tilray Signs Global Collaboration Agreement With Generic Pharmaceutical Company Sandoz AG

Financial news for NVS dated on 2018-12-17: Endocyte's Previously Announced Merger With Novartis Cleared by the Committee on Foreign Investment in the United States

Financial news for NVS dated on 2018-12-14: Fund Flow Data Suggests Traders Are Betting On Emerging Markets Heading Into 2019

Financial news for NVS dated on 2018-12-13: The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen

Financial news for NVS dated on 2018-12-13: Novartis Receives EC Approval for Self-administration of Xolair Across All Indications

Financial news for NVS dated on 2018-12-12: Novartis Exec On J&J Call To Discuss TREMFYA Says 'We believe data from ECLIPSE trial...will have limited clinical relevance'

Financial news for NVS dated on 2018-12-11: Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

Financial news for NVS dated on 2018-12-11: Jefferies Assumes Novartis at Buy, Announces Price Target \$105

Financial news for NVS dated on 2018-12-11: The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Financial news for NVS dated on 2018-12-10: 5 Biotech Companies To Keep On Your M&A Watchlist For 2019

Financial news for NVS dated on 2018-12-08: Novartis Says Data Demonstrates Consistent Efficacy And Tolerability Of Kisqali Combination Therapy In Hr+/her2- Advanced Breast Cancer In Patients With Difficult-to-treat Visceral Disease

Financial news for NVS dated on 2018-12-07: Novartis Shares Tick Lower Over Last Few Mins; Hearing Barclays Downgraded From Equalweight To Underweight

Financial news for NVS dated on 2018-12-07: Novartis to Launch Adamis' EpiPen Rival in U.S. in 2019

Financial news for NVS dated on 2018-12-06: QIAGEN Reports New Collaboration For Development Of Companion Diagnostics From Novartis Drug Candidate

Financial news for NVS dated on 2018-12-06: UPDATE: Intellia To Receive \$10M 1-Time Payment Related To Expansion Of Collab Deal With Novartis

Financial news for NVS dated on 2018-12-06: Intellia Therapeutics, Novartis Expand Existing Cell Therapy Collab To Include Ex Vivo Development Of Cell Therapies Using Certain Ocular Stem Cells

Financial news for NVS dated on 2018-12-06: Intec Pharma Reports Accordion Pill To Continue To Clinical PK Study Under Feasibility, Option Deal With Novartis

Financial news for NVS dated on 2018-12-04: Novartis Advances Ligelizumab in Urticaria to Phase III on Basis of Strong Phase II Head-to-head Data

Financial news for NVS dated on 2018-12-03: Novartis Announces FDA Filing Acceptance and Priority Review of AVXS-101 One-time Treatment Designed to Address Genetic Root Cause of SMA Type 1

Financial news for NVS dated on 2018-12-03: Novartis' Advanced Accelerator Applications Signs Exclusive Option and License Agreement with FUJIFILM Toyama Chemical to Develop and Commercialize Radiolabeled FF-10158 for Oncology Indications

Financial news for NVS dated on 2018-12-02: Novartis Announces Real-world Data Show Promacta Improves Outcomes for ITP Patients vs Other Second-line Therapies

Financial news for NVS dated on 2018-12-02: Novartis Announces Real-world Data Show Revolade Improves Outcomes For Itp Patients Compared To Other Second-line Therapies at ASH 2018

Financial news for NVS dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for NVS dated on 2018-11-29: Novartis Announces EU Approval of Gilenya for Children, Adolescents with MS

Financial news for NVS dated on 2018-11-27: Novartis Announces Sandoz Receives Eighth EC Approval for Biosimilar with Ziextenzo

Financial news for NVS dated on 2018-11-27: Novartis Announces First Capital Markets Day Ahead of Spinoff of Alcon

Financial news for NVS dated on 2018-11-26: Benzinga's Top Upgrades, Downgrades For November 26, 2018

Financial news for NVS dated on 2018-11-26: Cowen & Co. Upgrades Novartis to

Outperform, Announces \$100 Price Target

Financial news for NVS dated on 2018-11-23: Express Scripts' CMO Says \$4M for Novartis' Gene Therapy is Too Much

Financial news for NVS dated on 2018-11-23: Novartis Announces Landmark EU Approval For One-time Gene Therapy Luxturna(r) To Restore Vision In People With Rare Inherited Retinal Disease

Financial news for NVS dated on 2018-11-20: FDA Warns About Severe Worsening Of Multiple Sclerosis After Stopping GILENYA

Financial news for NVS dated on 2018-11-20: The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

Financial news for NVS dated on 2018-11-20: Sandoz, Pear Therapeutics Announce Launch of reSET for Treatment of Patients with Substance Use Disorder

Financial news for NVS dated on 2018-11-19: Novartis Is Set For 'Higher Returns And Growth,' Goldman Sachs Says In Upgrade

Financial news for NVS dated on 2018-11-19: Benzinga's Top Upgrades, Downgrades For November 19, 2018

Financial news for NVS dated on 2018-11-19: Goldman Sachs Upgrades Novartis to Conviction Buy

Financial news for NVS dated on 2018-11-19: Goldman Sachs Upgrades Novartis to Buy from Neutral;

Financial news for NVS dated on 2018-11-16: Novartis Reports FDA Approved Promacta For First-Line SAA, Granted Breakthrough Therapy Designation For Added New Indication For Low Platelet Counts In People Exposed To Radiation

Financial news for NVS dated on 2018-11-16: Novartis Reports Receive Positive CHMP Opinion For Expansion Of Kisqali Combo Therapy For Women With HR+/HER2-Locally Advance, Metastatic Breast Cancer

Financial news for NVS dated on 2018-11-15: Novartis Says Not Planning Split-off of Sandoz

Financial news for NVS dated on 2018-11-14: Hearing Novartis AG Has Approached Horizon Pharma With \$31/Share Takeover Bid; Unconfirmed

Financial news for NVS dated on 2018-11-11: Novartis Says Study Supports Entresto as Foundational HFREF Therapy and in-hospital Initiation in Appropriate Stabilized Heart Failure Patients

Financial news for NVS dated on 2018-11-11: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for NVS dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for NVS dated on 2018-11-05: Novartis Option Alert: Dec 21 \$90 Calls Sweep (2) above Ask!: 650 @ \$1.875 vs 7748 OI; Ref=\$88.85

Financial news for NVS dated on 2018-11-05: Novartis Provides R&D Update; Says Cosentyx Expected to Be Co' Largest Drug Next Year; Mayzent Expected to Launch in Q1 2019

Financial news for NVS dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for NVS dated on 2018-11-01: Novartis Receives Health Canada Approval For The Combination Therapy Of TAFINLAR Plus MEKINIST For Adjuvant Treatment Of Patients With BRAF V600 Mutation Melanoma

Financial news for NVS dated on 2018-11-01: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

Financial news for NVS dated on 2018-11-01: Novartis Has Applied To Appeals Court Following Judicial Review On Clinical Commissioning Group Policy Related To Routine Use Of Unlicensed Medicine On National Health Service

Financial news for NVS dated on 2018-10-29: Novartis, Pfizer Announce Clinical Collaboration to Advance Treatment of NASH

Financial news for NVS dated on 2018-10-27: The Week Ahead In Biotech: Conferences,

PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for NVS dated on 2018-10-26: The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

Financial news for NVS dated on 2018-10-26: Novartis Receives Approval for Cosentyx Label Update in Europe to Include Dosing Flexibility in Psoriatic Arthritis

Financial news for NVS dated on 2018-10-25: Compact Imaging Collaborates With Global Pharma To Accelerate Development Of Home Monitor For Age-Related Macular Degeneration And Diabetic Retinopathy

Financial news for NVS dated on 2018-10-22: 11 Stocks That Moved From ESMO 2018

Financial news for NVS dated on 2018-10-22: Novartis Announces COMBI-AD Study of Tafenlar + Mekinist Continues to Demonstrate Relapse Free Survival Benefit in Patients with BRAF V600-mutant Stage III Melanoma at ESMO 2018

Financial news for NVS dated on 2018-10-19: Novartis Reports Phase 2 GEOMETRY Mono-1 Trial Of Investigational INC280 Showed 'overall response rate of 72%, 39.1%, respectively, in treatment-naive, previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer'

Financial news for NVS dated on 2018-10-19: The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut

Financial news for NVS dated on 2018-10-19: 50 Biggest Movers From Yesterday

Financial news for NVS dated on 2018-10-19: Novartis Announces Presentation of New Lutathera Netter-1 Data at ESMO Demonstrating Significant Improvement in PFS Regardless of Baseline Liver Tumor Burden

Financial news for NVS dated on 2018-10-18: Mid-Afternoon Market Update: NASDAQ Down 2.3%; Textron Shares Fall After Q3 Results

Financial news for NVS dated on 2018-10-18: 41 Stocks Moving In Thursday's Mid-Day Session

Financial news for NVS dated on 2018-10-18: Mid-Day Market Update: Down Down Over 300 Points; Endocyte Shares Spike Higher

Financial news for NVS dated on 2018-10-18: Mid-Morning Market Update: Markets Open Lower; Philip Morris Profit Beats Estimates

Financial news for NVS dated on 2018-10-18: Novartis To Buy Endocyte In \$2.1B Deal

Financial news for NVS dated on 2018-10-18: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for NVS dated on 2018-10-18: The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs

Financial news for NVS dated on 2018-10-18: Endocyte shares are trading higher after Novartis announced it would buy Endocyte for \$24/Share.

Financial news for NVS dated on 2018-10-18: Earnings Scheduled For October 18, 2018

Financial news for NVS dated on 2018-10-18: Endocyte Enters Into Agreement to be Acquired by Novartis for \$24/Share

Financial news for NVS dated on 2018-10-17: Novartis Q3 Earnings Preview

Financial news for NVS dated on 2018-10-16: Benchmark Out Bullish On 'Well-Positioned' Tilray Ahead of Canada's Cannabis Legalization

Financial news for NVS dated on 2018-10-16: Novartis Announces 5-year Data in Psoriatic Arthritis and Ankylosing Spondylitis Reinforces Cosentyx Leadership in Spondyloarthritis

Financial news for NVS dated on 2018-10-14: 4 Major Market Opportunities For The Cannabis Industry

Financial news for NVS dated on 2018-10-14: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for NVS dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for NVS dated on 2018-10-10: Novartis Highlights New Data From First

Direct Head-To-Head Trial Showing Superior Efficacy Of Gilenya Over Cpaxone In Patients With Relapsing Remitting Multiple Sclerosis

Financial news for NVS dated on 2018-10-10: The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares

Financial news for NVS dated on 2018-10-09: Novartis Highlights Data Published In American Journal Of Hematology On SEGl01 For Sickle Cell Pain Crises: Data Showed 'more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis...'

Financial news for NVS dated on 2018-10-08: Novartis Announces FDA and EMA Filing Acceptance of Siponimod

Financial news for NVS dated on 2018-10-03: The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

Financial news for NVS dated on 2018-10-03: Novartis Licenses Three Novel Anti-infective Programs to Boston Pharmaceuticals

Financial news for NVS dated on 2018-09-25: Novartis Sees Exiting Its Grimsby, UK Site By End Of 2020, Sees 395 Employees Impacted

Financial news for NVS dated on 2018-09-25: Novartis CEO Says Up to 400 Jobs to be Cut in UK, Unrelated to Brexit

Financial news for NVS dated on 2018-09-22: Novartis Announces New Analysis of Phase Iii Brolucizumab Data Reinforces Superior Reduction of Retinal Fluid, a Key Marker of Disease Activity in nAMD

Financial news for NVS dated on 2018-09-22: Novartis to File for New Lucentis Indication in Retinopathy of Prematurity; Says Rainbow Phase III Study Marginally Missed Statistical Significance for Primary Endpoint

Financial news for NVS dated on 2018-09-21: Novartis Reports Positive CHMP Opinion For 1-Time Gene Therapy Luxturna For Treatment Of Children, Adults With Multiple Sclerosis

Financial news for NVS dated on 2018-09-19: Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish Initiation

Financial news for NVS dated on 2018-09-17: Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug

Financial news for NVS dated on 2018-09-17: Teva's Preventive Migraine Treatment Approved By FDA

Financial news for NVS dated on 2018-09-13: The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

Financial news for NVS dated on 2018-09-11: Benzinga's Top Upgrades, Downgrades For September 11, 2018

Financial news for NVS dated on 2018-09-11: Citigroup Upgrades Novartis to Buy

Financial news for NVS dated on 2018-09-11: Alcon Confirms Commitment to Switzerland Ahead of Proposed Spinoff from Novartis

Financial news for NVS dated on 2018-09-10: Bank of America Upgrades Novartis to Buy

Financial news for NVS dated on 2018-09-06: New Class of Migraine Drug Creates Four-Way Pharma Development Race

Financial news for NVS dated on 2018-09-06: Novartis Says They Face \$70M Impairment Related To Sale Of Assets To India's Aurobindo, Will Confirm At Q3 Earnings Report On Oct. 18th

Financial news for NVS dated on 2018-09-06: Benzinga Pro's 5 Stocks To Watch Today

Financial news for NVS dated on 2018-09-06: The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data

Financial news for NVS dated on 2018-09-06: Novartis Receives Health Canada Approval of its CAR-T Cell Therapy, Kymriah

Financial news for NVS dated on 2018-09-06: Aurobindo Pharma Unit to Buy Commercial Operations, 3 Manufacturing Facilities in U.S. from Novartis' Sandoz Unit

Financial news for NVS dated on 2018-09-05: UK's NHS Makes Novartis Cancer Cell Therapy Available to Children with Aggressive Leukaemia

Financial news for NVS dated on 2018-09-01: Novartis Chairman Says Co to Streamline Production in Response to Falling Drug Prices in U.S.

Financial news for NVS dated on 2018-08-31: Midatech Announces Interim Results From Proof Of Concept Exploratory Study For Oncology Candidate MTD201; Co. Says Interim Data For Establishes Favorable Clinical Profile Compared To Reference Product, Novartis' SLAR

Financial news for NVS dated on 2018-08-29: The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent

Financial news for NVS dated on 2018-08-29: Novartis Publishes A Media Release Saying Alcon Announces Voluntary Global Market Withdrawal Of CyPass Micro-Stent For Surgical Glaucoma

Financial news for NVS dated on 2018-08-29: EC Approves Novartis Combination Therapy Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600 Mutation-Positive Melanoma

Financial news for NVS dated on 2018-08-23: The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero

Financial news for NVS dated on 2018-08-23: SOLAR-1 trial of Novartis Investigational Alpha-specific PI3K Inhibitor BYL719 (alpelisib) Meets Primary Endpoint in HR+/HER2-Advanced Breast Cancer with PIK3CA Mutation

Financial news for NVS dated on 2018-08-20: Healint Announces Research Showing Increase in Anxiety and Depression with Higher Migraine Frequency Among Tens of Thousands of US Migraine Patients

Financial news for NVS dated on 2018-08-13: Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech

Financial news for NVS dated on 2018-08-01: Laekna Acquires Exclusive Worldwide Rights to Two Clinical Stage Oncology Assets; Terms Not Disclosed

Financial news for NVS dated on 2018-07-30: European Commission Has Approved Novartis' Aimovig For Prevention In Migraine In Adults Experiencing Migraines 4+ Times/Day

Financial news for NVS dated on 2018-07-21: Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus

Financial news for NVS dated on 2018-07-20: Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

Financial news for NVS dated on 2018-07-19: Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

Financial news for NVS dated on 2018-07-19: Barclays Upgrades Novartis to Equal-Weight

Financial news for NVS dated on 2018-07-19: 'Thank you to Novartis for not increasing your prices on prescription drugs. Likewise to Pfizer. We are making a big push to actually reduce the prices, maybe substantially, on prescription drugs.' -Tweet From Pres Trump

Financial news for NVS dated on 2018-07-19: MorphoSys, Galapagos Sign Global License Agreement for MOR106 with Novartis

Financial news for NVS dated on 2018-07-18: Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares

Financial news for NVS dated on 2018-07-18: Novartis Shares Up 1.7% Premarket Following Q2 Earnings: GAAP EPS \$0.84, After-Tax Profit \$7.77B, Sales \$13.16B vs \$12.94B Estimate

Financial news for NVS dated on 2018-07-18: Novartis Says It Will Not Hike Drug Prices In The U.S.

Financial news for NVS dated on 2018-07-18: Earnings Scheduled For July 18, 2018

Financial news for NVS dated on 2018-07-17: Earnings Outlook For Novartis

Financial news for NVS dated on 2018-07-13: Novartis Says it Disagrees With U.S. Senators Conclusion That Co. Issued A Misleading Public Statement About Contract With Cohen, Says It Only Had One Meeting With Cohen March 1, 2017

Financial news for NVS dated on 2018-07-12: Novartis to Shut Antibacterial, Antiviral Research Operations in San Francisco Area, Cut 140 Job

Financial news for NVS dated on 2018-07-10: Novartis, Roche, Gilead Have Cancelled Some Drug Price Increases

Financial news for NVS dated on 2018-07-09: Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports

Financial news for NVS dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for NVS dated on 2018-07-03: 44 Biggest Movers From Yesterday

Financial news for NVS dated on 2018-07-02: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for NVS dated on 2018-07-02: Adamis Pharma Soars 60% Amid New Partnership With Novartis To Commercialize Symjepi

Financial news for NVS dated on 2018-07-01: Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement with Sandoz for Symjepi

Financial news for NVS dated on 2018-06-30: The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus

Financial news for NVS dated on 2018-06-29: Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

Financial news for NVS dated on 2018-06-29: EU Recommends Approval Of Novartis Kymriah, Recommends Approval Of Utlragenyx Drug For Treatment Of Sly Syndrome, Recommends Approval Of Yescarta

Financial news for NVS dated on 2018-06-29: EMA Has Recommended Approval For Novartis's Kymriah

Financial news for NVS dated on 2018-06-29: Novartis CEO Says Alcon will be 100% Spinoff to Shareholders; Will Take 9 Months to Complete Spinoff

Financial news for NVS dated on 2018-06-28: Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig, Results From a One-Year Study of Efficacy and Safety of Aimovig in Chronic Migraine and Data From a Three-Year Analysis

Financial news for NVS dated on 2018-06-28: Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking

Financial news for NVS dated on 2018-06-28: Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut

Financial news for NVS dated on 2018-06-25: Everest Medicines Unit Entered Licensing Agreement to Develop Novartis' Novel FGFR4 Kinase Inhibitor, FGF401

Financial news for NVS dated on 2018-06-20: Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading

Financial news for NVS dated on 2018-06-19: Novartis Reports FDA Approval For Inclusion Of New Evidence Cosentyx Inhibits Progression Of Joint Structural Damage At Week 24 vs Placebo

Financial news for NVS dated on 2018-06-15: Novartis Reports Interim Results From I-WISH Study Showed '36% of patients said that having ITP had a high impact on their emotional well-being while 28% of patients had disease symptoms that caused them to miss work'

Financial news for NVS dated on 2018-06-12: Rovi Reports Deal With Novartis Unit Sandoz For Distribution, Marketing Of Enoxaparin Biosimilar

Financial news for NVS dated on 2018-06-11: REGENXBIO Reports Received \$100M Accelerated License Payment Due To Purchase Of AveXis By Novartis

Financial news for NVS dated on 2018-06-11: Crispr Therapeutics Falls As Studies Suggest Possible Cancerous Side Effect

Financial news for NVS dated on 2018-06-08: Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More

Financial news for NVS dated on 2018-06-03: The Week Ahead In Biotech: ASCO



## Presentations Dominate The Headlines

Financial news for NVS dated on 2018-06-01: Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

Financial news for NVS dated on 2018-06-01: EMA Has Recommended Approval Of Amgen, Novartis Migraine Drug Erenumab

Financial news for NVS dated on 2018-05-30: Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immuteq Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Financial news for NVS dated on 2018-05-30: Novartis Announces FDA Expedites Review of Promacta for First-line Severe Aplastic Anemia

Financial news for NVS dated on 2018-05-29: Benzinga's Top Upgrades, Downgrades For May 29, 2018

Financial news for NVS dated on 2018-05-29: The Market In 5 Minutes: Italy, ASCO, Roku And More

Financial news for NVS dated on 2018-05-29: A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Financial news for NVS dated on 2018-05-29: HSBC Downgrades Novartis to Hold

Financial news for NVS dated on 2018-05-25: Novartis Gets Approval For Remicade Biosimilar In Europe

Financial news for NVS dated on 2018-05-25: Benzinga's Top Upgrades, Downgrades For May 25, 2018

Financial news for NVS dated on 2018-05-25: Credit Suisse Upgrades Novartis to Neutral

Financial news for NVS dated on 2018-05-24: Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

Financial news for NVS dated on 2018-05-18: UPDATE: Amgen Shares Up 1.7%, Novartis Up 0.3%; Cos. Late Thurs. Disclosed FDA Approval Of Aimovig For Migraine Treatment

Financial news for NVS dated on 2018-05-18: Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Financial news for NVS dated on 2018-05-17: UPDATE: FDA Offers Guidelines, Background For Reference Listed Drug Access Inquiries, Related To Claim Of Blocking Generic Rivals

Financial news for NVS dated on 2018-05-17: Hearing FDA Names Drugmakers Accused Of Blocking Generic Rivals Including Gilead, Celgene, Novartis

Financial news for NVS dated on 2018-05-17: Novartis Reports Data Which Will Be Presented At ASCO, EHA

Financial news for NVS dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

Financial news for NVS dated on 2018-05-17: REMINDER: Novartis Has FDA PDUFA Date Today for Erenumab

Financial news for NVS dated on 2018-05-16: Ex-Novartis CEO Jimenez Tells Reuters A Novartis Search For Consultants Following The 2016 U.S. Election Resulted In 3rd-Party Referral To Trump's Lawyer Cohen

Financial news for NVS dated on 2018-05-16: 'JUST IN: Novartis top lawyer quits over Cohen payment'-CNN Money

Financial news for NVS dated on 2018-05-15: Novartis Completes Tender Offer for All Outstanding Shares of AveXis

Financial news for NVS dated on 2018-05-14: The Week Ahead: Coindesk Conference, Walmart And Retailers Close Out Earnings Season

Financial news for NVS dated on 2018-05-13: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for NVS dated on 2018-05-11: FDA Announces Approval of Novartis' Gilenya

Financial news for NVS dated on 2018-05-09: 3 Companies Tied Up With Cohen's Shell

Company -- And What They Need From Trump

Financial news for NVS dated on 2018-05-09: 'Trump's lawyer pitched himself as a fixer to Novartis and got paid \$1.2 million'

Financial news for NVS dated on 2018-05-09: DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR, Co. Is Now eligible For Up To \$30M In Milestone Payments, Down From \$43M In Payments Before

Financial news for NVS dated on 2018-05-02: Esperion Shares Plunge After Cholesterol-Lowering Drug's Phase 3 Results Stir Safety Concerns

Financial news for NVS dated on 2018-05-02: Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Financial news for NVS dated on 2018-05-01: Novartis Reports Kymriah Received Second FDA Approval To Treat Appropriate r/r Patients With Large B-Cell Lymphoma

Financial news for NVS dated on 2018-05-01: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Financial news for NVS dated on 2018-05-01: Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

Financial news for NVS dated on 2018-05-01: Novartis Provides Update on Proposed Acquisition of AveXis

Financial news for NVS dated on 2018-04-30: Novartis Reports Received FDA Approval For Tafinlar + Mekinist For Adjuvant Treatment Of BRAF V600-Mutant

Financial news for NVS dated on 2018-04-30: Novartis Reports Phase III Data For Brolucizumab Showed Reliability Of 12-Week Treatment Interval

Financial news for NVS dated on 2018-04-19: Endpoints Reports 'Novartis poaches Bristol-Myers/Amglen vet John Tsai for top drug development post in a \$9B organization'

Financial news for NVS dated on 2018-04-19: Novartis Shares Indicated Higher Premarket; Co. Early Thurs. Reported Q1 Operating Profit \$2.4B, Sales \$12.7B Beats \$12.57B Est.

Financial news for NVS dated on 2018-04-19: 10 Stocks To Watch For April 19, 2018

Financial news for NVS dated on 2018-04-19: Earnings Scheduled For April 19, 2018

Financial news for NVS dated on 2018-04-17: Novartis Commences Tender Offer for AveXis

Financial news for NVS dated on 2018-04-13: Jefferies On Novartis: Co. Could Use ~\$4B Of Proceeds From Sale Of Consumer JV To Fund A Buyback Plan

Financial news for NVS dated on 2018-04-11: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis To Merge With Novartis And More

Financial news for NVS dated on 2018-04-10: Novartis Afinitor DISPERZ Receives FDA Approval to Treat TSC-associated Partial-onset Seizures

Financial news for NVS dated on 2018-04-10: 40 Biggest Movers From Yesterday

Financial news for NVS dated on 2018-04-09: Mid-Afternoon Market Update: Crude Oil Up Over 2%; Therapix Biosciences Shares Spike Higher

Financial news for NVS dated on 2018-04-09: Analyst: AveXis M&A Could Support Interest In Regenxbio

Financial news for NVS dated on 2018-04-09: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for NVS dated on 2018-04-09: Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide

Financial news for NVS dated on 2018-04-09: Chardan Raised Its REGENXBIO Price Target From \$85 to \$90 On News Co.'s Partner, AveXis, Was Bought By Novartis, Believing This Could Support M&A Interest in RGNX & Suggesting 'Consensus is underestimating the impact of AVXS-101 royalties on REGENXBIO'

Financial news for NVS dated on 2018-04-09: Mid-Morning Market Update: Markets Open Higher; Novartis To Acquire AveXis For \$8.7B

Financial news for NVS dated on 2018-04-09: Regenxbio Inc To Receive \$180M From Novartis Takeover Of AveXis Per 2014 Agreement

Financial news for NVS dated on 2018-04-09: Why The Novartis-AveXis Deal Is Good News For The Gene Therapy Space

Financial news for NVS dated on 2018-04-09: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for NVS dated on 2018-04-09: A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Financial news for NVS dated on 2018-04-09: AveXis Announces Agreement to be Acquired by Novartis for \$8.7B; \$218/Share

Financial news for NVS dated on 2018-04-06: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for NVS dated on 2018-04-05: 8 Biotech Stocks With Clinical Trial Outcomes In April

Financial news for NVS dated on 2018-04-04: Novartis Announces JAMA Cardiology Publication of Data Showing Entresto improves Physical and Social Activity in HFrEF patients versus enalapril

Financial news for NVS dated on 2018-04-03: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for NVS dated on 2018-04-02: On World Autism Awareness Day, A Look At Biotech Firms With Potential Treatments In The Pipeline

Financial news for NVS dated on 2018-03-30: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences

Financial news for NVS dated on 2018-03-28: Hearing Dealreporter Said Novartis Is Weighing A Bid For Incyte

Financial news for NVS dated on 2018-03-27: GlaxoSmithKline To Buy Novartis' Stake in Consumer Health Care JV For \$13 Billion

Financial news for NVS dated on 2018-03-27: Novartis to Sell Stake in Consumer Healthcare JV to GSK for \$13B

Financial news for NVS dated on 2018-03-22: Novartis Announces Tasigna Approved By FDA As Treatment For Children With Rare Form Of Leukemia

Financial news for NVS dated on 2018-03-22: Biotech Winners And Losers From Congress' Latest Funding Bill

Financial news for NVS dated on 2018-03-07: Novartis Expands Alliance with Science 37 to Advance Virtual Clinical Trials Program

Financial news for NVS dated on 2018-03-01: Novartis, Pear Therapeutics to Develop Digital Therapeutics for Patients with Schizophrenia, MS

Financial news for NVS dated on 2018-02-28: Regulatory Concern For Celgene's Ozanimod Could Be Big For Arena Pharma, Novartis

Financial news for NVS dated on 2018-02-21: Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges

Financial news for NVS dated on 2018-02-20: Wedbush: Restorbio's Therapy For Aging-Related Diseases Has Best-In-Class Potential

Financial news for NVS dated on 2018-02-19: Novartis CEO Says Drugmaker to become Focused Medicines Company Powered by Data Science and Digital Technologies -Wall Street Journal

Financial news for NVS dated on 2018-02-09: Analyst: Regeneron Is Undervalued By The Street

Financial news for NVS dated on 2018-02-08: The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

Financial news for NVS dated on 2018-02-08: U.S. Regulators Delayed Approval of Generic Version of GSK's Advair by Novartis's Sandoz Unit

Financial news for NVS dated on 2018-02-08: Novartis Receives FDA Approval for Cosentyx Label Update to Include Moderate-to-severe Scalp Psoriasis

Financial news for NVS dated on 2018-02-07: Array's Melanoma Combo Shows Positive Overall Survival Data

Financial news for NVS dated on 2018-01-26: Novartis Reports Advanced Accelerator Applications Received US FDA Approval Of NDA For Lutathera For Treatment Of Somatostatin Receptor Positive GEP-NETs

Financial news for NVS dated on 2018-01-24: Earnings Scheduled For January 24, 2018

Financial news for NVS dated on 2018-01-24: Novartis Incoming CEO Sees No Change to Co's Position on GSK JV, Roche Stake -Reuters

Financial news for NVS dated on 2018-01-23: Pharma M&A Picks Up Momentum

Financial news for NVS dated on 2018-01-23: Teva's Asthma Therapy Reslizumab Fails In Late-Stage Studies

Financial news for NVS dated on 2018-01-22: Novartis completes tender offer for Advanced Accelerator Applications

Financial news for NVS dated on 2018-01-17: Novartis Granted FDA Priority Review for Kymriah for Adults with r/r DLBCL

Financial news for NVS dated on 2018-01-16: Novartis Repeats Sandoz Regulatory Submission for Proposed Biosimilar Adalimumab Accepted by FDA

Financial news for NVS dated on 2018-01-16: Novartis Announces New Data Reinforces Superiority of Cosentyx vs Stelara in Achieving Skin Clearance for Psoriasis Patients

Financial news for NVS dated on 2018-01-03: Novartis Kisqali Received FDA Breakthrough Therapy Designation for Initial Endocrine-Based Treatment in Premenopausal Women With HR+/HER2- Advanced Breast Cancer

Financial news for NVS dated on 2017-12-30: Attention Biotech Investors: Brace For These January PDUFA Events

Financial news for NVS dated on 2017-12-22: Novartis's TASIGNA Approved By FDA

Financial news for NVS dated on 2017-12-22: Novartis' Tassigna Label is Updated to Include How to Stop Treatment

Financial news for NVS dated on 2017-12-22: The Companies That Led 2017's Biotech Rally

Financial news for NVS dated on 2017-12-20: 3 Biotech Pipeline Areas To Keep An Eye On In 2018

Financial news for NVS dated on 2017-12-18: Ultragenyx Sells Priority Review Voucher To Novartis for \$130M

Financial news for NVS dated on 2017-12-13: ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

Financial news for NVS dated on 2017-12-13: Novartis Says Is Optimizing Its US Portfolio, Including Sale Or Closure Of Non-Core Products, Refers To Sandoz Generics Unit

Financial news for NVS dated on 2017-12-12: Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use

Financial news for NVS dated on 2017-12-11: Novartis' Crizanlizumab Shows Prolonging Of Time To Patients' First Sickle Cell Pain Crisis In Subgroup Analysis Of SUSTAIN Study

Financial news for NVS dated on 2017-12-06: Novartis Says Kisqali Benefited For Longer Time Until Health-Related QOL Deterioration Vs Those Taking Endocrine Therapy Alone

Financial news for NVS dated on 2017-12-05: Reuters Reporting ACCC Instituted Proceedings Against GlaxoSmithKline and Novartis Consumer Health In Australia

Financial news for NVS dated on 2017-12-05: Advanced Accelerator Application Recommends the \$82/ADS Takeover by Novartis

Financial news for NVS dated on 2017-12-05: Advanced Accelerator Applications Board of Directors Recommends \$3.B All Cash Tender Offer by Novartis

Financial news for NVS dated on 2017-12-05: Medigene Sells U.S. Rights For Veregen To

## Novartis Group's Fougere Pharmaceuticals

Financial news for NVS dated on 2017-12-05: Novartis Canada Announces Rydapt has Been Approved Following Priority Review by Health Canada

Financial news for NVS dated on 2017-12-04: Eli Lilly's Taltz Gets Approval For Label Expansion in US

Financial news for NVS dated on 2017-12-01: Citi Downgrades Regeneron, Citing 'Underappreciated' Risk

Financial news for NVS dated on 2017-11-29: Novartis Highlights Phase 3 STRIVE Data Showing 'significant and sustained efficacy of erenumab in migraine prevention' Will Be Published In NEJM

Financial news for NVS dated on 2017-11-27: Novartis' Ultibro Breezhaler Significantly Improved COPD Patients' Lung Function after Direct Switch from Seretide

Financial news for NVS dated on 2017-11-08: Novartis Announces Positive Results from Phase III Trial of Kisqali Combination Therapy in Premenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer

Financial news for NVS dated on 2017-11-06: 9 Notable Biotechs Presenting At This Year's ASH Meeting

Financial news for NVS dated on 2017-11-06: Pharma Stock Roundup: Pfizer, Teva, Novartis, And More

Financial news for NVS dated on 2017-11-02: Reuters Reports Novartis Could Receive \$1.5B from Sale of Dermatology Portfolio; Hires Centerview as Advisor

Financial news for NVS dated on 2017-11-02: Wall Street's M&A Chatter From November 1: Dunkin Brands, Novartis, Owens & Minor-Halyard Health

Financial news for NVS dated on 2017-11-01: Novartis Buys French Radiopharmaceutical Company

Financial news for NVS dated on 2017-11-01: Novartis Considering Sale Of Its Dermatology Generics Unit

Financial news for NVS dated on 2017-10-31: Novartis Submits Application to FDA for Kymriah in Adult Patients with r/r DLBCL

Financial news for NVS dated on 2017-10-30: Jim Cramer Shares His Thoughts On CSX Corporation, Baozun And More

Financial news for NVS dated on 2017-10-30: Novartis to Acquire Advanced Accelerator Applications for \$41/Share, \$82/ADS

Financial news for NVS dated on 2017-10-28: Novartis Reports PARADIGMS Data show Children, Adolescents with MS had 82% Lower Relapse Rate with Gilenya vs interferon beta-1a

Financial news for NVS dated on 2017-10-27: Novartis/Sandoz Proposed Biosimilar to Neulasta, Pegfilgrastim, Accepted by EMA for Regulatory Review

Financial news for NVS dated on 2017-10-25: Benzinga's Top Upgrades, Downgrades For October 25, 2017

Financial news for NVS dated on 2017-10-25: Barclays Downgrades Novartis AG Common Stock to Underweight

Financial news for NVS dated on 2017-10-24: Earnings Scheduled For October 24, 2017

Financial news for NVS dated on 2017-10-23: 8 Firms To Debut On The Markets This Week

Financial news for NVS dated on 2017-10-23: Novartis Combination Adjuvant Therapy Tafenlar + Mekinist Receives FDA Breakthrough Therapy Designation for Stage III BRAF V600 Mutation-positive Melanoma Patients

Financial news for NVS dated on 2017-10-19: Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug

Financial news for NVS dated on 2017-10-18: What's In The Cards For Novartis This Earnings Season?

Financial news for NVS dated on 2017-10-11: Novartis Decides Not Sell 33% Roche Stake -HandelsZeitung

Financial news for NVS dated on 2017-10-10: 5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

Financial news for NVS dated on 2017-10-06: Novartis Announces Alcon Receives CE Mark for First-of-its-kind AutonoMe Reloaded Intraocular Lens Delivery System with Clareon IOL

Financial news for NVS dated on 2017-09-29: Novartis Shares Unaffected Following Report Argentum Pharma Has Said It Succeeded In Starting Patent Cancellation Trial Against Co.'s Afinitor

Financial news for NVS dated on 2017-09-12: This Analyst Predicts Bullish Growth Outlook For Incyte

Financial news for NVS dated on 2017-09-12: Novartis' Sandoz Division Announces FDA Accepted BLA for Proposed Biosimilar Rituximab

Financial news for NVS dated on 2017-09-10: Novartis Announces Phase III Study Found Adjuvant Tafinlar + Mekinist Reduced Risk of Disease Recurrence by 53% in patients with Resected BRAF V600 Mutation-positive Melanoma

Financial news for NVS dated on 2017-09-09: What Pharmaceuticals Spend On Lobbying To Influence Trump

Financial news for NVS dated on 2017-09-05: Novartis Reports 6.6% Passive Stake in Xoma in 13G

Financial news for NVS dated on 2017-08-30: Novartis Lower Despite FDA Approval For Treatment Of Leukemia

Financial news for NVS dated on 2017-08-30: Novartis Reportedly Sets U.S. Price For KYMRIAH Gene Therapy At \$475K

Financial news for NVS dated on 2017-08-30: FDA Issues Release Highlighting Approval Of Novartis' Kymriah For Form Of ALL

Financial news for NVS dated on 2017-08-30: Novartis Shares Spike Higher Off Session Lows Following Circulation Of FDA.gov Approval For CAR T-Cell Therapy To Treat Certain Children, Young Adults With B-Cell Acute Lymphoblastic Leukemia

Financial news for NVS dated on 2017-08-30: GlaxoSmithKline Recent Pullback Delivers A Healthy Opportunity To Buy

Financial news for NVS dated on 2017-08-28: Adam Feuerstein Tweets: \$GILD should be more worried about \$NVS undercutting CAR-T pricing than any NIH-loving ninny.

Financial news for NVS dated on 2017-08-28: Novartis Announces Phase III CANTOS Study Shows Targeting Inflammation with ACZ885 Reduces Cardiovascular Risk

Financial news for NVS dated on 2017-08-27: Novartis Announces Lancet Report Shows ACZ885 Reduced Lung Cancer Mortality by 77% in CANTOS Study

Financial news for NVS dated on 2017-08-22: U.S. Files Claims Lawsuit Against U.S. Bioservices Over Kickback Relationship With Novartis Which Previously Settled Related Case

Financial news for NVS dated on 2017-08-21: Novartis, Medicines for Malaria Venture Launch Patient Trial in Africa for KAF156 in Multidrug-resistant Malaria

Financial news for NVS dated on 2017-08-18: Lightning Round: Jim Cramer Weighs In On Juno Therapeutics, Halliburton And More

Financial news for NVS dated on 2017-08-17: Democrats On House Committee On Oversight & Govt. Reform Say Launching Into MS Drug Pricing, Committee Send Letters To Biogen, Teva, Sanofi, Roche, Novartis, And Bayer

Financial news for NVS dated on 2017-08-07: Wall Street's M&A Chatter From August 4-7: Acadia Pharma, United Technologies-Rockwell Collins, United Therapeutics

Financial news for NVS dated on 2017-08-04: United Therapeutics Shares Up 7.7% On M&A Chatter; GSK, Gilead, Novartis Said To Be Possibly Considering Deal For Co.

Financial news for NVS dated on 2017-08-04: UK Evening Standard Reports GSK, Gilead, Novartis Could Pay Up to \$200/Share for United Therapeutics

Financial news for NVS dated on 2017-07-26: Reduced Risk, Upcoming Pipeline Inspire Bull Case For Novartis

Financial news for NVS dated on 2017-07-26: Benzinga's Top Upgrades, Downgrades For

July 26, 2017

Financial news for NVS dated on 2017-07-26: Morgan Stanley Upgrades Novartis AG Common Stock to Overweight

Financial news for NVS dated on 2017-07-25: Cryoport Announces a 3 Year Contract with Novartis for Logistics Support

Financial news for NVS dated on 2017-07-21: Novartis Reports Received CHMP Opinion For Rydapt For Newly-Diagnosed FLT3-Mutated Acute Myeloid Leukemia, 3 Types Of Advanced Systemic Mastocytosis

Financial news for NVS dated on 2017-07-20: Watching Novartis Shares As FDA Accepted BLA For AMG-334

Financial news for NVS dated on 2017-07-20: Amgen Reports FDA Accepts Biologics License Application For Aimovig

Financial news for NVS dated on 2017-07-18: Hearing Novartis CEO Joseph Jimenez Said Does Not Know Timing Of Trump Admin.'s Action On Outcomes-Based Pricing Model, Sees Proposal 'This Summer'

Financial news for NVS dated on 2017-07-18: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NVS dated on 2017-07-18: Earnings Scheduled For July 18, 2017

Financial news for NVS dated on 2017-07-17: 4 Sell-Ranked Drug Stocks To Avoid Ahead Of Q2 Earnings

Financial news for NVS dated on 2017-07-16: Prima BioMed Announces Second Milestone Payment for IMP701 Program; Payment Amount from Novartis Not Disclosed

Financial news for NVS dated on 2017-07-14: Novartis Confirms 5-Year data For CoSentyx

Financial news for NVS dated on 2017-07-12: Novartis Shares Spike to \$84 High Following Panel Approval, Now Relatively Unaffected; Shares Of Bristol Myers Fell 1.8%

Financial news for NVS dated on 2017-07-12: FDA Advisory Panel Backs Approval Of Novartis' Pioneering Gene Therapy

Financial news for NVS dated on 2017-07-11: Adam Feuerstein Tweets: The \$NVS CTL019 PDUFA date is Oct. 3. Did we know this? I thought \$NVS was always cagey about exact date. It's in briefing document.

Financial news for NVS dated on 2017-07-10: Novartis Gene Therapy Leukemia Drug Raises Concern To FDA Staff In Review Over Potential To Cause New Malignancies

Financial news for NVS dated on 2017-07-10: Adam Feuerstein Tweets: FDA on \$NVS CAR-T: "The overall effectiveness of this product is not the primary issue for consideration by this Committee.

Financial news for NVS dated on 2017-07-10: Adam Feuerstein Tweets: FDA discussion points for \$NVS CAR-T adcomm center on manufacturing, safety, risk mitigation. One voting question -- benefit-risk.

Financial news for NVS dated on 2017-07-10: Adam Feuerstein Tweets: \$NVS -- CAR-T briefing documents posted --> [fda.gov/AdvisoryCommit...](http://fda.gov/AdvisoryCommit...)

Financial news for NVS dated on 2017-07-05: Benzinga's Top Upgrades, Downgrades For July 5, 2017

Financial news for NVS dated on 2017-07-05: The Market In 5 Minutes

Financial news for NVS dated on 2017-07-05: Credit Suisse Downgrades Novartis AG Common Stock to Underperform

Financial news for NVS dated on 2017-06-27: Adam Feuerstein Tweets: '\$NVS 'A huge win for biology': Trial shows anti-inflammatory drugs may reduce heart disease'

Financial news for NVS dated on 2017-06-26: Attention To Details: Neos' ADHD Portfolio

Financial news for NVS dated on 2017-06-23: How Altimimmune Is Trying To Get Ahead Of A Potentially Fatal 'Flu Pandemic'

Financial news for NVS dated on 2017-06-23: Novartis Kisqali Receives Positive CHMP

Opinion as First-Line Treatment for HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Combination With Any Aromatase Inhibitor

Financial news for NVS dated on 2017-06-22: FDA Approves Novartis Combination Therapy Tafenlar And Mekinist For BRAF V600E Mutant Metastatic Non-small Cell Lung Cancer

Financial news for NVS dated on 2017-06-22: Regeneron Provides Deal Details On Royalty Agreement With Novartis For ACZ885

Financial news for NVS dated on 2017-06-22: Novartis Phase III Study Shows ACZ885 Reduces Cardiovascular Risk in People who Survived Heart Attack

Financial news for NVS dated on 2017-06-20: Novartis +1.4% Premarket @\$82.59; Co Said RTH258 Achieved Primary Efficacy Endpoint of Non-inferiority to Aflibercept

Financial news for NVS dated on 2017-06-15: Hearing FDA Has Accepted Sandoz's Regulatory Submission Related To Generic Version Of Advair Diskus

Financial news for NVS dated on 2017-06-12: Pegfilgrastim To Help Chemotherapy Patients Fails To Clear Regulatory Hurdle; Coherus Receives CRL

Financial news for NVS dated on 2017-06-08: The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired

Financial news for NVS dated on 2017-06-08: Key Reasons BTIG Just Upgraded Kite Pharma

Financial news for NVS dated on 2017-06-07: Novartis Exec Says Latest Data For CTL019 Similar To Results From Rivals' Blood Cancer Trials, Showed Overall Response Rate At 3 Months In Adults Was 45%, 37% Complete Responses

Financial news for NVS dated on 2017-06-07: Adam Feuerstein Tweets: Full response from \$NVS spox on CTL019 manufacturing in JULIET trial. \$KITE

Financial news for NVS dated on 2017-06-07: Kite Pharma Shares Dip Lower Over Last Few Mins, Pullback from Session High As Traders Circulating Word Novartis Has Said Co.'s Manufacturing Improved To 97% In The Last 30 Patients

Financial news for NVS dated on 2017-06-06: Novartis Says FDA Panel Meeting for CTL019 CAR-T Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia Set for Jul. 12

Financial news for NVS dated on 2017-06-04: Novartis Announces Study of Tafenla + Mekinis Demonstrates Durable Survival BenefitaAt Five Years in Patients With Braf Mutation-Positive Metastatic Melanoma #ASCO17

Financial news for NVS dated on 2017-06-02: Jim Cramer Gives His Opinion On Exxon Mobil, Allegiant Travel Company And Novartis AG

Financial news for NVS dated on 2017-06-02: Novartis Presents Updated Data That Reinforce Efficacy, Safety of Kisqal + Letrozole as First-Line Option for HR+/HER2- Advanced or Metastatic Breast Cancer

Financial news for NVS dated on 2017-05-31: From Novartis Investor Event: CEO Jimenez Says There's Been No Change to Plans for Roche Stake

Financial news for NVS dated on 2017-05-31: From Novartis Investor Event: CEO Joseph Jimenez Says Sees Trump Suggesting Proposals on Addressing Drug Prices Within 3 Months

Financial news for NVS dated on 2017-05-30: Monday's Market In 5 Minutes

Financial news for NVS dated on 2017-05-30: 5 Stocks To Watch For May 30, 2017

Financial news for NVS dated on 2017-05-26: Novartis Receives FDA Approval For Expanded Use Of Zykadia In Metastatic NSCLC

Financial news for NVS dated on 2017-05-26: Novartis Reports Received FDA Approval for Expanded Use of Zykadia

Financial news for NVS dated on 2017-05-23: The Current State Of The Breast Cancer Treatment Space

Financial news for NVS dated on 2017-05-19: Novartis Reports Received CHMP Opinion for Zykadia in ALK-Positive Advanced NSCLC

Financial news for NVS dated on 2017-05-16: A Smart Idea Among Europe ETFs

Financial news for NVS dated on 2017-05-15: GlaxoSmithKline to Acquire Novartis's



36.5% stake in GSK Consumer Healthcare -UK Sunday Times

Financial news for NVS dated on 2017-05-08: Novartis Reports Received FDA Approval for Kisqali Femara Co-Pack for Initial Treatment of HR+/HER2- Advanced, Metastatic Breast Cancer

Financial news for NVS dated on 2017-05-08: Analyst: Kite Pharma's CAR-T Patient Death, Stock Selloff Is A Buying Opportunity

Financial news for NVS dated on 2017-05-08: DURECT to get \$20M Payment from a Division of Novartis, Up to \$43M of Development Milestones, Up to \$230M of Sales Milesones

Financial news for NVS dated on 2017-05-07: Barron's Picks And Pans: Amazon, Novartis, Tesla And More

Financial news for NVS dated on 2017-05-04: Novartis Exercises Exclusive Option Agreement with Conatus for Treatment of NASH

Financial news for NVS dated on 2017-05-02: Celyad Grants to Novartis a Non-Exclusive License for Its Allogeneic TCR-Deficient CAR-T Cells Patents; Celyad to Receive Payments of Up to \$96M

Financial news for NVS dated on 2017-04-30: Weed Vs. Opioids: Nontraditional And Traditional Biotech Take On Wall Street, But Who's Winning?

Financial news for NVS dated on 2017-04-28: Novartis Receives FDA Approval For Rydapt In AML And 3 Types of Systemic Mastocytosis

Financial news for NVS dated on 2017-04-25: Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates

Financial news for NVS dated on 2017-04-25: Novartis Shares Up 2+% Premarket as Hearing Report Co. Has Pushed Its M&A Efforts Toward Early-Stage Drugs

Financial news for NVS dated on 2017-04-25: Earnings Scheduled For April 25, 2017

Financial news for NVS dated on 2017-04-24: Amgen Reports Expanded Commercial Collaboration with Novartis for Erenumab in Migraine

Financial news for NVS dated on 2017-04-20: What Would A \$5.8 Billion NIH Cut Look Like? Devastation

Financial news for NVS dated on 2017-04-19: Parvus Therapeutics Reports Exclusive Global License, Collab Deal with Novartis for Development, Commercialization of Lead Nanomedicine to Treat Type 1 Diabetes

Financial news for NVS dated on 2017-04-18: Allergan, Novartis Enter Phase 2b Clinical Trial to Evaluate Use of Allergan's Cenicriviroc, Novartis Lead FXR Agonist to Treat NASH

Financial news for NVS dated on 2017-04-05: Cowen Downgrades Novartis, Strengths 'Now Balance Its Risks'

Financial news for NVS dated on 2017-04-05: TheStreet's Adam Feuerstein Tweets '\$NVS Keeps 'JULIET' Study Results Close as Investors and Rival \$KITE'

Financial news for NVS dated on 2017-04-05: 5 Biggest Price Target Changes For Wednesday

Financial news for NVS dated on 2017-04-05: Benzinga's Top Upgrades, Downgrades For April 5, 2017

Financial news for NVS dated on 2017-04-05: The Market In 5 Minutes

Financial news for NVS dated on 2017-04-05: Cowen & Co. Downgrades Novartis AG To Market Perform, Lowers Price Target To \$77

Financial news for NVS dated on 2017-04-03: Forbes Reporter Matthew Herper Tweets: \$NVS spox: "We are track with our regulatory filings and we will present the data from JULIET at an upcoming medical meeting." \$KITE

Financial news for NVS dated on 2017-04-03: Novartis Drug Combination Tafinlar + Mekinist Receives EU Approval for BRAF V600-positive Advanced NSCLC

Financial news for NVS dated on 2017-03-30: Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'

Financial news for NVS dated on 2017-03-29: Novartis Announces First CAR-T Cell

Therapy BLA for Pediatric and Young Adult Patients with R/R B-cell ALL Granted FDA Priority Review

Financial news for NVS dated on 2017-03-20: UPDATE: Cerulean To Sell Dynamic Tumor Targeting Platform To Novartis For \$6M

Financial news for NVS dated on 2017-03-18: New Analysis Shows Novartis' Entresto Improves Glycemic Control in Reduced Ejection Fraction Heart Failure Patients with Diabetes

Financial news for NVS dated on 2017-03-14: Gilead Looking To Buy Incyte? It Makes Sense

Financial news for NVS dated on 2017-03-13: Novartis Kisqali Receives FDA Approval As First-Line Treatment For HR+/HER2 Metastatic Breast Cancer

Financial news for NVS dated on 2017-03-10: How The Ultra-Wealthy Are Helping Advance Health And Life Sciences

Financial news for NVS dated on 2017-03-06: RBC Hints At Potential M&A For Kite Pharma

Financial news for NVS dated on 2017-03-06: Novartis Division Sandoz Announces Proposed Biosimilar Adalimumab Shown to have Equivalent Efficacy, Similar Safety Profile as Humira

Financial news for NVS dated on 2017-03-02: Synergy's Safety Profile Should Boost Trulance Uptake, Takeover Prospects Remain Favorable

Financial news for NVS dated on 2017-02-24: Carl Icahn's Track Record In Big Pharma

Financial news for NVS dated on 2017-02-23: Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'

Financial news for NVS dated on 2017-02-23: Novartis' Zykadia Gets FDA Priority Review for First-line Use in Patients with ALK+ Metastatic NSCLC

Financial news for NVS dated on 2017-02-21: Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?

Financial news for NVS dated on 2017-02-16: Ionis, Akcea Close on Strategic Collaboration with Novartis to Develop and Commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx, Will Pay \$75M Up-Front Payment

Financial news for NVS dated on 2017-02-15: Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers

Financial news for NVS dated on 2017-01-31: A District Court's Ruling Against Teva Pharma Opens The Door For Generics

Financial news for NVS dated on 2017-01-31: President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'

Financial news for NVS dated on 2017-01-28: What We Learned From The Last Avian Flu Outbreak

Financial news for NVS dated on 2017-01-27: A CEO Who's Who Of Trump's Manufacturing Council

Financial news for NVS dated on 2017-01-25: Novartis Under Investigation By DoJ, SEC Over Greece Payments

Financial news for NVS dated on 2017-01-25: Q4 2016 Real-Time Call Brief

Financial news for NVS dated on 2017-01-25: Novartis Says Elevates Cart Therapy CTL019 To Group Of Drugs It Expects Will Be Blockbuster, With At Least \$1B in Sales

Financial news for NVS dated on 2017-01-25: Novartis Says Initiating Share Buyback of Up to \$5B in 2017 Under Existing Shareholder Authority

Financial news for NVS dated on 2017-01-25: Novartis CEO Says Review of Options for Alcon Could Lead to IPO

Financial news for NVS dated on 2017-01-25: Earnings Scheduled For January 25, 2017

Financial news for NVS dated on 2017-01-23: Health Canada Wants Warning Stickers on Prescription Painkillers -Reuters

Financial news for NVS dated on 2017-01-13: Hearing Supreme Court Will Agree to Hear

Dispute Between Novartis, Amgen Related to Biosimilar Drugs

Financial news for NVS dated on 2017-01-13: Short Interest In Conatus Pharmaceuticals Surges

Financial news for NVS dated on 2017-01-11: Credit Suisse Downgrades Novartis AG Common Stock to Neutral

Financial news for NVS dated on 2017-01-10: The Fentanyl Abuse Epidemic

Financial news for NVS dated on 2017-01-09: Novartis CEO At JPM Healthcare Conf. Says Company's Pipeline Is Underappreciated, Too Much Focus Has Been On Alcon

Financial news for NVS dated on 2017-01-09: The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know

Financial news for NVS dated on 2017-01-06: 15 Biggest Mid-Day Gainers For Friday

Financial news for NVS dated on 2017-01-06: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for NVS dated on 2017-01-06: Ionis Pharmaceuticals +5.8% Premarket @\$49.85; Co Announced Licensing Deal With Novartis

Financial news for NVS dated on 2017-01-06: UPDATE: Ionis, Akcea are Eligible to Receive \$225M in Near-term Payments, Including Immediate \$75M Up-front Option Payment, \$100M Equity Investment Which Equates to 1,631,435 Shares at \$61.30/Share

Financial news for NVS dated on 2017-01-06: Ionis, Akcea Enter into Strategic Collaboration with Novartis Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx

Financial news for NVS dated on 2017-01-03: Novartis Shares Turn Negative as Hearing JP Morgan Issued Mid-Day Downgrade to Neutral

Financial news for NVS dated on 2017-01-02: Barron's Best Income Ideas For 2017

Financial news for NVS dated on 2016-12-29: Wall Street's M&A Chatter From December 28

Financial news for NVS dated on 2016-12-28: Intercept Shares Higher After It Requests To Keep Piece Of Q3 Info Secret Until 2020

Financial news for NVS dated on 2016-12-23: 6 Worst Biotech Stocks Of 2016

Financial news for NVS dated on 2016-12-21: Novartis To File Annulment Action In Colombia Challenging Ministry Of health Decision To Enforce A Declaration Of Public Interest On Cancer Medicine Glivec

Financial news for NVS dated on 2016-12-20: Mid-Afternoon Market Update: Worthington Drops On Earnings Miss; Fred's Shares Spike Higher

Financial news for NVS dated on 2016-12-20: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for NVS dated on 2016-12-20: Mid-Day Market Update: Conatus Jumps Following Announcement of Licensing Deal With Novartis; Sucampo Shares Slide

Financial news for NVS dated on 2016-12-20: Mid-Morning Market Update: Markets Open Higher; BlackBerry Earnings Beat Views

Financial news for NVS dated on 2016-12-20: 18 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NVS dated on 2016-12-20: Novartis to Acquire Encore Vision; Terms Not Disclosed

Financial news for NVS dated on 2016-12-19: Conatus Shares Rise as High as \$5.90 After-Hours Following Announcement of Licensing Deal with Licensing Deal With Novartis

Financial news for NVS dated on 2016-12-19: Jefferies' 2017 Global Pharma Outlook

Financial news for NVS dated on 2016-12-16: Novartis AG Receives Positive CHMP For Ilaris To Treat Rare Disease In Adults & Children Called Periodic Fever Syndromes

Financial news for NVS dated on 2016-12-09: Novartis, Biomarin, Alexion Shares All Moving Higher On AstraZeneca Halt

Financial news for NVS dated on 2016-12-07: What If Trump Keeps Badmouthing Drug

Pricing?

Financial news for NVS dated on 2016-12-06: 8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting

Financial news for NVS dated on 2016-12-06: Novartis Tells Benzinga On Intereconomia Report It Expressed Takeover Interest In Depomed 'We Don't Comment On Rumors And Speculation'

Financial news for NVS dated on 2016-12-06: Intereconomia Reporting That Novartis Is Interesting In Buying Depomed

Financial news for NVS dated on 2016-12-06: Novartis To Put Some Older Neuroscience Drugs Up For Sale In Possible \$500M Deal

Financial news for NVS dated on 2016-12-06: Novartis Announces Zykadia First-line Study Results Showing 16.6 Month Progression-free Survival in Patients with ALK+ Advanced NSCLC

Financial news for NVS dated on 2016-12-03: Novartis Announces Data Showing SEG101 Significantly Reduces Frequency of Sickle Cell Pain Crises in Phase II Study at ASH 2016

Financial news for NVS dated on 2016-11-30: Forbes Healthcare Summit Begins Today, Day 1 Of 2; Presenters Include Novartis, Walgreens

Financial news for NVS dated on 2016-11-29: Martin Shkreli Tweets: \$NVS slightly undervalued, no surprise--market is good at arbitraging large cos. Moving to penny stock trash \$IMNP. [hitbox.tv/martinshkrelilil...](http://hitbox.tv/martinshkrelilil...)

Financial news for NVS dated on 2016-11-23: Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock

Financial news for NVS dated on 2016-11-22: Stocks Hitting 52-Week Lows

Financial news for NVS dated on 2016-11-21: The Market In 5 Minutes: Symantec To Buy LifeLock, New Netflix Buy Rating

Financial news for NVS dated on 2016-11-21: A Peek Into The Markets: U.S. Stock Futures Edge Higher; Symantec To Acquire Lifelock

Financial news for NVS dated on 2016-11-21: Novartis Acquires Selexys Pharmaceuticals Corporation for Up to \$665M Upfront, Plus Milestone Payments

Financial news for NVS dated on 2016-11-14: Novartis Announces New Cosentyx Data Showing Long-lasting Efficacy In Psoriatic Arthritis Over 3 Years Including Patient-reported Pain

Financial news for NVS dated on 2016-11-14: Novartis Chairman Considering Sale of Alcon - SonntagsZeitung

Financial news for NVS dated on 2016-11-14: Novartis Said to Hold Talks to Buy Generics Maker Amneal for as Much as \$8B -Bloomberg

Financial news for NVS dated on 2016-11-14: Novartis PKC412 Granted FDA Priority Review for Newly-diagnosed FLT3-mutated AML and Advanced Systemic Mastocytosis

Financial news for NVS dated on 2016-11-11: Novartis Tells Benzinga On Intereconomia Article Suggesting Deal With AstraZeneca 'Novartis Doesn't Comment On Market Rumor Or Speculation'

Financial news for NVS dated on 2016-11-10: Why The Time Has Come To Buy Novartis

Financial news for NVS dated on 2016-11-10: Benzinga's Top Upgrades

Financial news for NVS dated on 2016-11-10: Argus Research Upgrades Novartis AG Common Stock to Buy

Financial news for NVS dated on 2016-11-09: Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%

Financial news for NVS dated on 2016-11-09: Biotech Is Getting A Big Boost Following Clinton's Loss

Financial news for NVS dated on 2016-10-31: Novartis Bioventures Reports 11.8% Passive Stake in RA Pharmaceuticals in 13G

Financial news for NVS dated on 2016-10-25: 6 Big Pharma Companies Left To Report September Quarterly Figures

Financial news for NVS dated on 2016-10-25: Novartis Reports Q3 EPS \$1.23 vs \$1.19 Est; Revenue \$12.126B vs \$12.23B Est

Financial news for NVS dated on 2016-10-25: Earnings Scheduled For October 25, 2016

Financial news for NVS dated on 2016-10-20: Roche Holding Says Still Expects MS Drug Ocrevus to be Approved in US This Year; Says Expects Aphinity Trial Readout in Q1 2017; Roche CEO Declines Comment on Novartis Stake in Roche -Reuters

Financial news for NVS dated on 2016-10-19: Mid-Afternoon Market Update: Imperva Tumbles Amid Sale Concerns; Banc of California Shares Surge

Financial news for NVS dated on 2016-10-19: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for NVS dated on 2016-10-19: Mid-Day Market Update: Crude Oil Up 2.75%; Cerulean Pharma Shares Surge On News Of Novartis Collaboration

Financial news for NVS dated on 2016-10-19: Cerulean Stock Shoots Higher On News Of Novartis Collaboration

Financial news for NVS dated on 2016-10-17: Shares of AstraZeneca Trading Higher Over Past Few Minutes On Rumor Of Potential Roche Acquisition of AstraZeneca

Financial news for NVS dated on 2016-09-27: Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19

Financial news for NVS dated on 2016-09-26: vTv Therapeutics Shares Initiated With Buy Rating, \$13 Target

Financial news for NVS dated on 2016-09-26: The Market In 5 Minutes: Oil, Debates And Epidiolex

Financial news for NVS dated on 2016-09-26: Can You Guess This Chart?

Financial news for NVS dated on 2016-09-23: Glaukos Way Ahead Of The Glaucoma Competition

Financial news for NVS dated on 2016-09-23: Novartis Reports Three New FDA Approvals for Expanded Use of Ilaris Treating Rare Periodic Fever Syndrome Conditions

Financial news for NVS dated on 2016-09-22: Hearing Novartis M&A Chatter For Celgene, Unconfirmed

Financial news for NVS dated on 2016-09-20: Novartis A Buy At Chardan

Financial news for NVS dated on 2016-09-20: Chardan Capital Initiates Coverage on Novartis at Buy, Announces \$95.00 PT

Financial news for NVS dated on 2016-09-16: Novartis Earlier Announced Data Presented at ECTRIMS Showed Benefit of Gilenya on Patient Disability Progression at 10 Years

Financial news for NVS dated on 2016-09-11: Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression

Financial news for NVS dated on 2016-09-06: Gretchen Carlson's \$20 Million And Some Of The Biggest Sexual Harassment Payouts Ever

Financial news for NVS dated on 2016-09-06: Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids

Financial news for NVS dated on 2016-09-01: GenVec Says Novartis Remains Engaged on CGF166 Program

Financial news for NVS dated on 2016-08-31: BTIG Is 'Generally Skeptical' On Kite Pharma Expectations

Financial news for NVS dated on 2016-08-30: FDA Approves Novartis Drug Sandoz Erelzi To Treat Multiple Inflammatory Diseases

Financial news for NVS dated on 2016-08-29: Almost The Whole World In This ETF's Hands

Financial news for NVS dated on 2016-08-24: Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares

Financial news for NVS dated on 2016-08-24: Hearing Handelszeitung Reporting Novartis

## Preparing Sale of Stake in Roche

Financial news for NVS dated on 2016-08-23: Novartis Enters License Agreement With Cyon Therapeutics For LGT-209 Worldwide Rights

Financial news for NVS dated on 2016-08-14: Barron's Picks And Pans: Trump Stocks, Hillary Stocks, Safe European Yields And More

Financial news for NVS dated on 2016-08-08: Canada's Plan To Fight Opioid Addiction Might Hurt Its Weakest Patients

Financial news for NVS dated on 2016-08-03: Generics Keeping The Pressure On Big Pharma

Financial news for NVS dated on 2016-07-27: Watch Potential Buyers of Generic Assets Following Report FTC Will Require Teva to Divest Generic Drugs: Valeant, Mylan, Akorn, Novartis

Financial news for NVS dated on 2016-07-25: FDA Lifts Clinical Hold On CGF166

Financial news for NVS dated on 2016-07-25: GenVec Reports FDA Lifts Clinical Hold On CGF166

Financial news for NVS dated on 2016-07-21: Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science

Financial news for NVS dated on 2016-07-19: Earnings Scheduled For July 19, 2016

Financial news for NVS dated on 2016-07-11: Hearing FDA Staff Review Has Shown Novartis's Biosimilar is 'Highly' Similar to Amgen's Enbrel

Financial news for NVS dated on 2016-07-11: Novartis Says Health Canada Approves Afinitor Tablets for Progressive, Non-Functional GI and Lung Neuroendocrine Tumors

Financial news for NVS dated on 2016-07-07: Novartis Reports FDA Approval Of Xolair For Pediatric Asthma Allergy

Financial news for NVS dated on 2016-07-07: Novartis Announces New Data Show Sandoz Biosimilar Etanercept Candidate has Equivalent Efficacy to Originator Product

Financial news for NVS dated on 2016-06-29: Regeneron Is 'One Of The Stronger Growers In Biotech'

Financial news for NVS dated on 2016-06-28: Mid-Afternoon Market Update: Crude Oil Up 2.5%; Xencor Shares Surge Following Deal With Novartis

Financial news for NVS dated on 2016-06-28: Xencor Up 36% After Deal With Novartis

Financial news for NVS dated on 2016-06-28: 10 Biggest Mid-Day Gainers For Tuesday

Financial news for NVS dated on 2016-06-28: Mid-Day Market Update: Dow Surges 150 Points; Regulus Therapeutics Shares Tumble

Financial news for NVS dated on 2016-06-28: Benzinga's Volume Movers

Financial news for NVS dated on 2016-06-28: Mid-Morning Market Update: Markets Open Higher; Gannett To Acquire ReachLocal

Financial news for NVS dated on 2016-06-28: Xencor Announces Strategic Collaboration With Novartis

Financial news for NVS dated on 2016-06-14: Jefferies Shares Pharma Stock Catalyst Outlook

Financial news for NVS dated on 2016-06-13: Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators

Financial news for NVS dated on 2016-06-10: Novartis Presents Data Showing Jakavi is Superior to Best Available Therapy in Patients with Less Advanced Polycythemia Vera at EHA

Financial news for NVS dated on 2016-06-10: Novartis Announces Long-Term Safety Data of Revolade in Adults With Chronic Immune Thrombocytopenia at EHA

Financial news for NVS dated on 2016-06-09: Bernstein Lists Active Buyers Of Ophthalmology Companies

Financial news for NVS dated on 2016-06-09: Spectrum Pharmaceuticals Subsidiary Enters into Patent Litigation Settlement Agreement with Sandoz

Financial news for NVS dated on 2016-06-08: UPDATE: Amgen Meets Erenumab Phase 2 Primary Endpoint, Erenumab Co-Developed By Novartis

Financial news for NVS dated on 2016-06-08: Novartis Reports AMG334 Significant Reduced Patients' Monthly Migraine Days in Phase II Study of CMP

Financial news for NVS dated on 2016-06-06: 4 Key Takeaways From ASCO

Financial news for NVS dated on 2016-06-06: Novartis Announces Tafenlar + Mekinist Combo Therapy Showed Overall Survival Benefit at Three Year Follow Up in Patients with Advanced Melanoma

Financial news for NVS dated on 2016-06-06: UPDATE: Novartis Release Shows Median Duration of Response for BRAF V600E-Mutant NSCLC Patients Treated with Tafenlar + Mekinist Combo Was 9 Mos.

Financial news for NVS dated on 2016-06-06: Novartis Offers Pivotal Data for Tafenlar + Mekinist Which Showed 63% Overall Response Rate in Treating Rare Form of Lung Cancer

Financial news for NVS dated on 2016-06-04: Novartis Announces Data Show 50%+ of Eligible Ph+ CML Patients Maintain Treatment-free Remission after Stopping Tasigna; Data Presented at #ASCO16

Financial news for NVS dated on 2016-06-03: Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions

Financial news for NVS dated on 2016-06-03: Novartis Bioventures Ltd. Reports 13.6% Passive Stake in Merus in 13G

Financial news for NVS dated on 2016-06-02: Eisai, Novartis Report Deal to Collaborate on Commercial, Medical Affairs Activities for LENVIMA Caps in Combo with Everolimus in US

Financial news for NVS dated on 2016-06-02: Novartis' Afinitor Receives EU Approval to Treat Certain Types of Advanced Gastrointestinal, Lung Neuroendocrine Tumors

Financial news for NVS dated on 2016-05-25: Novartis' CEO Says Company Open To Selling Its \$14 Billion Stake In Roche 'If The Opportunity Were Right'

Financial news for NVS dated on 2016-05-25: Novartis Holds Third Annual Meet Novartis Management Event

Financial news for NVS dated on 2016-05-25: Novartis CEO Says Would Potentially Sell Roche Stake Without a Premium, if Opportunity Were Right -Reuters

Financial news for NVS dated on 2016-05-20: How Big Pharma Uses Charity Programs To Cover Drug Price Hikes

Financial news for NVS dated on 2016-05-19: Novartis Announces The Establishment Of FortiHFy, But What Is It?

Financial news for NVS dated on 2016-05-19: Novartis Announces investment in FortiHFy Clinical Program of Entresto and Heart Failure

Financial news for NVS dated on 2016-05-17: UPDATE: Novartis Says They Expect 'No Big Costs' From Pharma Reorganization

Financial news for NVS dated on 2016-05-17: UPDATE: Novartis Announces Novartis Pharmaceuticals, Novartis Oncology Units

Financial news for NVS dated on 2016-05-17: Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology

Financial news for NVS dated on 2016-05-16: Benzinga's M&A Chatter for Monday May 16, 2016

Financial news for NVS dated on 2016-05-16: Shares of Anacor Spike Higher as Hearing JMP Has Said Expects a Competing \$130/Share Bid from Novartis

Financial news for NVS dated on 2016-05-16: Novartis Announces Major Study Published in NEJM Confirms Ultibro Breezhaler Superiority vs Seretide in Preventing COPD Exacerbations

Financial news for NVS dated on 2016-05-13: Teva, Mylan, Novartis Shares Largely Unaffected Following Bloomberg Report Teva's European Unit Has Drawn Interest from Mylan, Novartis

Financial news for NVS dated on 2016-05-11: Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead

Financial news for NVS dated on 2016-05-05: Benzinga's M&A Chatter for Thursday May 5, 2016

Financial news for NVS dated on 2016-05-03: Benzinga's M&A Chatter for Tuesday May 3, 2016

Financial news for NVS dated on 2016-05-01: Benzinga's Weekend M&A Chatter

Financial news for NVS dated on 2016-04-29: UPDATE: Novartis Also Said to be Considering Options with Advisors for Potential Medivation Bid

Financial news for NVS dated on 2016-04-29: Pfizer Shares Also Spiked Slightly Higher with Medivation, Novartis Moves

Financial news for NVS dated on 2016-04-29: Novartis Shares Tick Slightly Higher as Medivation Spikes Sharply Higher

Financial news for NVS dated on 2016-04-27: Novartis Announces Three FDA Breakthrough Therapy Designations for Ilaris to Treat Rare Types of Periodic Fever Syndromes

Financial news for NVS dated on 2016-04-22: The Market In 5 Minutes: Sometimes It Snows In April

Financial news for NVS dated on 2016-04-22: Benzinga's Top Upgrades

Financial news for NVS dated on 2016-04-21: Novartis CEO Says Sees Lack of Urgency Among U.S. Doctors to Switch Patients to Entresto, Says Still Bullish on Heart Drug -Reuters

Financial news for NVS dated on 2016-04-21: Earnings Scheduled For April 21, 2016

Financial news for NVS dated on 2016-04-18: Hearing Negative Comments On Novartis From A Boutique Firm

Financial news for NVS dated on 2016-04-12: Morgan Stanley Downgrades Novartis to Underperform

Financial news for NVS dated on 2016-04-11: Switzerland ETF Sort Of Stable, But Currency Is An Issue

Financial news for NVS dated on 2016-04-07: Ligand Partner Novartis Gets Key E.U. Approval: Roth Capital Likes It

Financial news for NVS dated on 2016-04-06: Incyte Acquires Rights To Develop and Commercialize Ruxolitinib From Lilly, Will Make \$35M Upfront Payment As Well As Additional Potential Payments Contingent On Certain Regulatory Milestones; Novartis Granted Right To Develop & Commercialize Ruxolitinib

Financial news for NVS dated on 2016-04-05: Argus Initiates Novartis With A Hold, Highlights Underperformance Vs. S&P 500

Financial news for NVS dated on 2016-04-01: Stocks Hitting 52-Week Lows

Financial news for NVS dated on 2016-04-01: UBS Downgrades Novartis To Neutral, Sees 'No Meaningful Earnings Growth Expected Before '18'

Financial news for NVS dated on 2016-04-01: UBS Downgrades Novartis, Says 'no meaningful earnings growth before 2018'

Financial news for NVS dated on 2016-04-01: UBS Downgrades Novartis to Neutral

Financial news for NVS dated on 2016-04-01: Novartis -2.7% Premarket @\$70.49, UBS Downgrade from Buy to Neutral

Financial news for NVS dated on 2016-04-01: Office of Ankara's Chief Prosecutor has Launched Investigation into Novartis' Turkish Unit

Financial news for NVS dated on 2016-03-31: Novartis Is Under SEC Investigation, Probes Reporter Says

Financial news for NVS dated on 2016-03-31: Probes Reporter Tells Benzinga Novartis Has 'Stealth Disclosure' Of SEC Probe

Financial news for NVS dated on 2016-03-31: Turkish Health Ministry Launches Investigation Into Bribery Allegations Involving Novartis; Co Says Allegations are Unfounded -Reuters



Financial news for NVS dated on 2016-03-29: Citi Downgrades Novartis Following SAG Investigation

Financial news for NVS dated on 2016-03-29: Citigroup Downgrades Novartis to Neutral

Financial news for NVS dated on 2016-03-23: SEC Says Novartis To Pay \$1.47M Interest To Settle Bribery Case Without Admitting Or Denying Its Finding-Reuters

Financial news for NVS dated on 2016-03-23: Novartis Shares Downgraded, Leerink Says 'Consensus Still Way Too High'

Financial news for NVS dated on 2016-03-23: Benzinga's Top Downgrades

Financial news for NVS dated on 2016-03-23: Leerink Swann Downgrades Novartis to Market Perform, Lowers PT to \$85.00

Financial news for NVS dated on 2016-03-05: Novartis Reports Cosentyx Superior to Stelara in Delivering Long-lasting Skin Clearance for Psoriasis Patients at 52 Weeks

Financial news for NVS dated on 2016-03-03: Bernstein Cuts LLY FY 2017 EPS From \$4.23 To \$4.07, Cuts NVS FY 2017 EPS From \$5.21 To \$5.17

Financial news for NVS dated on 2016-02-26: FDA Approves New Indication for Novartis Drug Afinitor for Progressive, Nonfunctional GI and Lung Neuroendocrine Tumors

Financial news for NVS dated on 2016-02-22: Report Says Novartis Office in S. Korea Raided Over Bribery Issues

Financial news for NVS dated on 2016-02-19: Novartis Reports PKC412 Received Breakthrough Therapy Designation from FDA Related to FLT3-AML

Financial news for NVS dated on 2016-02-19: Novartis PKC412 Receives Breakthrough Therapy Designation from FDA for Newly-diagnosed FLT3-mutated AML

Financial news for NVS dated on 2016-02-18: Novartis Announces Health Canada Has Approved PrJakavi for Polycythemia

Financial news for NVS dated on 2016-01-27: Earnings Recap For January 27

Financial news for NVS dated on 2016-01-27: Radius Health, Novartis Pharma. Partner To Evaluate RAD1901 Combo In Advanced Breast Cancer Regimens

Financial news for NVS dated on 2016-01-27: Novartis Reports Q4 EPS 1.14 vs 1.18 Est; Revenue \$12.52B vs 12.64B Est

Financial news for NVS dated on 2016-01-27: Novartis CEO Sees More Consolidation in Drug Sector in 2016; Says Seeking Bolt-On Assets for Three Divisions -Reuters

Financial news for NVS dated on 2016-01-27: Earnings Scheduled For January 27, 2016

Financial news for NVS dated on 2016-01-25: Regeneron Is Now A Sell For Chardan

Financial news for NVS dated on 2016-01-20: Bloomberg: GlaxoSmithKline, Qualcomm To Jointly Develop Medical Technology

Financial news for NVS dated on 2016-01-19: Hearing FDA Has Approved Novartis' Ofatumumab

Financial news for NVS dated on 2016-01-11: On January 8, Novartis Notified Genvec That It Was Pausing Enrollment In The Clinical Trial Of Cgfl66 To Conduct A Safety Review Of Patient Data

Financial news for NVS dated on 2016-01-11: Novartis Announces Collaboration and Licensing Agreement with Surface Oncology

Financial news for NVS dated on 2015-12-31: A New ETF Avenue To Europe

Financial news for NVS dated on 2015-12-22: Watch Stocks of Co.'s with Flu-Related Solutions; Macquarie Note Earlier Highlighted 'Early Flu Results Lagging

Financial news for NVS dated on 2015-12-07: Novartis Issues Release Highlighting New CTL019 Phase 2 Data Shows 93% Complete Remission in Pediatric Patients with r/r ALL

Financial news for NVS dated on 2015-12-07: Novartis Issues Release Reporting Phase 3 Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim Has Similar Safety, Efficacy as Reference Product

Financial news for NVS dated on 2015-12-06: Novartis Announces New CTL019 Study Data

Demonstrating Overall Response in Adults with Certain Types of Lymphoma at #ASH2015

Financial news for NVS dated on 2015-12-05: Novartis Announces Phase III Studies of Jakavi Show Disease Improvement in Patients with Myelofibrosis and Polycythemia Vera

Financial news for NVS dated on 2015-12-02: Hearing Charterhouse Considering Sale of Doc Generici for ~EUR600M, PE Suitors Could Be Blackstone, CVC

Financial news for NVS dated on 2015-11-25: Seqirus Receives Fda Approval for Fluvad Flu Vaccine for Adults Aged 65 Years+

Financial news for NVS dated on 2015-11-23: Novartis Announces EC Approvals for Cosentyx to Treat Patients with Ankylosing Spondylitis, Psoriatic Arthritis

Financial news for NVS dated on 2015-11-20: DOJ Says Novartis Agrees to \$370M Settlement in Kickback Case -DJ

Financial news for NVS dated on 2015-11-20: Hearing Novartis Will Pay \$390M to Settle with US Gov't Related to Kickbacks Paid to Specialty Pharmacies

Financial news for NVS dated on 2015-11-17: Ophthotech Shares Up 7-8% Following Earlier News Roche's Genentech Has Elected to Exercise Right to Opt-In to Novartis Portion of Ophthotech/Novartis Excluding US Deal for Fovista

Financial news for NVS dated on 2015-11-10: Novartis Heart Failure Medicine Entresto Substantially Cuts Hospital Re-admissions, New Post-Hoc Analysis Shows

Financial news for NVS dated on 2015-11-07: Novartis Presents New Two-year Data for Cosentyx Showing No Progression in Joint Damage in 84% of Psoriatic Arthritis Patients

Financial news for NVS dated on 2015-10-29: Novartis Announces FDA Approval of New Dual Combo Bronchodilator Utibron Neohaler

Financial news for NVS dated on 2015-10-29: FDA Approves New Novartis Dual Combination Bronchodilator Utibron Neohaler for Patients With Chronic Obstructive Pulmonary Disease

Financial news for NVS dated on 2015-10-27: Earnings Scheduled For October 27, 2015

Financial news for NVS dated on 2015-10-23: Novartis Receives Positive CHMP Opinion for First IL-17A Inhibitor Cosentyx to Treat Ankylosing Spondylitis, Psoriatic Arthritis

Financial news for NVS dated on 2015-10-21: Xoma +11% Premarket Following Announcement of Licensing Deal With Novartis

Financial news for NVS dated on 2015-10-16: Credit Suisse: 12 U.S.-Listed European Stocks To Buy Now

Financial news for NVS dated on 2015-10-12: Elbit Imaging Announces Novartis to Invest \$5M in Gamida for ~2.5% Stake

Financial news for NVS dated on 2015-10-05: Novartis Division Alcon Receives FDA Approval for AcrySof(r)IQ Aspheric IOL with UltraSert Pre-loaded Delivery System

Financial news for NVS dated on 2015-10-02: US Stock Futures Up; All Eyes On Jobs Report

Financial news for NVS dated on 2015-10-02: FDA Accepts Novartis/Sandoz Regulatory Submission for Proposed Biosimilar to Enbrel

Financial news for NVS dated on 2015-10-01: Xoma +86% Premarket After Resumption of Trading

Financial news for NVS dated on 2015-09-30: Novartis Announces NEJM Publication Of Secukinumab Phase III Data Confirming Significant Efficacy In Patients With Psoriatic Arthritis

Financial news for NVS dated on 2015-09-27: Novartis Reports Patients with Aggressive Form of Melanoma Lived Average of Two+ Years When Taking Tafinlar + Mekinist

Financial news for NVS dated on 2015-09-27: Novartis' Afinito Significantly Improves Progression-Free Survival In Advanced Nonfunctional GI and Lung NET

Financial news for NVS dated on 2015-09-25: Novartis' New Heart Failure Medicine Entresto Receives CHMP Recommendation for EU Approval

Financial news for NVS dated on 2015-09-18: Novartis CEO, Speaking on CNBC, Says

Still Looking at Possible Acquisitions, But Assets are Expensive

Financial news for NVS dated on 2015-09-16: FIPB Approves Proposal from Elanco India to Acquire Novartis' Animal Health Division -Reuters

Financial news for NVS dated on 2015-09-08: A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month

Financial news for NVS dated on 2015-09-04: US Stock Futures Tumble; Jobs Report In Focus

Financial news for NVS dated on 2015-09-04: Novartis Announces EU approval for Farydak

Financial news for NVS dated on 2015-09-01: Novartis Receives EU Approval for Tafinlar and Mekinist for Patients with Aggressive Form of Melanoma

Financial news for NVS dated on 2015-08-28: Swiss Miss: Switzerland Skirts Recession, But ETFs Struggle

Financial news for NVS dated on 2015-08-24: Novartis Announces FDA Expansion of Uses for Co.'s Promacta to Include Treatment of Children Ages 1+ with Chronic Immune Thrombocytopenia

Financial news for NVS dated on 2015-08-21: US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings

Financial news for NVS dated on 2015-08-21: Novartis Acquires Rremaining Rgths to GSK's Ofatumumab to Develop Treatments for MS, Other Autoimmune Indications

Financial news for NVS dated on 2015-08-20: Novartis Receives EU Approval for Skin Cancer Treatment Odomzo

Financial news for NVS dated on 2015-08-19: O'Leary's O'Shares Triples The Size Of Its ETF Stable

Financial news for NVS dated on 2015-08-17: Morning Market Gainers

Financial news for NVS dated on 2015-08-17: Benzinga's Top #PreMarket Gainers

Financial news for NVS dated on 2015-08-17: UPDATE: AVEO +107% Premarket Following Announcement of Licensing Deal With Novartis

Financial news for NVS dated on 2015-08-17: Aveo Shares Rise 28% Premaket Following Announcement of Licensing Agreement With Novartis

Financial news for NVS dated on 2015-08-17: UPDATE: AVEO to Receive \$15M Upfront Payment from Novartis, Up to \$311M in Milestone Payments

Financial news for NVS dated on 2015-08-17: AVEO Announces Exclusive Worldwide License Agreement for, Development, Commercialization of AV-380 and Related Antibodies

Financial news for NVS dated on 2015-08-14: Morning Market Gainers

Financial news for NVS dated on 2015-08-14: Benzinga's Top #PreMarket Gainers

Financial news for NVS dated on 2015-08-14: US Stock Futures Slip Ahead Of Economic Data

Financial news for NVS dated on 2015-08-14: Prima Biomed Shares +50% Following Announcement of Milestone Payment from Novartis

Financial news for NVS dated on 2015-08-14: Prima Biomed to Receive Undisclosed Milestone Payment from Novartis

Financial news for NVS dated on 2015-08-04: Shares of Novartis Volatile Over Last Few Mins Following FDA Warning Related to First Cases of PML Being Reported in Patients Taking Gilenya

Financial news for NVS dated on 2015-08-04: FDA Warns About Cases of Rare Brain Infection With Ms Drug Gilenya in Two Patients With No Prior Exposure to Immunosuppressant Drugs -Reuters

Financial news for NVS dated on 2015-08-03: 5 Biotechs With Catalysts Coming This Week

Financial news for NVS dated on 2015-08-02: Novartis Completes Divestiture of Influenza Vaccines Business to CSL Limited for \$275M

Financial news for NVS dated on 2015-07-21: Novartis' Sandoz Unit Can't Sell Biosimilar Drug Zarxio Until September 2, 2015, According to Appeals Court Decision -Reuters

Financial news for NVS dated on 2015-07-10: Novartis CEOS Says Looking at Offering Extra Health-Care Services With Heart Drug Entresto -DJ

Financial news for NVS dated on 2015-07-07: FDA Approves New Drug To Treat Heart Failure

Financial news for NVS dated on 2015-07-01: Alcon Receives European Approval for Pre-loaded Intraocular Lens Delivery System to Treat Patients Undergoing Cataract Surgery

Financial news for NVS dated on 2015-06-29: Must Watch Stocks for June 29, 2015

Financial news for NVS dated on 2015-06-29: Novartis Acquires Spinifex Pharmaceuticals

Financial news for NVS dated on 2015-06-28: Novartis Announces Publication in The Lancet Showing Positive Results with Secukinumab Over One Year in PsA Patients

Financial news for NVS dated on 2015-06-22: Bryan Garnier Upgrades Novartis to Buy

Financial news for NVS dated on 2015-06-17: The Note Moving Pharma Giants Today

Financial news for NVS dated on 2015-06-16: New Report: Abbvie Is Jefferies' Top Global Pharma Stock

Financial news for NVS dated on 2015-06-16: Novartis Division Alcon Receives CE Mark for CrySof IQ PanOptix Trifocal Intraocular Lens

Financial news for NVS dated on 2015-06-13: Novartis Reports European Study Data Reinforce Benefit of First-line Tassigna in Newly-diagnosed Patients with CML

Financial news for NVS dated on 2015-06-13: Novartis Announces Majority of Patients with Polycythemia Vera Treated with Jakavi Achieved Long-term Disease Control

Financial news for NVS dated on 2015-06-12: Novartis Data at EHA Show Increased PFS Benefit of Farydak in New Subgroup of Patients With Previously Treated Multiple Myeloma

Financial news for NVS dated on 2015-06-12: Hearing Novartis Panobinostat Combo Data Presented at EHA Showed More Than Double Median PFS Benefit by 7.8 Months

Financial news for NVS dated on 2015-06-11: Novartis Considers Delisting Indian Unit -Bloomberg

Financial news for NVS dated on 2015-06-10: Novartis Announces New one-year Results Demonstrating Sustained Secukinumab Efficacy in Ankylosing Spondylitis Patients

Financial news for NVS dated on 2015-06-02: Novartis Presents New Positive One-Year Secukinumab Data at EULAR, WCD

Financial news for NVS dated on 2015-06-01: Novartis Highlights CTL019 Data Showing Potential as Treatment for Specific Types of non-Hodgkin Lymphoma

Financial news for NVS dated on 2015-05-31: Novartis Reports Combination of Tafenlar, Mekinist Shows Significant Survival Benefit in Patients with Metastatic Melanoma

Financial news for NVS dated on 2015-05-22: Merus Labs Acquires Specialty Product Rights from Novartis for \$29.5M

Financial news for NVS dated on 2015-05-21: 8K Filing: Immunogen Receives \$5M Milestone Payment From Novartis Institutes

Financial news for NVS dated on 2015-05-21: Novartis' Afinitor Extended Progression-free Survival in Phase III Trial

Financial news for NVS dated on 2015-05-20: Novartis Reports Two Positive US Phase III Programs in COPD for QVA149, NVA237

Financial news for NVS dated on 2015-05-15: Microbix Provides Update on US VIRUSMAX Litigation vs Novartis

Financial news for NVS dated on 2015-05-08: Novartis Lung Cancer Drug Zykadia Receives EU Approval

Financial news for NVS dated on 2015-04-27: Novartis Reports Phase III Study of

Arzerra Met Primary Endpoint of Improved Progress-Free Survival in Patients with Relapsed CLL

Financial news for NVS dated on 2015-04-23: Novartis Reports Q1 EPS \$1.33 vs \$1.10 Est; Revenue \$11.935B vs \$12.90B Est; Confirms Full-Year Guidance

Financial news for NVS dated on 2015-04-23: Novartis Posts Higher Q1 Profit

Financial news for NVS dated on 2015-04-20: CAR-T Therapy Stocks Hit Hard Following AACR Data

Financial news for NVS dated on 2015-04-17: It's A Big Weekend For Biotech

Financial news for NVS dated on 2015-04-17: Mylan Scores Final Win In Patent Challenge On Inhalation Drug

Financial news for NVS dated on 2015-04-16: Novartis' Alcon Receives FDA Approval of New Multifocal Intraocular Lens for Cataract Patients in US

Financial news for NVS dated on 2015-04-15: SocGen Initiates Big Drug/Pharma Names

Financial news for NVS dated on 2015-04-13: Gilenya Data at AAN to Highlight How Novartis is Advancing Methods Assessing Impact of RMS

Financial news for NVS dated on 2015-04-08: FDA Says High-Dose Influenza Vaccine Significantly More Effective Than Standard Dose in Elderly -Reuters

Financial news for NVS dated on 2015-04-06: Icon Bioscience Announces Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation with Cataract Surgery

Financial news for NVS dated on 2015-03-30: Novartis Reports Approval For Jadenutm For Chronic Iron Overload

Financial news for NVS dated on 2015-03-30: Advaxis Shares Rise 13% Premarket; May be Attributed to Novartis Deal with Aduro Biotech

Financial news for NVS dated on 2015-03-30: Novartis Announces Alliance With Aduro Biotech; Includes \$250M Upfront Payment

Financial news for NVS dated on 2015-03-25: Amgen to Appeal Rejection of Bid to Block Sale of Novartis Biosimilar form of Neupogen, According to Court Filing -Reuters

Financial news for NVS dated on 2015-03-25: Novartis Announces Positive Cosentyx Results

Financial news for NVS dated on 2015-03-23: Novartis' Cosentyx 2-year Data Shows Sustained Effect, Favorable Safety Profile in Psoriasis Patients

Financial news for NVS dated on 2015-03-20: Novartis International AG: New Novartis data shows Cosentyx is significantly superior to Stelara and clears skin (PASI 90

Financial news for NVS dated on 2015-03-19: US Judge Denies Amgen Bid for Preliminary Injunction vs Novartis' Sandoz Unit Regarding Disputed Biologic Products -Reuters

Financial news for NVS dated on 2015-03-17: Incyte Announces Jakavi Receives EC Approval as First Targeted Therapy for Patients with Polycythemia Vera

Financial news for NVS dated on 2015-03-10: 8 Healthcare Names Cowen & Co Are Talking About

Financial news for NVS dated on 2015-03-10: UPDATE: Ophthotech Announces Second \$50M Enrollment Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista

Financial news for NVS dated on 2015-03-09: Analyst: 'Mess Continues' With Amgen Neupogen Competitor

Financial news for NVS dated on 2015-03-06: Novartis Reports FDA Approval of First Biosimilar ZarxioTM from Sandoz

Financial news for NVS dated on 2015-03-05: Arrowhead Research Soars After Acquiring Novartis' RNAi Portfolio

Financial news for NVS dated on 2015-03-05: Omnicare Announces Specialty Care Group ACS Will Provide Specialty Pharmacy Services for Novartis' Farydak

Financial news for NVS dated on 2015-03-04: Report: Pharmacyclics Inc. To Be Acquired By Johnson & Johnson

Financial news for NVS dated on 2015-03-04: Natixis Upgrades Novartis To Buy

Financial news for NVS dated on 2015-03-04: Benzinga's Top Upgrades

Financial news for NVS dated on 2015-03-04: Natixis Upgrades Novartis to Buy

Financial news for NVS dated on 2015-02-27: Novartis International Reports Phase II Study Of Alcon's RTH258 Meets Primary Endpoint

Financial news for NVS dated on 2015-02-25: Benzinga's M&A Chatter for Wednesday February 25, 2015

Financial news for NVS dated on 2015-02-25: Deutsche Bank On Pharmacyclics: 'We Do Not See Much Upside'

Financial news for NVS dated on 2015-02-23: Novartis Release Confirms FDA Approval of Farydak

Financial news for NVS dated on 2015-02-23: FDA Reports Approval of Novartis' Farydak for Treatment of Multiple Myeloma

Financial news for NVS dated on 2015-02-23: Canada Competition Bureau Says Won't Block Glaxosmithkline-Novartis Deal

Financial news for NVS dated on 2015-02-23: FTC Puts Conditions on Novartis AG's Proposed Acquisition of GlaxoSmithKline's Oncology Drugs

Financial news for NVS dated on 2015-02-13: Novartis, Verastem & Cepheid Making Biotech Headlines On Friday

Financial news for NVS dated on 2015-02-13: Novartis' LCZ696 Granted FDA Priority Review

Financial news for NVS dated on 2015-02-09: Novartis Shares Rise 2% Premarket; Citi Resumes With Buy; Adds to Europe Focus List

Financial news for NVS dated on 2015-02-06: After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?

Financial news for NVS dated on 2015-02-05: Credit Suisse Adds 10 Names To European 'Top Picks'

Financial news for NVS dated on 2015-02-04: Pfizer Just Won With This Breast Cancer Drug

Financial news for NVS dated on 2015-02-02: Novartis Announces Alcon Receives FDA Approval for Pazeo Solution for Ocular Allergy Itch Relief

Financial news for NVS dated on 2015-01-30: Stocks That Battle Cancer Were The Best-Performing Biotechs In January

Financial news for NVS dated on 2015-01-27: Morning Market Gainers

Financial news for NVS dated on 2015-01-27: Benzinga's Top #PreMarket Gainers

Financial news for NVS dated on 2015-01-27: Novartis Posts Drop In Q4 Net Profit

Financial news for NVS dated on 2015-01-27: From Conf Call: Novartis CEO Says Franc Appreciation Won't Have Any Material Effect on Sales

Financial news for NVS dated on 2015-01-27: Novartis Reports Q4 EPS of \$1.21, Inline; Revenue of \$14.63B vs \$14.58B Est

Financial news for NVS dated on 2015-01-27: Earnings Scheduled For January 27, 2015

Financial news for NVS dated on 2015-01-26: Trio Of Wall Street Firms Up Array BioPharma Price Targets

Financial news for NVS dated on 2015-01-25: Benzinga's Weekend M&A Chatter

Financial news for NVS dated on 2015-01-23: FDA Approves Second Vaccine to Prevent Serogroup B Meningococcal Disease

Financial news for NVS dated on 2015-01-23: Adam Feuerstein @adamfeuerstein Tweet: FDA approval PRs coming. \$NVS vaccine.

Financial news for NVS dated on 2015-01-23: Why Shares Of Array Biopharma Are Surging More Than 35%

Financial news for NVS dated on 2015-01-23: Array BioPharma Shares Rise 47% on Announcement of Deal to Acquire Encorafenib from Novartis

Financial news for NVS dated on 2015-01-23: Novartis' Jakav Recommended by CHMP for EU Approval for Adults with Rare Blood Cancer polycythemia vera

Financial news for NVS dated on 2015-01-23: Novartis CEO: Supporting Affordable Care Act Supports Insuring Americans

Financial news for NVS dated on 2015-01-23: Aspen Pharmacare Acquires Rights to Mono-embolex from Novartis for \$142.3M

Financial news for NVS dated on 2015-01-21: Novartis Announces FDA Approval for Cosentyx for Moderate-to-Severe Plaque Psoriasis

Financial news for NVS dated on 2015-01-16: Watchmakers Caught In The #Francogeddon Storm

Financial news for NVS dated on 2015-01-15: Benzinga's Volume Movers

Financial news for NVS dated on 2015-01-15: Swiss ADRs Gain Big As Swiss National Bank Surprises With Currency Revaluation

Financial news for NVS dated on 2015-01-08: US Stock Futures Jump Ahead Of Jobless Claims

Financial news for NVS dated on 2015-01-08: Novartis Announces Positive Phase III Results for QVA149 and NVA237

Financial news for NVS dated on 2015-01-07: FDA Panel Gives Unanimous Backing to Novartis Copy of Amgen Cancer Drug Neupogen

Financial news for NVS dated on 2015-01-07: Novartis Announces Collaborations With Intellia Therapeutics, Caribou Biosciences Related to CRISPR Genome Editing Technology

Financial news for NVS dated on 2015-01-05: Qualcomm Reports Strategic Collaboration with Novartis Related to Optimization of Global Clinical Trials

Financial news for NVS dated on 2015-01-05: Benzinga's Top Upgrades

Financial news for NVS dated on 2015-01-05: Cowen Upgrades Novartis To Outperform

Financial news for NVS dated on 2015-01-05: Cowen & Company Upgrades Novartis to Outperform, Raises PT to \$105.00

Financial news for NVS dated on 2015-01-04: CORRECTION -- Pot Stocks Pay Off: Here's How The Marijuana Sector Fared Last Year

Financial news for NVS dated on 2015-01-01: Lilly Completes Acquisition of Novartis Animal Health

Financial news for NVS dated on 2014-12-26: Novartis Announces Regulatory Approval of Cosentyx in Japan for Psoriasis and Psoriatic Arthritis

Financial news for NVS dated on 2014-12-23: Benzinga's Volume Movers

Financial news for NVS dated on 2014-12-23: Mid-Morning Market Update: Markets Mostly Higher; Walgreen Profit Beats Expectations

Financial news for NVS dated on 2014-12-23: Morning Market Movers

Financial news for NVS dated on 2014-12-23: Benzinga's Top #PreMarket Gainers

Financial news for NVS dated on 2014-12-23: Vanda Pharmaceuticals And Novartis Settle License Dispute

Financial news for NVS dated on 2014-12-22: UPDATE: Vanda to Acquire Rights to Phase II Clinical Compound From Novartis

Financial news for NVS dated on 2014-12-22: Novartis to Purchase \$25M Og Vanda Common Stock

Financial news for NVS dated on 2014-12-22: Novartis Reports 12.8% Passive Stake in BioLineRx as of December 16

Financial news for NVS dated on 2014-12-19: Dr. Reddy's Closes Acquisition of Habitro Brand from Novartis

Financial news for NVS dated on 2014-12-17: Novartis Shares Volatile Here as Seeing FDA Has Approved Alcon's Xtoro for Treatment of Swimmer's Ear

Financial news for NVS dated on 2014-12-16: Morning Market Movers

Financial news for NVS dated on 2014-12-16: Benzinga's Top #PreMarket Gainers

Financial news for NVS dated on 2014-12-16: UPDATE: Bioline RX Said Novartis Made \$10M Initial Investment for ~12.8% of Co., Has Option to Pay \$5M Fee, Could Fund 50% of Development Costs

Financial news for NVS dated on 2014-12-16: UPDATE: BioLine RX Shares Rise 20% Premarket on Announcement of Strategic Collaboration Agreement With Novartis

Financial news for NVS dated on 2014-12-16: US Stock Futures Edge Lower; Crude Oil Drops

Financial news for NVS dated on 2014-12-16: Novartis Announces FDA Approval for Signifor LAR to Treat Patients with Acromegaly

Financial news for NVS dated on 2014-12-12: Novartis Reports Results of Trial Evaluating Use of Afinitor

Financial news for NVS dated on 2014-12-12: Novartis Cosentyx Superior to Stelara in Clearing Skin in Head-to-Head Psoriasis Study

Financial news for NVS dated on 2014-12-06: Novartis Announces Positive CTL019 Clinical Data in Children, Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Financial news for NVS dated on 2014-12-02: Morgan Stanley Pair Trade On Novartis And AstraZeneca

Financial news for NVS dated on 2014-12-02: Morgan Stanley Upgrades Novartis AG to Equalweight

Financial news for NVS dated on 2014-12-02: Novartis Says Italian Court Has Upheld Decision Related to Lucentis/Avastin, Calls Allegations of Anti-Competitive Behavior 'Unfounded,' Says Can Not Comment on Rationale of Italian Court Decision

Financial news for NVS dated on 2014-12-01: Novartis Fingolimod Phase III Trial in Primary Progressive MS did Not Meet Primary Endpoint

Financial news for NVS dated on 2014-11-26: FTC Places Conditions on JV Between GlaxoSmithKline, Novartis

Financial news for NVS dated on 2014-11-25: US Stock Futures Edge Higher Ahead Of GDP, Housing Data

Financial news for NVS dated on 2014-11-25: Novartis Announces FDA Grants Extension to NDA Review Period for Multiple Myeloma Investigational Compound LBH589

Financial news for NVS dated on 2014-11-24: Novartis' Signifor Approved in EU

Financial news for NVS dated on 2014-11-21: Novartis Psoriasis Treatment Receives Positive Opinion from CHMP

Financial news for NVS dated on 2014-11-17: Novartis Int'l Reports Nine New Analyses Show Co.'s LCZ696 Could Avert Course of Heart Failure for Patients

Financial news for NVS dated on 2014-11-16: Novartis First IL-17A Phase III Trial Results Show AIN457 Significantly Improves Psoriatic Arthritis

Financial news for NVS dated on 2014-11-15: Novartis Says Secukinumab Met Primary Endpoint Demonstrating Statistically Significant Improvements Versus Placebo With AS

Financial news for NVS dated on 2014-11-06: Novartis Does Not Receive FDA Advisory Committee Recommendation for Panobinostat

Financial news for NVS dated on 2014-10-28: Markets Continue To Rally As The Dow Closes Above 17,000

Financial news for NVS dated on 2014-10-28: Novartis Posts Higher Q3 Profit

Financial news for NVS dated on 2014-10-28: Earnings Scheduled For October 28, 2014

Financial news for NVS dated on 2014-10-28: Novartis AG Reports Q3 EPS of \$1.37 vs \$1.29 Est; Revenue of \$14.70B vs \$14.34B Est



Financial news for NVS dated on 2014-10-26: Novartis Divests Influenza Vaccines Business to CSL for \$275M

Financial news for NVS dated on 2014-10-22: Drug ETFs Attractive Buys On Pullback

Financial news for NVS dated on 2014-10-20: Novartis Reports FDA AdCom Unanimously Recommended Approval of AIN457 for Patients with Moderate-to-Severe Plaque Psoriasis

Financial news for NVS dated on 2014-10-10: US Stock Futures Signal Lower Start On Wall Street

Financial news for NVS dated on 2014-10-10: Novartis Presents Data Showing Consistent Efficacy of AIN457 in Clearing Skin of Psoriasis Patients at EADV

Financial news for NVS dated on 2014-10-07: 8-K from Immunogen Shows Has Recorded \$25.7M in Current Qtr. Related to Licenses, Novartis Deal, Each License Entitles Co. to Up to \$199.5M in Milestone Payments

Financial news for NVS dated on 2014-09-27: Novartis Reports Afinitor First Treatment for Advanced Pancreatic NET to Provide Overall Survival of 3.5+ Years in Phase III Trial

Financial news for NVS dated on 2014-09-26: Novartis Reports CHMP Has Recommended EU Approval for Signifor LAR for Treatment of Patients with Acromegaly

Financial news for NVS dated on 2014-09-23: Could European Funds Offer An Opportunity Now?

Financial news for NVS dated on 2014-09-14: 3 Companies Investing In Stem Cell Research

Financial news for NVS dated on 2014-09-08: PREVIEW: Merus Labs to Resume Trading at 9:00 AM ET

Financial news for NVS dated on 2014-09-08: Merus Labs Reports Purchase of Sintrom(R) from Novartis, No Terms Disclosed

Financial news for NVS dated on 2014-09-08: Ophthotech Wins \$50M Milestone Under Ex-US Licensing Deal with Novartis, Related to Fovista

Financial news for NVS dated on 2014-09-04: ECB Decision Boosts ETFs

Financial news for NVS dated on 2014-09-02: Benzinga's Volume Movers

Financial news for NVS dated on 2014-08-30: Novartis' LCZ696 Reduced Cardiovascular Deaths by 20% vs ACE-inhibitor in PARADIGM-HF Trial

Financial news for NVS dated on 2014-08-28: Novartis Reports Xolair Approved in Canada as Licensed Therapy for CIU Patients

Financial news for NVS dated on 2014-08-19: Elbit Imaging Announces Novartis to Invest \$35M in Gamida Cell

Financial news for NVS dated on 2014-08-07: Enanta Pharmaceuticals Announces Novartis Advanced EDP-239 into Combination Studies with Alisporivir

Financial news for NVS dated on 2014-08-05: Novartis Announces Investigational Secukinumab Met All Primary, Key Secondary Endpoints at Week 12

Financial news for NVS dated on 2014-07-28: Alcon's Simbrinza Approved in EU to Treat Patients with Glaucoma

Financial news for NVS dated on 2014-07-24: FDA Accepts Novartis' Sandoz Application for Biosimilar Filgrastim

Financial news for NVS dated on 2014-07-18: 5 New Medical Technologies For Diabetics

Financial news for NVS dated on 2014-07-18: Novartis Joins Google To Develop Contacts For Diabetics

Financial news for NVS dated on 2014-07-18: #PreMarket Primer: Friday, July 18: Tension Between Russia And The West At An All Time High

Financial news for NVS dated on 2014-07-17: Markets Sell-Off After Malaysian Airline Crash In Ukraine

Financial news for NVS dated on 2014-07-17: Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results

Financial news for NVS dated on 2014-07-17: From Novartis Earnings Conference Call: CEO Says Co. Not Considering Sale of Mature Drugs Right Now But 'Never Say Never' on Possibility of Sale

Financial news for NVS dated on 2014-07-17: 8-K from Vanda Pharma Shows Novartis is Counter-Claimant in Arbitration Proceeding, Expecting Closing or Proceeding in 12-18 Mos.

Financial news for NVS dated on 2014-07-17: #PreMarket Primer: Thursday, July 17: Russia Hit With New Sanctions

Financial news for NVS dated on 2014-07-17: Novartis Reports Q2 EPS of \$1.34 vs \$1.42 Est; Revenue of \$14.60B vs \$14.81B Est

Financial news for NVS dated on 2014-07-17: Novartis Reconfirms Full Year Outlook

Financial news for NVS dated on 2014-07-17: Earnings Scheduled For July 17, 2014

Financial news for NVS dated on 2014-07-15: Markets Mixed, NASDAQ Lower As Yellen Suggests Valuations Are Stretched

Financial news for NVS dated on 2014-07-15: Novartis to License Google Smart Lens Technology

Financial news for NVS dated on 2014-07-11: Benzinga Weekly Preview: Earnings Season Kicks Into High Gear

Financial news for NVS dated on 2014-07-08: Incyte Announces \$25M Milestone Payment for Approval of Jakavi in Japan, Will Receive Payment from Novartis

Financial news for NVS dated on 2014-07-07: Novartis Personalized Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation

Financial news for NVS dated on 2014-07-07: Novartis Int'l Reports FDA Breakthrough Designation for Personalized Cell Therapy CTL019

Financial news for NVS dated on 2014-07-02: Novartis Announces Beginning of Shipment of Seasonal Influenza Vaccines to US Market for '14-'15 Season

Financial news for NVS dated on 2014-07-01: Novartis Faces Charges in Japan Regarding Data Manipulation by Former Staff -FT

Financial news for NVS dated on 2014-06-26: FDA Approves Ranbaxy Laboratories' Generic Version of Novartis Blood Pressure Pill Diovan

Financial news for NVS dated on 2014-06-25: Shire Announces Vyvanse Patents Found to Be Infringed and Valid by US District Court

Financial news for NVS dated on 2014-06-24: Delaware Judge Rules Novartis Pharma Patents Not Infringed by Alvogen

Financial news for NVS dated on 2014-06-24: FDA Reports Approved Novartis' Request to Supplement BLA for FluCelVax

Financial news for NVS dated on 2014-06-17: US Stock Futures Edge Higher Ahead Of Consumer Price Index

Financial news for NVS dated on 2014-06-17: Novartis Submits BLA to FDA for Meningitis B Vaccine Candidate Bexsero

Financial news for NVS dated on 2014-06-04: ASCO Meeting Day 1: Preserving Fertility And Reducing Side Effects

Financial news for NVS dated on 2014-06-03: UPDATE: Incyte Announces Trial Met Endpoint

Financial news for NVS dated on 2014-06-03: Watch Shares of Novartis Following News from Incyte

Financial news for NVS dated on 2014-06-02: Novartis Reports Study Shows Zykadia(TM) Shrank Tumors in Majority of ALK+ NSCLC Patients

Financial news for NVS dated on 2014-06-02: Novartis Data Presented at ASCO Shows LBH589 Significantly Improved Progression-Free Survival in Patients with Multiple Myeloma

Financial news for NVS dated on 2014-06-01: Novartis' investigational Compound LDE225 Shows Marked Tumor Responses in Advanced Basal Cell Carcinoma

Financial news for NVS dated on 2014-06-01: Novartis Names Bruno Strigini as President of Novartis Oncology

Financial news for NVS dated on 2014-05-29: Judge Has Denied Novartis Offer to Throw Out Drug Sales Kickback Lawsuit - Bloomberg

Financial news for NVS dated on 2014-05-29: US Judge Denies Novartis Motion to Dismiss US Lawsuit Over Alleged Kickback Scheme -Reuters

Financial news for NVS dated on 2014-05-28: Italy Health Ministry Asks for EUR1.2B of Compensation from Roche, Novartis, EUR14M Euros from Pfizer Following Anti-Trust Ruling -Reuters

Financial news for NVS dated on 2014-05-23: Novartis Alcon Reports Positive CHMP Opinion for Simbrinza

Financial news for NVS dated on 2014-05-20: Ophthotech Mega Million Deal With Novartis; Oncolytics Biotech Brain Cancer Trial Positive Data; Tarena International Solid Results

Financial news for NVS dated on 2014-05-19: Ophthotech Announces Has Entered Into Ex-US Licensing, Commercialization Deal with Novartis, Will Potentially Get Upfront Payment of \$200M, Receive Over \$1B

Financial news for NVS dated on 2014-05-14: Two New WisdomTree International ETFs (IHDG, EUDG, BHP, NVS)

Financial news for NVS dated on 2014-05-09: UPDATE: Allergan Rumored to Contact Glaxo, Novartis About Possible Interest

Financial news for NVS dated on 2014-05-07: FDA Approves Xolair for Treatment of Chronic Hives

Financial news for NVS dated on 2014-05-05: Novartis' Announces Positive Results in Phase III Trial of Signifor LAR

Financial news for NVS dated on 2014-05-02: Jefferies Upgrades Novartis AG to Buy

Financial news for NVS dated on 2014-04-29: Novartis Release Confirms FDA Approval for Zykadia to Treat ALK+ NSCLC Previously Treated with ALK Inhibitor Crizotinib

Financial news for NVS dated on 2014-04-29: FDA Issues Approval for Novartis' Zykadia for Late-Stage Lung Cancer

Financial news for NVS dated on 2014-04-29: JP Morgan Upgrades Novartis to Overweight - Bloomberg

Financial news for NVS dated on 2014-04-25: Novartis' INSTEAD Study for Onbrez Breezhaler Meets Primary Objective

Financial news for NVS dated on 2014-04-24: Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns

Financial news for NVS dated on 2014-04-24: RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis

Financial news for NVS dated on 2014-04-24: Natixis Downgrades Novartis AG to Neutral

Financial news for NVS dated on 2014-04-24: UPDATE: Novartis Posts Rise In Q1 Profit

Financial news for NVS dated on 2014-04-24: Earnings Scheduled For April 24, 2014

Financial news for NVS dated on 2014-04-22: Benzinga's M&A Chatter for Tuesday April 22, 2014

Financial news for NVS dated on 2014-04-22: Market Wrap For April 22: S&P Rises For Sixth Straight Day, Dow & Nasdaq Also Positive

Financial news for NVS dated on 2014-04-22: Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)

Financial news for NVS dated on 2014-04-22: US Stock Futures Edge Higher Ahead Of McDonald's Earnings

Financial news for NVS dated on 2014-04-22: Novartis Acquires GSK Oncology Products Business for \$14.5B

Financial news for NVS dated on 2014-04-22: Lilly to Acquire Novartis Animal Health

for Approximately \$5.4B in Cash

Financial news for NVS dated on 2014-04-14: Thrombogenics Says Review is at Prelim. Stage, Does Not Intend to Comment on Market Speculation - Bloomberg

Financial news for NVS dated on 2014-04-14: Novartis, Shire Could Be Weighing Bids for ThromboGenics - Bloomberg

Financial news for NVS dated on 2014-04-11: Adam Feuerstein Tweet: '\$NVS spokesperson says FDA still reviewing Zykadia. Approval email sent in error by an online health community'

Financial news for NVS dated on 2014-04-07: Novartis Meningitis B Vaccine Bexsero Receives FDA Breakthrough Therapy Designation

Financial news for NVS dated on 2014-04-03: Novartis Says Court Has Blocked Biocon from Making Vildagliptin - Bloomberg

Financial news for NVS dated on 2014-04-03: Novartis Presenting Data on 19 Compounds at AACR

Financial news for NVS dated on 2014-03-31: UPDATE: Novartis Announces PARADIGM-HF Trial of LCZ696 for Chronic Heart Failure Closes Early on Strength of Interim Results

Financial news for NVS dated on 2014-03-31: Novartis PARADIGM-HF Trial of LCZ696 for Chronic Heart Failure Closes Early on Strength of Interim Results, Shares Rise 4% in Premarket

Financial news for NVS dated on 2014-03-27: Market Wrap For March 27: Markets Lower Following Mixed Economic Data

Financial news for NVS dated on 2014-03-27: FDA Panel Votes 11-0 Novartis' Serelaxin Should Not Be Approved

Financial news for NVS dated on 2014-03-27: FDA Advisory Panel Recommends Against Approval of Novartis Drug Serelaxin to Treat Acute Heart Failure -Reuters

Financial news for NVS dated on 2014-03-26: Novartis Announces Study Published in New England Journal of Medicine Showed LDK378 Demonstrated Overall Response Rate of 58% in Patients with ALK+ NSCLC

Financial news for NVS dated on 2014-03-25: Market Wrap For March 25: Markets Snap Two-Day Losing Steak On Confidence Data

Financial news for NVS dated on 2014-03-25: FDA Staff Recommends Rejection of Novartis Heart-Failure Drug Serelaxin

Financial news for NVS dated on 2014-03-24: Google Honors Activist Dorothy Height & Her Contributions

Financial news for NVS dated on 2014-03-21: Novartis Announces FDA Has Approved XOLARI for CIU

Financial news for NVS dated on 2014-03-21: US Stock Futures Signal Higher Start On Wall Street

Financial news for NVS dated on 2014-03-21: Novartis Initiates Secukinumab vs Stelara Phase IIIb Head-to-Head Psoriasis Study at AAD 2014

Financial news for NVS dated on 2014-03-20: UPDATE: Novartis CEO Says Aims to File Cart-19 T-Cell Cancer Therapy for Approval in 2016

Financial news for NVS dated on 2014-03-20: UPDATE: Novartis CEO Says Co Could Do Bolt-On Buys in Range Of \$2B-\$5B in Any Year

Financial news for NVS dated on 2014-03-20: Novartis CEO Says Co in Talks With Other Companies Interested in Potential Asset Swaps -Reuters Interview

Financial news for NVS dated on 2014-03-20: Novartis Launches Lucentis in State of the Art Pre-Filled Syringe

Financial news for NVS dated on 2014-03-19: Novartis Offers Data at EBCC-9 Related to Secondary Survival Endpoint of Afinitor Trial in HR+/HER2- Advanced Breast Cancer

Financial news for NVS dated on 2014-03-18: Market Wrap For March 18: Markets Positive Despite Crimea Concerns

Financial news for NVS dated on 2014-03-13: Morgan Stanley Issues Mid-Day Downgrade

on Novartis, Shares Turn Well Into Negative Territory

Financial news for NVS dated on 2014-03-13: Novartis Bexsero Meningitis B Vaccine Receives Clinical Recommendation For Use In Infants And Adolescents In Australia

Financial news for NVS dated on 2014-03-07: Market Wrap For March 7: Markets Cap Off Positive Week With Small Gains

Financial news for NVS dated on 2014-03-07: Novartis Announces Positive Phase III Study for Jakavi in Patients with Polycythemia Vera

Financial news for NVS dated on 2014-02-26: Market Wrap For February 26: Markets Slightly Higher On Housing Data

Financial news for NVS dated on 2014-02-26: GenVec Shares Surge Nearly 20% on Very Light Pre-Market Volume, 8-K from This Morning Showed Third Milestone Had Been Achieved Related to Research, Collaboration, License Deal with Novartis

Financial news for NVS dated on 2014-02-25: European ETFs Flying Under The Radar

Financial news for NVS dated on 2014-02-21: Novartis Announces Lucentis Approval in Japan for Diabetic Macular Edema

Financial news for NVS dated on 2014-02-19: Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak

Financial news for NVS dated on 2014-02-04: Market Wrap For February 4: Investors And Traders Go Bargain Hunting

Financial news for NVS dated on 2014-02-04: Novartis Shares Nearing Session Lows as Bloomberg Highlighting Unconfirmed Story Vaccines Unit is Drawing Interest

Financial news for NVS dated on 2014-02-03: Market Wrap For February 3: Bears In Complete and Absolute Control

Financial news for NVS dated on 2014-01-29: Market Wrap For January 29: Markets Lower on Fed Taper, Emerging Markets Worries

Financial news for NVS dated on 2014-01-28: Tug Of War In Ariad Pharmaceuticals

Financial news for NVS dated on 2014-01-27: Benzinga's M&A Chatter for Monday January 27, 2014

Financial news for NVS dated on 2014-01-24: Market Wrap For January 24: Fear Is Back In The Markets

Financial news for NVS dated on 2014-01-24: Novartis Positive Opinion from CHMP for Xolair in Severe Form of Skin Disease CSU

Financial news for NVS dated on 2014-01-19: NJ Woman Sues Novartis over Pricing of Similar Excedrin Pain Medicines

Financial news for NVS dated on 2014-01-14: UPDATE: Allergan Has Won a Ruling Blocking Generics of Lumigan Until 2027

Financial news for NVS dated on 2014-01-13: Novartis Pharma Canada Receives Health Canada Approval for Ultibro Breezhaler for COPD

Financial news for NVS dated on 2014-01-13: Novartis CEO Jimenez at JP Morgan Conference Says Co Will Provide 2014 Outlook on Jan. 29th, Will Return At Least \$17B Through Buybacks, Dividends Over Next Two Years

Financial news for NVS dated on 2014-01-13: Novartis CEO Jimenez Speaking at JP Morgan Healthcare Conference: Says Portfolio Review is Ongoing

Financial news for NVS dated on 2014-01-13: Cell Therapeutics to Reacquire Rights to Two Anti-Cancer Compounds from Novartis

Financial news for NVS dated on 2014-01-12: No Imminent Widespread Outbreak of Human-to-Human Transmitted Avian Flu Expected

Financial news for NVS dated on 2014-01-09: Jefferies Downgrades Novartis AG to Hold

Financial news for NVS dated on 2014-01-08: UPDATE: NY AG Says Pharmacy Will Pay \$15M to Settle

Financial news for NVS dated on 2014-01-08: UPDATE: NY AG Claiming Novartis Paid Kickbacks to Pharmacy Co.

Financial news for NVS dated on 2014-01-08: NY AG Reports Suit Against Novartis

Financial news for NVS dated on 2014-01-08: UPDATE: Novartis Could Swap Its Animal-Health, Human Vaccines Units for Merck's OTC Health-Products Unit

Financial news for NVS dated on 2014-01-08: Bloomberg Reporting Novartis Said to Be in Talks with Merck on \$5B Unit Swap

Financial news for NVS dated on 2013-12-27: Form 8-K from Wright Medical Group Shows Co. Received (on Dec 20th) Notice from Novartis, Biomimetic of Intent to End Manufacturig, Supply Pact

Financial news for NVS dated on 2013-12-18: Novartis' Sandoz Receives First Approval for AirFluSal Forspiro

Financial news for NVS dated on 2013-12-17: Novartis Pharma Reports Health Canada Approval for ILARIS in SJIA

Financial news for NVS dated on 2013-12-16: Apricus Expands Exclusive License Agreement With Sandoz Affiliate, Apricus to Receive Up to \$63M in Milestone Payments

Financial news for NVS dated on 2013-12-12: Retrophin Signs US License Agreement for Syntocinon Nasal Spray with Novartis

Financial news for NVS dated on 2013-12-09: Novartis Says Jakavi Improved Overall Survival of Patients with Myelofibrosis

Financial news for NVS dated on 2013-12-09: Novartis to Supply Bexsero to Princeton

Financial news for NVS dated on 2013-12-06: US Stock Futures Rise; All Eyes On Jobs Report

Financial news for NVS dated on 2013-12-06: Novartis Investigational Compound LBH589 Met Primary Endpoint in Phase III Study

Financial news for NVS dated on 2013-12-03: Bloomberg Reporting Merck, Eli Lilly Rumored to Be Interested in Novartis' Veterinary Unit

Financial news for NVS dated on 2013-12-03: Novartis Wins Orphan Drug Designation for Polymyositis Treatment

Financial news for NVS dated on 2013-12-03: Stocks Hitting 52-Week Highs

Financial news for NVS dated on 2013-12-03: Morning Market Movers

Financial news for NVS dated on 2013-12-03: Benzinga's Top #PreMarket Gainers

Financial news for NVS dated on 2013-12-03: Reuters Reports Novartis Letting Bayer, Other Potential Buyers Look at Animal Health Business Books, According to Sources

Financial news for NVS dated on 2013-11-25: Natixis Upgrades Novartis AG to Buy

Financial news for NVS dated on 2013-11-22: Market Wrap For November 22: Markets Finish The Week On a Positive Note

Financial news for NVS dated on 2013-11-22: US Stock Futures Flat After Record Close

Financial news for NVS dated on 2013-11-22: Novartis Announces \$5B Share Buyback

Financial news for NVS dated on 2013-11-18: UPDATE: IntelliPharmaCeutics Will Have 180 Days Exclusivity of Generic Sales

Financial news for NVS dated on 2013-11-18: IntelliPharmaCeutics to Make Immediate Commercial Launch of 15, 30mg Generic Focalin XR

Financial news for NVS dated on 2013-11-11: Mid-Day Market Update: Gogo Jumps On Upbeat Results; 8x8 Shares Tumble

Financial news for NVS dated on 2013-11-11: Mid-Morning Market Update: Markets Edge Higher; Shire To Acquire ViroPharma For \$4.2B

Financial news for NVS dated on 2013-11-11: ImmunoGen Announces License Agreement with Novartis

Financial news for NVS dated on 2013-11-11: Grifols to Acquire Transfusion Diagnostics Business of Novartis for \$1,675M

Financial news for NVS dated on 2013-11-04: Bloomberg Reporting Novartis Said to Explore Sale of Animal-Health Unit

Financial news for NVS dated on 2013-10-29: Questcor Says in Process of Transferring Critical Data from Novartis

Financial news for NVS dated on 2013-10-22: Alcon Receives Positive NICE Recommendation for Jetrea

Financial news for NVS dated on 2013-10-22: Novartis AG Reports Q3 Core EPS of \$1.26 vs \$1.31 Est; Revenue of \$14.30B vs \$14.28B Est

Financial news for NVS dated on 2013-10-14: Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Financial news for NVS dated on 2013-10-11: US Stock Futures Up; J.P. Morgan Earnings In Focus

Financial news for NVS dated on 2013-10-11: ImmunoGen Announces New License Agreement with Novartis

Financial news for NVS dated on 2013-10-09: Shares of Vanda Pharma Bouncing Off Session Lows Despite Concern Related to Novartis's Fanapt Winning Paragraph IV Patent Notification from FDA

Financial news for NVS dated on 2013-10-09: MainFirst Initiates Coverage on Novartis AG at Underperform

Financial news for NVS dated on 2013-10-08: JP Morgan Downgrades Novartis AG to Neutral

Financial news for NVS dated on 2013-10-03: Novartis Reports Evidence Gilenya Reduce MS Relapse Rates More Effectively than Interferons or Glatiramer Acetate

Financial news for NVS dated on 2013-09-27: Novartis Shares Higher as Co. Says Newest Lucentis Data Reinforces Efficacy; UBS Removed Stock from 'Most Preferred' List

Financial news for NVS dated on 2013-09-25: BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

Financial news for NVS dated on 2013-09-22: Barron's Recap: Protecting Your Health and Wealth

Financial news for NVS dated on 2013-09-19: Novartis Wins FDA Orphan Drug Designation for Cushing's Disease Treatment

Financial news for NVS dated on 2013-09-19: Write A Prescription For Health Care ETFs

Financial news for NVS dated on 2013-09-16: Barclays Downgrades Novartis AG to Underweight

Financial news for NVS dated on 2013-09-08: Novartis Data Demonstrates Efficacy of Ultibro Breezhaler

Financial news for NVS dated on 2013-09-06: FDA Approves Novartis Request to Supplement BLA for Fluvirin at Speke Site

Financial news for NVS dated on 2013-08-27: Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

Financial news for NVS dated on 2013-08-26: Amgen and Onyx Finally Ink Deal Two Months In The Making

Financial news for NVS dated on 2013-08-15: US Stock Futures Down Ahead Of Economic Data

Financial news for NVS dated on 2013-08-15: Novartis Vaccine Bexsero Approved in Australia

Financial news for NVS dated on 2013-08-13: Benzinga's M&A Chatter for Tuesday August 13, 2013

Financial news for NVS dated on 2013-08-13: Bloomberg Reporting Novartis Said to Be Out of Running for Onyx

Financial news for NVS dated on 2013-08-13: Onyx Not Speculating on Novartis CEO Comments Regarding Potential \$10B Acquisition

Financial news for NVS dated on 2013-08-13: UPDATE: Novartis Chair Says Will Review Business Including Animal Health, Vaccines, Calls Bolt-On Acquisitions Attractive

Financial news for NVS dated on 2013-08-13: Bloomberg Reporting Novartis Chair Reinhardt Speaking in Interview Said \$10B Acquisition is Not 'Out of Reach'

Financial news for NVS dated on 2013-08-05: Apple, Wal-Mart And Other Companies With Monster Share Buyback (AAPL, WMT)

Financial news for NVS dated on 2013-08-01: (ONE) Novartis International AG : FDA Expands Age Indication for Menveo(r), First and Only Quadrivalent Meningococcal Vaccine

Financial news for NVS dated on 2013-07-30: Benzinga's M&A Chatter for Tuesday July 30, 2013

Financial news for NVS dated on 2013-07-30: Hearing Deal Reporter Says Novartis Submits Bid for Onyx

Financial news for NVS dated on 2013-07-26: Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

Financial news for NVS dated on 2013-07-23: Bloomberg Reporting a Novartis Spokesperson Has Said the Co. Has Not Been contacted by Chinese Authorities

Financial news for NVS dated on 2013-07-22: Benzinga's M&A Chatter for Monday July 22, 2013

Financial news for NVS dated on 2013-07-22: Bloomberg Reporting Pfizer, Novartis, AstraZeneca Said to Be Preparing Onyx Pharma Bids

Financial news for NVS dated on 2013-07-17: UPDATE: Novartis Posts 4.7% Fall In Q2 Profit, Lifts Sales Forecast

Financial news for NVS dated on 2013-07-11: Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)

Financial news for NVS dated on 2013-07-08: A Peek Into The Market Before The Trading Starts

Financial news for NVS dated on 2013-07-08: Novartis and Biological E Enter License Agreement

Financial news for NVS dated on 2013-07-08: Novartis Announces Secukinumab Demonstrated Superiority to Enbrel

Financial news for NVS dated on 2013-07-05: 5 Healthcare Stocks With The Highest Revenue

Financial news for NVS dated on 2013-07-04: Financial Times Reporting That China Is Investigating 33 Foreign Pharmaceutical Companies For Pricing Irregularities

Financial news for NVS dated on 2013-07-03: Novartis Files Suit Against Intas Pharma Claiming Patent Infringement on Generic Myfortic

Financial news for NVS dated on 2013-07-02: Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)

Financial news for NVS dated on 2013-07-01: Afternoon Market Losers

Financial news for NVS dated on 2013-07-01: Lazard Calls Insmed's Arikace 'Still Viable' Following Competitor Concern, Continues to See Massive Upside in Shares

Financial news for NVS dated on 2013-06-26: Novartis reports Omalizumab Met All Primary and Secondary Endpoints in Pivotal GLACIAL Study

Financial news for NVS dated on 2013-06-24: ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM)

Financial news for NVS dated on 2013-06-14: Leerink Swann's Gerberry Sees a Likely Win or Settle from Actavis in Litigation with Novartis, Maintains Market Perform

Financial news for NVS dated on 2013-06-13: UPDATE: Novartis Spokesperson Says 'Has Confidence in Integrity' of Gleevac Patent

Financial news for NVS dated on 2013-06-13: Sun Pharma Challenges Novartis Patent on Gleeevec Crystal Form in US District Court in NJ

Financial news for NVS dated on 2013-06-12: Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Financial news for NVS dated on 2013-06-11: Jefferies Says Questcor's Acquisition of



## Synacthen Rights Should Soothe Investor Fears

Financial news for NVS dated on 2013-06-11: UPDATE: Questcor Rises 23% Pre-Market on Synacthen Rights Acquisition from Novartis

Financial news for NVS dated on 2013-06-11: UPDATE: Questcor Rises 20% Pre-Market on Synacthen Acquisition from Novartis

Financial news for NVS dated on 2013-06-11: UPDATE: Questcor Rises 12% Pre-Market on Synacthen Acquisition

Financial news for NVS dated on 2013-06-11: Questcor Acquires Rights to Synacthen from Novartis

Financial news for NVS dated on 2013-06-10: AstraZeneca to Acquire Pearl Therapeutics to Gain Foothold into Lucrative Market (AZN, GSK, NVS)

Financial news for NVS dated on 2013-06-08: Top-Performing Dividend Payers in Health Care with the Most Upside Potential (AET, ENSG, QCOR)

Financial news for NVS dated on 2013-06-06: Drug Company Profits Set to Increase from Additions to DSM-5 (LLY, NVS, PFE)

Financial news for NVS dated on 2013-06-05: Novartis Receives FDA Warning Over Austria Ebewe Plant - FiercePharma

Financial news for NVS dated on 2013-06-03: Novartis Says Breakthrough Therapy LDK378 Shows Marked Clinical Response

Financial news for NVS dated on 2013-06-02: Novartis Afinitor Pivotal Phase 3 Trial Shows Significant Delay in Tumor Growth In HER2 Positive Advanced Breast Cancer

Financial news for NVS dated on 2013-05-31: Novartis Wins Positive Opinion for Patients with Myopic Choroidal Neovascularization Showing Vision Gains with Only Two Injections

Financial news for NVS dated on 2013-05-29: Short Interest in Vertex Rises, in Biogen Idec Falls

Financial news for NVS dated on 2013-05-28: Valeant Pharmaceuticals to Buy Bausch & Lomb

Financial news for NVS dated on 2013-05-21: New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations

Financial news for NVS dated on 2013-05-21: Novartis Says New Data Reinforce Strength of Once-Daily COPD Portfolio

Financial news for NVS dated on 2013-05-16: Bloomberg Reporting Novartis Spokesperson Says Has 'No Intention' of Pursuing Actavis Bid

Financial news for NVS dated on 2013-04-26: Novartis Sued by US for Paying Kickbacks to Doctors

Financial news for NVS dated on 2013-04-26: Short Sellers Move into Celgene, Regeneron

Financial news for NVS dated on 2013-04-24: Novartis Says Vaccines, Diagnostics Unit Received Subpoena from US Attorney in Q1 Related to Quality

Financial news for NVS dated on 2013-04-24: Novartis AG Reports Q1 Revenue of \$14.02B vs \$13.98B Est

Financial news for NVS dated on 2013-04-24: Earnings Scheduled For April 24, 2013

Financial news for NVS dated on 2013-04-11: Benzinga's M&A Chatter for Thursday April 11, 2013

Financial news for NVS dated on 2013-04-11: ETF Showdown: A Pharma Fight

Financial news for NVS dated on 2013-04-11: Novartis Spokesperson Declines Comment on Rumor of Bid for Prolor Biotech

Financial news for NVS dated on 2013-04-11: Globes Says Earlier Takeover Chatter in Prolor Biotech is Not True

Financial news for NVS dated on 2013-04-11: Hearing Unconfirmed Takeover Chatter in Prolor Biotech

Financial news for NVS dated on 2013-04-08: UPDATE: Bank of America Upgrades Novartis AG to Neutral on Sector Re-Rating

Financial news for NVS dated on 2013-04-08: A Peek Into The Market Before The Trading Starts

Financial news for NVS dated on 2013-04-08: Bank of America Upgrades Novartis AG to Neutral, Raises to \$74.71

Financial news for NVS dated on 2013-04-04: Four Dow Components Due for a Dividend Hike (CVX, XOM, IBM, JNJ)

Financial news for NVS dated on 2013-03-23: Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR)

Financial news for NVS dated on 2013-03-15: UPDATE: JP Morgan Upgrades Novartis to Overweight; Multiple Should Approach Peers

Financial news for NVS dated on 2013-03-15: JP Morgan Upgrades Novartis AG to Overweight

Financial news for NVS dated on 2013-03-05: 3 ADR ETFs Your Broker Forgot to Mention

Financial news for NVS dated on 2013-02-22: Are Global Health Care ETFs Worth Prescribing?

Financial news for NVS dated on 2013-02-08: Moody's Cuts Novartis Long-Term Rating to Aa3 from Aa2

Financial news for NVS dated on 2013-01-25: Apple Finds A Sweet Spot In China, But Other American Brands?

Financial news for NVS dated on 2013-01-23: FDA Approves Exjade to Remove Excess Iron in Some Patients; Exjade Marketed by Novartis

Financial news for NVS dated on 2013-01-23: Citigroup Upgrades Novartis AG to Buy

Financial news for NVS dated on 2013-01-23: Novartis AG Reports Q4 EPS of \$1.27 vs \$1.19 Est; Revenue of \$14.80B vs \$14.42B Est

Financial news for NVS dated on 2013-01-23: UPDATE: Novartis Posts Rise In Q4 Profit

Financial news for NVS dated on 2013-01-18: EMA Says Novartis, Regeneron Win Backing for Ilaris

Financial news for NVS dated on 2013-01-16: Hamburger Sparkasse Downgraded Novartis AG to Hold

Financial news for NVS dated on 2013-01-11: Three Stocks to Buy for Flu Season

Financial news for NVS dated on 2013-01-07: Endo Health, Novartis Mutually Ended Master Development/Toll Pact

Financial news for NVS dated on 2012-12-28: Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

Financial news for NVS dated on 2012-12-20: Dendreon Announces Sale of New Jersey Plant to Novartis for \$43M in Cash

Financial news for NVS dated on 2012-12-12: Benzinga's Top Downgrades

Financial news for NVS dated on 2012-12-12: Deutsche Bank Downgrades Novartis AG to Hold

Financial news for NVS dated on 2012-12-10: Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)

Financial news for NVS dated on 2012-12-10: 10 For '13: Top Picks Among Europe ETFs For 2013

Financial news for NVS dated on 2012-12-08: Barron's Recap (12/8/12): Ten Stock Picks for 2013

Financial news for NVS dated on 2012-11-20: Novartis's FlucelVax Receives FDA Approval

Financial news for NVS dated on 2012-11-12: Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

Financial news for NVS dated on 2012-11-07: Novartis Announces Signifor for Cushing's Disease Recommended by FDA Panel

Financial news for NVS dated on 2012-10-03: Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

Financial news for NVS dated on 2012-10-03: FDA Cancels November 8, 2012 Oncologic Drugs Advisory Committee Meeting

Financial news for NVS dated on 2012-09-28: ETF Showdown: Swiss Beats

Financial news for NVS dated on 2012-09-25: Warning of New SARS-Like Virus -WantChinaTimes

Financial news for NVS dated on 2012-09-17: Benzinga's Top Upgrades

Financial news for NVS dated on 2012-08-30: FDA approves Novartis Afinitor Disperz for Children with Rare Brain Tumor

Financial news for NVS dated on 2012-07-19: UPDATE: Novartis Posts Upbeat Q2 Profit

Financial news for NVS dated on 2012-06-26: Benzinga's M&A Chatter for Tuesday June 26, 2012

Financial news for NVS dated on 2012-06-26: Spokesperson for Novartis Declines Comment on Amylin Bid

Financial news for NVS dated on 2012-06-26: Spokesperson for Amylin Pharmaceuticals Won't Comment on Rumor of Bids from Pharma Companies

Financial news for NVS dated on 2012-06-26: Novartis, Sanofi, Merck, Bristol, AstraZeneca Weigh Amylin Final Bids; Amylin Expects Final Bids Starting End of the Week -Reuters

Financial news for NVS dated on 2012-06-12: 5 Healthcare Stocks With The Highest Revenue

Financial news for NVS dated on 2012-05-23: Blueberries, Gold Bond, Ovaltine and Obesity: The Makings for a Very Good Story (Part 1)

Financial news for NVS dated on 2012-05-14: Novartis Sues Lupin, Torrent Over Blood-Pressure Drug -Bloomberg

Financial news for NVS dated on 2012-05-02: Novartis Will Buy Fougera Pharma for \$1.525B

Financial news for NVS dated on 2012-04-24: Novartis AG Reports Q1 EPS \$1.27 vs \$1.32 Est; Revenues \$13.73B vs \$13.95B Est

Financial news for NVS dated on 2012-04-24: UPDATE: Novartis Reports Decline In Q1 Profit

Financial news for NVS dated on 2012-03-20: Benzinga's M&A Chatter for Tuesday March 20, 2012

Financial news for NVS dated on 2012-03-20: Novartis Spokesperson Would Not Comment on Rumor of Hospira Takeover by Sandoz

Financial news for NVS dated on 2012-03-18: Barron's Recap: Home Prices on the Rebound, the BATS Global Markets IPO

Financial news for NVS dated on 2012-03-15: EMA Says Novartis Withdraws Applications For Revastigmine Extn

Financial news for NVS dated on 2012-03-13: Positive Rumors Circulate About Celgene

Financial news for NVS dated on 2012-03-06: UPDATE: JP Morgan Downgrades Novartis to Neutral

Financial news for NVS dated on 2012-03-06: Benzinga's Top Downgrades

Financial news for NVS dated on 2012-03-06: Financial Breakfast: Morning News Summary for March 6, 2012

Financial news for NVS dated on 2012-03-06: JP Morgan Downgrades Novartis AG from Overweight to Neutral

Financial news for NVS dated on 2012-02-28: FDA Approves Important Safety Label

Changes For The Class Of Cholesterol-Lowering Drugs Known As Statins -Reuters

Financial news for NVS dated on 2012-02-24: Option Alert: Heavy Call Buying in Novartis, April 50, 52.5, 55 Calls

Financial news for NVS dated on 2012-02-06: UPDATE: Bank of America Downgrades Novartis to Underperform

Financial news for NVS dated on 2012-02-01: From Earlier: FDA Approves Novartis Drug Gleevec Label Recommending Extending Treatment to Three Years for Certain GIST Patients After Surgery

Financial news for NVS dated on 2012-01-25: Earnings Roundup

Financial news for NVS dated on 2012-01-25: Financial Breakfast: Morning News Summary for January 25, 2012

Financial news for NVS dated on 2012-01-25: Novartis AG Reports Q4 EPS \$1.23 vs \$1.24 Est; Revenues \$14.78B vs \$14.93B Est

Financial news for NVS dated on 2012-01-25: Novartis Q4 Net Profit Drops 46%

Financial news for NVS dated on 2012-01-17: Benzinga's M&A Chatter for Tuesday January 17, 2012

Financial news for NVS dated on 2012-01-13: Drug Failures and Firings will Hurt Novartis, But Can a Dividend Heal All Ills?

Financial news for NVS dated on 2012-01-13: US Stock Futures Mixed; J.P. Morgan Earnings In Focus

Financial news for NVS dated on 2012-01-13: Novartis To Lower 1,960 Job

Financial news for NVS dated on 2012-01-13: Stocks To Watch For January 13

Financial news for NVS dated on 2012-01-11: How to Trade Biotechs Based on the JP Morgan Health Care Conference

Financial news for NVS dated on 2012-01-10: Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target?

Financial news for NVS dated on 2012-01-09: Will the Swiss Guide Europe?

Financial news for NVS dated on 2011-12-29: Stay Safe in 2012 With These 5 Stocks

Financial news for NVS dated on 2011-12-27: Best Biotech Stocks of 2011

Financial news for NVS dated on 2011-12-20: Benzinga's M&A Chatter for Tuesday December 20, 2011

Financial news for NVS dated on 2011-12-20: Notable Call Options Activity in Novartis

Financial news for NVS dated on 2011-12-20: Dendreon Spiking Higher on Rumored Discussion with Novartis

Financial news for NVS dated on 2011-12-19: Key Phase IIb Clinical Trial Results Await Smoking Cessation Player This Week

Financial news for NVS dated on 2011-12-12: Notable Put Options Activity in Novartis

Financial news for NVS dated on 2011-12-12: Novartis Says Patient Died Day After Beginning Gilenya Therapy

Financial news for NVS dated on 2011-12-09: Five Biotech Stocks to Watch Going into Big Doctors' Meeting

Financial news for NVS dated on 2011-12-06: GenVec Achieves Second Milestone in Collaboration

Financial news for NVS dated on 2011-11-29: Citigroup Initiates Novartis at Neutral

Financial news for NVS dated on 2011-11-25: Novartis AG Hits 52-Week Low of \$51.75

Financial news for NVS dated on 2011-11-22: Mad Money Lightning Round: Cramer Likes Waste Management

Financial news for NVS dated on 2011-11-18: Will Incyte's Blood Cancer Drug Bring Dividends?

Financial news for NVS dated on 2011-11-17: Study Shows Novartis Malaria Drug Kills Bugs at Earliest Stage

Financial news for NVS dated on 2011-11-01: Intellipharma Announces Milestone; Analysts Raise Firm's Price Targets Ahead of Another

Financial news for NVS dated on 2011-10-31: Watch for YM BioSciences' Upcoming Clinical Data Catalyst

Financial news for NVS dated on 2011-10-25: End-of-Day Market Summary for October 25, 2011

Financial news for NVS dated on 2011-10-25: What Does Novartis' Earnings Release Really Mean for the Company?

Financial news for NVS dated on 2011-10-25: Novartis Spiking Lower on Heavy Volume

Financial news for NVS dated on 2011-10-25: Earnings Roundup

Financial news for NVS dated on 2011-10-25: From Earlier: Novartis Reports Q3 EPS \$1.45 vs \$1.45 Est; Revenues \$14.8B vs \$15.09B Est

Financial news for NVS dated on 2011-10-25: Novartis Reports 7.9% Rise In Q3 Net Profit

Financial news for NVS dated on 2011-10-24: 13 Drug Companies Trying to Beat the Odds in Pancreatic Cancer

Financial news for NVS dated on 2011-10-05: Regeneron Shares Falling On Competitor Concerns

Financial news for NVS dated on 2011-09-27: New Novartis Data Show Potential Of Respiratory Portfolio To Help COPD Patients Maintain Active And Productive Lives

Financial news for NVS dated on 2011-09-16: UPDATE: Novartis Drug Gives Relief Of Symptoms In 84% Of Study Patients; Will File Ilaris For SJIA Indication Next Year

Financial news for NVS dated on 2011-09-16: Novartis: Ilaris Gives Good Results In Study

Financial news for NVS dated on 2011-09-05: Novartis gets European Commission Approval for Afinitor to Treat Advanced Pancreatic Tumors

Financial news for NVS dated on 2011-08-10: How to Profit from Swiss Central Bank's Efforts to Halt Rise of Swiss Franc

Financial news for NVS dated on 2011-08-08: Calls Purchased on Novartis

Financial news for NVS dated on 2011-08-05: Swiss Stocks: The Last Haven?

Financial news for NVS dated on 2011-08-02: Amneal Announces Four New Generic Drugs

Financial news for NVS dated on 2011-07-25: Watson Pharmaceuticals Earnings Preview

Financial news for NVS dated on 2011-07-22: Earnings Preview: Mylan Laboratories EPS, Revenue Expected to Rise from Previous Quarter

Financial news for NVS dated on 2011-07-19: Earnings Roundup

Financial news for NVS dated on 2011-07-19: UPDATE: Novartis Reports 12% Rise In Q2 Net Profit

Financial news for NVS dated on 2011-07-18: Novartis: Earnings Preview

Financial news for NVS dated on 2011-07-08: Five Undervalued Blue Chips with Above-average and Growing Yield

Financial news for NVS dated on 2011-07-07: Five Undervalued Blue Chips with Above-average and Growing Yield

Financial news for NVS dated on 2011-07-05: News Summary for July 5, 2011

Financial news for NVS dated on 2011-07-05: Novartis Drug Afinitor(r) Met Primary Endpoint Of Phase III Study In Women

Financial news for NVS dated on 2011-07-05: Stocks To Watch For July 5

Financial news for NVS dated on 2011-07-01: Novartis Receives Approval In Japan For Onbrez; Inhalation Capsules, For Patients With COPD

Financial news for NVS dated on 2011-06-23: Forest Labs and Watson Pharma to Open Near 52-Week Highs

Financial news for NVS dated on 2011-06-21: UPDATE: The Panel has Voted 11-1 Against the Approval of the Novartis Drug

Financial news for NVS dated on 2011-06-21: UPDATE: FDA Voting on Novartis Approval

Financial news for NVS dated on 2011-06-21: FDA Panel has Voted 12-0 that Novartis Gout Drug is Not Considered Safe

Financial news for NVS dated on 2011-06-17: Gen-Probe Incorporated: Hearing Chatter of Novartis and "Expensive" Assets, According to Sources

Financial news for NVS dated on 2011-06-17: FDA Comments in Staff Report About Novartis Drug Ilaris Reducing Gout Pain, May Increase Risk of Infection

Financial news for NVS dated on 2011-06-16: Novartis Application for Expanded Menveo Indication from 2 Months of Age Accepted for Review by FDA

Financial news for NVS dated on 2011-06-06: It's Inverted Hammertime! 06-06-2011

Financial news for NVS dated on 2011-05-23: Parkinson's Disease Bacteria Link Discovered: Companies Looking for a Cure

Financial news for NVS dated on 2011-05-23: Europe's sovereign-debt crisis Effects on Drug Stocks

Financial news for NVS dated on 2011-05-22: Top Healthcare and Major Drugs stocks to watch- Sector Performance

Financial news for NVS dated on 2011-05-18: WSJ: Novartis, Life Technologies Also In The Mix For Gen-Probe - Sources

Financial news for NVS dated on 2011-05-17: 10 Stocks Billionaire Steven Cohen Is Buying

Financial news for NVS dated on 2011-05-15: CEOWORLD Most Promising Top Dividend Stock Picks To Buy Right Now

Financial news for NVS dated on 2011-05-11: Emerging Markets

Financial news for NVS dated on 2011-05-10: Novartis Fires Senior Managers for Misconduct -WSJ (NVS)

Financial news for NVS dated on 2011-05-06: UPDATE: FDA Approves New Treatment for Rare Type of Pancreatic Cancer (NVS)

Financial news for NVS dated on 2011-05-05: Top Gainers and Losers Stock Picks based on mkt cap (5/5/11)- PG, INTC, MSFT, NVS, GMCR, BHP, PBR, VALE, VALE.P, PBR.A

Financial news for NVS dated on 2011-05-02: CEOWORLD Top 5 Analyst Calls of the Week-DNDN, INSP, MCP, SIRI, VICL

Financial news for NVS dated on 2011-04-28: Potential Buyers For Gen-Probe (GPRO, ABT, CELG, NVS, TMO)

Financial news for NVS dated on 2011-04-27: Earnings Preview For Celgene Corporation (CELG, NVS)

Financial news for NVS dated on 2011-04-20: Five Stocks that May End Up, umm, Higher, if Marijuana is Legalized

Financial news for NVS dated on 2011-04-19: Novartis Reports Q1 EPS of \$1.41

Financial news for NVS dated on 2011-04-12: Hapoalim Securities Reiterates Buy Rating, \$15 PT On VNDA

Financial news for NVS dated on 2011-04-07: LifeTech Capital Comments On Merck Acquisition (MRK, ISPH)

Financial news for NVS dated on 2011-02-16: Unconfirmed Rumors circulate that Novartis AG (NVS) Is in talks with Star Scientific, Inc. (CIGX) on a major Joint Venture.Would be huge positive for (CIGX).

Financial news for NVS dated on 2011-02-14: Valentine's KISS 02-14-2011

Financial news for NVS dated on 2011-02-04: Vanda Pharmaceuticals Falling On

## Disappointing Drug Sales (VNDA)

Financial news for NVS dated on 2011-02-01: Biogen Beats by a Wide Margin - Analyst Blog

Financial news for NVS dated on 2011-02-01: Biogen Beats by a Wide Margin - Analyst Blog

Financial news for NVS dated on 2011-02-01: Onyx Makes Headway with Carfilzomib - Analyst Blog

Financial news for NVS dated on 2011-02-01: Onyx Makes Headway with Carfilzomib - Analyst Blog

Financial news for NVS dated on 2011-01-31: Piper Jaffray Defends THRX Following Delayed Sell-Off

Financial news for NVS dated on 2011-01-28: Vaccines Pull Down NVS Q4 Earnings - Analyst Blog

Financial news for NVS dated on 2011-01-28: Vaccines Pull Down NVS Q4 Earnings - Analyst Blog

Financial news for NVS dated on 2011-01-28: Novartis to Buy Genoptix - Analyst Blog

Financial news for NVS dated on 2011-01-28: Novartis to Buy Genoptix - Analyst Blog

Financial news for NVS dated on 2011-01-27: Alcon's Winning Streak Continues - Analyst Blog

Financial news for NVS dated on 2011-01-27: Alcon's Winning Streak Continues - Analyst Blog

Financial news for NVS dated on 2011-01-24: Market Roundup (HAL, GXDX, NVS, INTC, AXP, CSX, TXN)

Financial news for NVS dated on 2011-01-24: Top Narrow Based Indexes For January 24 (CLDA, LDK, GXDX)

Financial news for NVS dated on 2011-01-24: Benzinga's Volume Movers (GXDX, CLDA, HUGH, LPHI)

Financial news for NVS dated on 2011-01-24: Morning Market Movers (CLDA, OCCF, SCCC, GXDX)

Financial news for NVS dated on 2011-01-24: Benzinga's Top Pre-Market NASDAQ Gainers (CLDA, GXDX, NVDA, ATPG)

Financial news for NVS dated on 2011-01-20: 5 Drug Stocks With Upside Potential of 25%

Financial news for NVS dated on 2011-01-20: MannKind in Jeopardy - Analyst Blog

Financial news for NVS dated on 2011-01-20: MannKind in Jeopardy - Analyst Blog

Financial news for NVS dated on 2011-01-19: Cooper Launches Avaira Toric - Analyst Blog

Financial news for NVS dated on 2011-01-19: Cooper Launches Avaira Toric - Analyst Blog

Financial news for NVS dated on 2011-01-13: Biogen's Business Update - Analyst Blog

Financial news for NVS dated on 2011-01-13: Biogen's Business Update - Analyst Blog

Financial news for NVS dated on 2011-01-13: Lucentis Gains EU Approval for DME - Analyst Blog

Financial news for NVS dated on 2011-01-13: Lucentis Gains EU Approval for DME - Analyst Blog

Financial news for NVS dated on 2011-01-03: Xoma: Key Diabetes Drug Study Preview

Financial news for NVS dated on 2010-12-30: XOMA Shares Climb 8.6% (XOMA, NVG, MRK)

Financial news for NVS dated on 2010-12-30: Thursday's Put/Call Ratio Leaders (CTXS, NTAP, BCS, NVS, MDT)

Financial news for NVS dated on 2010-12-30: Top 10 Emerging Markets Stocks in 2010

Financial news for NVS dated on 2010-12-22: INCY's INC424 Meets Goal - Analyst Blog

Financial news for NVS dated on 2010-12-22: INCY's INC424 Meets Goal - Analyst Blog

Financial news for NVS dated on 2010-12-21: Cooper Remains at Outperform - Analyst Blog

Financial news for NVS dated on 2010-12-21: Cooper Remains at Outperform - Analyst Blog

Financial news for NVS dated on 2010-12-21: Cooper Remains at Outperform - Analyst Blog

Financial news for NVS dated on 2010-12-21: Cooper Remains at Outperform - Analyst Blog

Financial news for NVS dated on 2010-12-21: Big Pharma in Frenzy of Drug Deals

Financial news for NVS dated on 2010-12-20: Genzyme Up After Analyst Day (GENZ)

Financial news for NVS dated on 2010-12-20: Novartis Commits \$500 Million to Russia

Financial news for NVS dated on 2010-12-17: Amgen Drug Meets Primary Endpoint - Analyst Blog

Financial news for NVS dated on 2010-12-17: Amgen Drug Meets Primary Endpoint - Analyst Blog

Financial news for NVS dated on 2010-12-16: Watching the Strength of this Uptrend 12-16-2010

Financial news for NVS dated on 2010-12-16: Novartis to Wrap Up Alcon Buy - Analyst Blog

Financial news for NVS dated on 2010-12-16: Novartis to Wrap Up Alcon Buy - Analyst Blog

Financial news for NVS dated on 2010-12-16: Stock Market News for Dec 16, 2010 - Market News

Financial news for NVS dated on 2010-12-16: Novartis Trading Lower Today

Financial news for NVS dated on 2010-12-16: Stock Market News for Dec 16, 2010 - Market News

Financial news for NVS dated on 2010-12-15: Good Data on Teva's Laquinimod - Analyst Blog

Financial news for NVS dated on 2010-12-15: Good Data on Teva's Laquinimod - Analyst Blog

Financial news for NVS dated on 2010-12-15: Large Cap Winners & Losers (NVS, CAT, HDB, FBR)

Financial news for NVS dated on 2010-12-15: Novartis' Zometa Disappoints - Analyst Blog

Financial news for NVS dated on 2010-12-15: Novartis' Zometa Disappoints - Analyst Blog

Financial news for NVS dated on 2010-12-15: Company News for December 15, 2010 - Corporate Summary

Financial news for NVS dated on 2010-12-15: Company News for December 15, 2010 - Corporate Summary

Financial news for NVS dated on 2010-12-15: M&A News (CYPB, NVS, ACL, RF)

Financial news for NVS dated on 2010-12-15: A Peek Into The Market Before The Trading Starts

Financial news for NVS dated on 2010-12-15: Novartis Completes Takeover Of Alcon

Financial news for NVS dated on 2010-12-15: US Stock Futures Down As Investors Await Economic Data

Financial news for NVS dated on 2010-12-15: Novartis Buys Rest of Alcon Stake for \$12.9B



Financial news for NVS dated on 2010-12-14: Novartis Presents Positive Data - Analyst Blog

Financial news for NVS dated on 2010-12-14: Novartis Presents Positive Data - Analyst Blog

Financial news for NVS dated on 2010-12-10: NVS Presents Positive Data at ASH - Analyst Blog

Financial news for NVS dated on 2010-12-10: Friday's Put/Call Ratio Leaders (NVS, STD, BPOP, GCI, MU)

Financial news for NVS dated on 2010-12-10: NVS Presents Positive Data at ASH - Analyst Blog

Financial news for NVS dated on 2010-12-09: Cooper Outperforms, Profit Zooms - Analyst Blog

Financial news for NVS dated on 2010-12-08: Cooper Outperforms, Profit Zooms - Analyst Blog

Financial news for NVS dated on 2010-12-08: Cooper Outperforms, Profit Zooms - Analyst Blog

Financial news for NVS dated on 2010-12-08: Cooper Outperforms, Profit Zooms - Analyst Blog

Financial news for NVS dated on 2010-12-08: Some Good News for Onyx Pharma - Analyst Blog

Financial news for NVS dated on 2010-12-08: Some Good News for Onyx Pharma - Analyst Blog

Financial news for NVS dated on 2010-12-08: Wednesday's Put/Call Ratio Leaders (NVS, JDSU, DHI, FLR, DG)

Financial news for NVS dated on 2010-12-08: Phase III Data on PFE's Bosutinib - Analyst Blog

Financial news for NVS dated on 2010-12-08: Phase III Data on PFE's Bosutinib - Analyst Blog

Financial news for NVS dated on 2010-12-07: Good News for Bristol-Myers - Analyst Blog

Financial news for NVS dated on 2010-12-07: Good News for Bristol-Myers - Analyst Blog

Financial news for NVS dated on 2010-12-07: Benzinga's Top Upgrades (GFI, NVS, VE, TEL)

Financial news for NVS dated on 2010-12-03: Neutral on Incyte - Analyst Blog

Financial news for NVS dated on 2010-12-03: Neutral on Incyte - Analyst Blog

Financial news for NVS dated on 2010-12-03: CBST's Fast-Injection Cubicin OK'd - Analyst Blog

Financial news for NVS dated on 2010-12-03: CBST's Fast-Injection Cubicin OK'd - Analyst Blog

Financial news for NVS dated on 2010-12-03: Economy Adds Fewer Jobs in November

Financial news for NVS dated on 2010-12-01: ADP: November Payrolls Rise 93,000

Financial news for NVS dated on 2010-11-29: Neutral on Regeneron - Analyst Blog

Financial news for NVS dated on 2010-11-29: Neutral on Regeneron - Analyst Blog

Financial news for NVS dated on 2010-11-23: Tuesday's Put/Call Ratio Leaders (IFF, GVA, NVS, ANN, TLAB)

Financial news for NVS dated on 2010-11-19: Unconfirmed Rumors continue to swirl that Questcor Pharmaceuticals, Inc. (QCOR) will be acquired by a Major Pharma at \$24.00 a share

Financial news for NVS dated on 2010-11-19: Amgen's Xgeva Approved - Analyst Blog

Financial news for NVS dated on 2010-11-19: Amgen's Xgeva Approved - Analyst Blog

Financial news for NVS dated on 2010-11-17: WCRX Beats on Earnings, Ups Outlook - Analyst Blog

Financial news for NVS dated on 2010-11-17: WCRX Beats on Earnings, Ups Outlook - Analyst Blog

Financial news for NVS dated on 2010-11-16: Ardea Biosciences Evenly Poised - Analyst Blog

Financial news for NVS dated on 2010-11-16: Tuesday's Put/Call Ratio Leaders (CADX, ROC, LH, MNTA, NVS)

Financial news for NVS dated on 2010-11-16: Positive on Biogen - Analyst Blog

Financial news for NVS dated on 2010-11-16: PDLI Meets EPS, Beats on Top Line - Analyst Blog

Financial news for NVS dated on 2010-11-16: PDLI Meets EPS, Beats on Top Line - Analyst Blog

Financial news for NVS dated on 2010-11-16: PDLI Meets EPS, Beats on Top Line - Analyst Blog

Financial news for NVS dated on 2010-11-15: Deflation Takes Back Seat 11-15-2010

Financial news for NVS dated on 2010-11-15: Financials Show Strength 11-15-2010

Financial news for NVS dated on 2010-11-15: Monday's Mid-Day Options Volume Leaders (NVS, QCOM, F, AAPL, CSCO)

Financial news for NVS dated on 2010-11-11: Zacks Analyst Blog Highlights: Alnylam Pharmaceuticals, Roche, Novartis, Cubist Pharmaceuticals and Biogen Idec - Press Releases

Financial news for NVS dated on 2010-11-08: Unconfirmed Rumor: Novartis AG to Acquire Onyx Pharmaceuticals (NVS, ONXX)

Financial news for NVS dated on 2010-11-03: Positive Results In Study of Novartis Drug Afinitor (NVS)

Financial news for NVS dated on 2010-11-02: Benzinga's Top ETF Decliners (SRTY, EPV, EDZ, TMV)

Financial news for NVS dated on 2010-10-29: Friday's Put/Call Ratio Leaders (NWL, RYL, NVS, QSII, BMY)

Financial news for NVS dated on 2010-10-28: Benzinga's Top ETF Decliners (AGA, ZSL, DZZ, EPV)

Financial news for NVS dated on 2010-10-28: Thursday's Put/Call Ratio Leaders (LBTYA, MFN, RYL, NVS, GENZ)

Financial news for NVS dated on 2010-10-27: Zacks Bull and Bear of the Day Highlights: Gilead Sciences, Linear Technology, Biogen Idec, Elan and Novartis - Press Releases

Financial news for NVS dated on 2010-10-26: Benzinga's Top ETF Gainers (TMV, TBT, PALL, DPK)

Financial news for NVS dated on 2010-10-21: New Products Drive Novartis - Analyst Blog

Financial news for NVS dated on 2010-10-21: Earnings Scheduled For October 21 (MCD, CAT, T, LLY, CS, UAL, BAX, NVS, UNP, UPS, BBT, PM, RAI, CTXS, SNDK, JBLU, AXP, TRV, LUV, AMZN, STI, HSY, XRX, CB)

Financial news for NVS dated on 2010-10-06: S&P Downgrades Novartis AG (NVS) From Buy to Hold

Financial news for NVS dated on 2010-10-05: Tuesday's Put/Call Ratio Leaders (CAVM, WL, AVP, CHTP, NVS)

Financial news for NVS dated on 2010-10-04: Bristol Myers at Neutral - Analyst Blog

Financial news for NVS dated on 2010-10-03: Biogen Cut to Neutral - Analyst Blog

Financial news for NVS dated on 2010-09-29: Wednesday's Put/Call Ratio Leaders (NVS,

DTV, JWN, CIM, MOT)

Financial news for NVS dated on 2010-09-27: Jefferies Raises Price Target On Warner Chilcott (WCRX)

Financial news for NVS dated on 2010-09-24: Piper Jaffray Neutral On Alnylam Pharmaceuticals (ALNY)

Financial news for NVS dated on 2010-09-22: Biogen Falling On Novartis Approval

Financial news for NVS dated on 2010-09-22: US Stock Futures Signals A Low Start After Federal Reserve Warning On Economic Recovery

Financial news for NVS dated on 2010-09-22: Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest EPS Estimates (AZN, NVS, ABT, GSK)

Financial news for NVS dated on 2010-09-18: J&J Makes a Pitch for Crucell - Analyst Blog

Financial news for NVS dated on 2010-09-03: Cooper Profit Grows, Lifts View - Analyst Blog

Financial news for NVS dated on 2010-09-03: Bausch + Lomb to Acquire Miochol(R)-E (NVS)

Financial news for NVS dated on 2010-09-02: Upside Purchased on Novartis AG (NVS)

Financial news for NVS dated on 2010-08-31: New Dosages of Solodyn Approved - Analyst Blog

Financial news for NVS dated on 2010-08-30: Novartis' Tekamlo Gains FDA Nod - Analyst Blog

Financial news for NVS dated on 2010-08-30: Incyte Evenly Poised - Analyst Blog

Financial news for NVS dated on 2010-08-26: NVS Acquires Majority Share in ACL - Analyst Blog

Financial news for NVS dated on 2010-08-23: Generic Risk For Gilead's Hepsera - Analyst Blog

Financial news for NVS dated on 2010-08-19: FDA to Withdraw Shire Drug Approval - Analyst Blog

Financial news for NVS dated on 2010-08-18: Puts Purchased on Novartis AG (NVS)

Financial news for NVS dated on 2010-08-17: Ardea remains Neutral - Analyst Blog

Financial news for NVS dated on 2010-08-17: Zacks Analyst Blog Highlights: Elan, Transition Therapeutics, Pfizer, Novartis AG, Johnson & Johnson and Forest Laboratories - Press Releases

Financial news for NVS dated on 2010-08-17: Lower Q2 Loss at Marina - Analyst Blog

Financial news for NVS dated on 2010-08-16: Elan to Move ELND005 to Phase III - Analyst Blog

Financial news for NVS dated on 2010-08-10: Fed's Mood Altering Statement 08-10-2010

Financial news for NVS dated on 2010-08-09: Q2 Loss Widens at Ardea - Analyst Blog

Financial news for NVS dated on 2010-08-09: Finally There Is A Cure For Tobacco Addiction (CIGX)

Financial news for NVS dated on 2010-08-05: ALNY's 2Q Loss Down on Lower Costs - Analyst Blog

Financial news for NVS dated on 2010-07-30: Gen-Probe Leaps Ahead of Forecast - Analyst Blog

Financial news for NVS dated on 2010-07-23: Pharma Names Rallying on FDA Decision about Lovenox (INSM, MNTA, ABC, MHS)

Financial news for NVS dated on 2010-07-22: Benzinga's Top ETF Decliners (DRV, TZA, SRTY, DPK)

Financial news for NVS dated on 2010-07-16: Citigroup Reiterates Buy Rating on Novartis (NVS)

Financial news for NVS dated on 2010-07-15: Company News for July 15, 2010 - Corporate Summary

Financial news for NVS dated on 2010-07-13: Miller Tabak Likes Bristol Myers Squibb (BMY), Novartis (NVS) And Merck (MRK)

Financial news for NVS dated on 2010-07-07: Bid Lacks Conviction 07-07-2010

Financial news for NVS dated on 2010-07-07: Alcon, Inc.Acquires LenSx, Still In Negotiations With Novartis (ACL, NVS)

Financial news for NVS dated on 2010-06-25: Is Star Scientific Being Shopped? (CIGX, NVS)

Financial news for NVS dated on 2010-06-09: Safety Concerns Main Topic of Novartis' Gilenia FDA Meeting Tomorrow (NVS, TEVA, BIIB)

Financial news for NVS dated on 2010-05-28: Puts Purchased on Novartis (NVS)

Financial news for NVS dated on 2010-05-24: Karen Finerman Sees An Opportunity In ACL, ARG, SII, GGP

Financial news for NVS dated on 2010-05-21: Calls Sold on Novartis (NVS)

Financial news for NVS dated on 2010-05-20: Bulls Target Novartis (NVS)

Financial news for NVS dated on 2010-05-19: Market Roundup (HON, NVS, FNXMF, QADMF, GS)

Financial news for NVS dated on 2010-05-18: Put Volume Grows in Novartis (NVS)

Financial news for NVS dated on 2010-04-19: Top 5 Stocks In The Healthcare Sector With Highest Cash (PFE, WLP, JNJ, NVS, AMGN)

Financial news for NVS dated on 2010-04-13: Pete Najarian Likes NVS

Financial news for NVS dated on 2010-04-07: Sanofi-Aventis Settles Law Suit (SNY, TEVA, NVS)

Financial news for NVS dated on 2010-03-25: Under The Hood: Europe 2001 HOLDRs

Financial news for NVS dated on 2010-03-24: Human Genome Sciences (HGSI) and Novartis (NVS) Hepatitis Treatment Awaits Approval

Financial news for NVS dated on 2010-03-18: US Stock Futures Mixed (PFE, TEVA, GSK, NKE, NVS, FDX)

Financial news for NVS dated on 2010-03-03: Top 5 NYSE Stocks In The Healthcare Sector With The Highest Dividend (ACL, AZN, GSK, NVS, JNJ)

Financial news for NVS dated on 2010-02-26: Novartis CEO Says Company Will Go For Bolt-On Acquisitions (NVS)

Financial news for NVS dated on 2010-02-04: Merck (MRK) Is A Frontrunner Among Pharma Stocks

Financial news for NVS dated on 2010-01-22: Benzinga's Volume Movers (MNTA, ISRG, TRGL, IPGP, JCOM)

Financial news for NVS dated on 2010-01-22: M&A Funds Are Hot

Financial news for NVS dated on 2010-01-20: Market Round-up (C, BAC, BRK.A, XTO, XOM, ACL, NVS, AAPL, MSFT, GOOG)

Financial news for NVS dated on 2010-01-14: ACL's Stock To Be Volatile On Novartis Deal

Financial news for NVS dated on 2010-01-13: Alcon (ACL), Novartis (NVS), Nestle (NSRGY) Sued By Pension Fund

Financial news for NVS dated on 2010-01-13: Alcon (ACL) CEO To Recuse Himself, (NVS)

Financial news for NVS dated on 2010-01-13: Novartis (NVS) To Raise Bid For Alcon (ACL)

Financial news for NVS dated on 2010-01-12: Market Round-Up (INTC, WMT, ACL, NVS, NSRGY.PK, KBH)

Financial news for NVS dated on 2010-01-11: Novartis (NVS) Launches Schizophrenia

Treatment Fanapt

Financial news for NVS dated on 2010-01-04: NVS Acquiring ACL

Financial news for NVS dated on 2010-01-04: Company News for January 04, 2010 - Corporate Summary

Financial news for NVS dated on 2010-01-04: Benzinga's Top Pre-Market Gainers (OSIS, BFRM, ACL, BIOD, CHK, MAGS, WYNN)

Financial news for NVS dated on 2010-01-04: Benzinga's News Roundup (BFRM, INTC, NVS, SYT, ITMN, CHK, MS)

Financial news for NVS dated on 2009-12-31: Benzinga's Top Stocks Picks of 2010 (NVS, CAT, SMBL)

Financial news for NVS dated on 2009-12-14: Pfizer (PFE), Gold (GLD) Are Big Picks

Financial news for NVS dated on 2009-12-09: BarclaysTreats Novartis (NVS) With Care

Financial news for NVS dated on 2009-12-07: Fast Money Guys Share Their Dividend Play (VZ, JNJ, JPM, DUK, BP, MCD, NVS, TE, DD, DVY)

Financial news for NVS dated on 2009-12-02: Cowen stays Neutral On Santarus (SNTS), Cites Litigation Concerns , PRX, MRK, AZN, NVS

Financial news for NVS dated on 2009-11-25: Benzinga's Top Gainers (RTK, INCY, HEV, QADI, JDSU)

Financial news for NVS dated on 2009-11-25: Benzinga's News Roundup (TIF, WBD, NVS)

Financial news for NVS dated on 2009-11-25: Benzinga's Top Pre- Market Gainers (TIF, RFMD, AIXG, INCY, SOLF, QGEN, CYTX, SVA)

Financial news for NVS dated on 2009-11-24: Cramer Talks About VIP, T, VZ, NVS, SNY, CIEN

Financial news for NVS dated on 2009-11-23: Barron's Stock List For A Solid Retirement Plan, STD, JNJ, NVS, MCD, NSRGY, INTC, CVX

Financial news for NVS dated on 2009-11-20: Benzinga's ETF Gainers (FRN, SZO, REC, EPV, ERY, DUG, DPK)

Financial news for NVS dated on 2009-11-04: Tim Seymour Is Keen On DIS, NVS, CSCO

Financial news for NVS dated on 2009-10-29: Novartis (NVS) On Track To Deliver 90M Units of The H1N1 Vaccine

Financial news for NVS dated on 2009-10-29: Human Genome Sciences Discusses The Company's Products (HGSI)

Financial news for NVS dated on 2009-10-26: Looking To Europe For A Long ETF Play (IEV)

Financial news for NVS dated on 2009-10-22: Novartis AG (NYSE: NVS) Reports Net Income Of \$2.1 Billion

Financial news for NVS dated on 2009-08-17: Trends in the U.K. and Irish Pharmaceutical and Biotechnology Industry, an Industrial Info News Alert

Financial news for NVS dated on 2009-08-13: AnalystChoice.com Brings You the Best Complimentary Research Report on MDU, NVS, BKS, MA, NGD and NBR